

# Philip Scheltens

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2896216/publications.pdf>

Version: 2024-02-01

1,386  
papers

125,039  
citations

300

143  
h-index

249

310  
g-index

1593  
all docs

1593  
docs citations

1593  
times ranked

73346  
citing authors

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 1  | Nutritional Status Is Associated With Clinical Progression in Alzheimer's Disease: The NUDAD Project. <i>Journal of the American Medical Directors Association</i> , 2023, 24, 638-644.e1.  | 1.2 | 10        |
| 2  | Identifying best practices for disclosure of amyloid imaging results: A randomized controlled trial. <i>Alzheimer's and Dementia</i> , 2023, 19, 285-295.   | 0.4 | 12        |
| 3  | Cerebrospinal fluid proteomic profiling of individuals with mild cognitive impairment and suspected non-Alzheimer's disease pathophysiology. <i>Alzheimer's and Dementia</i> , 2023, 19, 807-820.   | 0.4 | 4         |
| 4  | Description of a European memory clinic cohort undergoing amyloid PET: The AMYPAD Diagnostic and Patient Management Study. <i>Alzheimer's and Dementia</i> , 2023, 19, 844-856.   | 0.4 | 6         |
| 5  | Early life involvement in C9orf72 repeat expansion carriers. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, 93-100.   | 0.9 | 16        |
| 6  | The natural history of primary progressive aphasia: beyond aphasia. <i>Journal of Neurology</i> , 2022, 269, 1375-1385.   | 1.8 | 23        |
| 7  | Generating diagnostic profiles of cognitive decline and dementia using magnetoencephalography. <i>Neurobiology of Aging</i> , 2022, 111, 82-94.   | 1.5 | 5         |
| 8  | The probabilistic model of Alzheimer disease: the amyloid hypothesis revised. <i>Nature Reviews Neuroscience</i> , 2022, 23, 53-66.   | 4.9 | 203       |
| 9  | Psychosocial Effects of COVID-19 Measures on (Pre-)Dementia Patients During Second Lockdown. <i>Journal of Alzheimer's Disease</i> , 2022, 86, 931-939.   | 1.2 | 7         |
| 10 | Differential associations between neocortical tau pathology and blood flow with cognitive deficits in early-onset vs late-onset Alzheimer's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 1951-1963. | 3.3 | 8         |
| 11 | Research Criteria for the Behavioral Variant of Alzheimer Disease. <i>JAMA Neurology</i> , 2022, 79, 48.  | 4.5 | 44        |
| 12 | Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum. <i>JAMA Neurology</i> , 2022, 79, 228.  | 4.5 | 97        |
| 13 | Association of the ATN Research Framework With Clinical Profile, Cognitive Decline, and Mortality in Patients With Dementia With Lewy Bodies. <i>Neurology</i> , 2022, 98, .  | 1.5 | 10        |
| 14 | Validation and test-retest repeatability performance of parametric methods for [11C]UCB-J PET. <i>EJNMMI Research</i> , 2022, 12, 3.  | 1.1 | 3         |
| 15 | Genetically identical twins show comparable tau PET load and spatial distribution. <i>Brain</i> , 2022, 145, 3571-3581.   | 3.7 | 12        |
| 16 | Neuropsychiatric Symptoms as Predictor of Poor Clinical Outcome in Patients With Vascular Cognitive Impairment. <i>American Journal of Geriatric Psychiatry</i> , 2022, , .   | 0.6 | 1         |
| 17 | Acute response to cholinergic challenge predicts long-term response to galantamine treatment in patients with Alzheimer's disease. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 2814-2829.                                     | 1.1 | 7         |
| 18 | Association of CSF, Plasma, and Imaging Markers of Neurodegeneration With Clinical Progression in People With Subjective Cognitive Decline. <i>Neurology</i> , 2022, 98, .  | 1.5 | 41        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 19 | Considerations regarding a diagnosis of Alzheimer's disease before dementia: a systematic review. <i>Alzheimer's Research and Therapy</i> , 2022, 14, 31.  | 3.0 | 25        |
| 20 | Grey matter network markers identify individuals with prodromal Alzheimer's disease who will show rapid clinical decline. <i>Brain Communications</i> , 2022, 4, fca026.   | 1.5 | 4         |
| 21 | Vascular Cognitive Impairment and cognitive decline; a longitudinal study comparing different types of vascular brain injury - The TRACE-VCI study. <i>Cerebral Circulation - Cognition and Behavior</i> , 2022, 3, 100141.  | 0.4 | 2         |
| 22 | Decreased integrity of the monoaminergic tract is associated with a positive response to MPH in patients with vascular cognitive impairment - proof of principle study STREAM-VCI. <i>Cerebral Circulation - Cognition and Behavior</i> , 2022, 3, 100128.                               | 0.4 | 0         |
| 23 | CSF proteomic signature predicts progression to Alzheimer's disease dementia. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2022, 8, e12240.  | 1.8 | 3         |
| 24 | Sensitive and reproducible MEG resting-state metrics of functional connectivity in Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2022, 14, 38.  | 3.0 | 14        |
| 25 | Rare variants in IFFO1, DTNB, NLRC3 and SLC22A10 associate with Alzheimer's disease CSF profile of neuronal injury and inflammation. <i>Molecular Psychiatry</i> , 2022, 27, 1990-1999.  | 4.1 | 9         |
| 26 | Spatial-Temporal Patterns of $\beta$ -Amyloid Accumulation. <i>Neurology</i> , 2022, 98, .   | 1.5 | 40        |
| 27 | The Importance of Phase 2 in Drug Development for Alzheimer's Disease. , 2022, , 150-161.  |     | 0         |
| 28 | Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer's disease. <i>Molecular Neurodegeneration</i> , 2022, 17, 27.   | 4.4 | 30        |
| 29 | Genome-Wide Association Study of Alzheimer's Disease Brain Imaging Biomarkers and Neuropsychological Phenotypes in the European Medical Information Framework for Alzheimer's Disease Multimodal Biomarker Discovery Dataset. <i>Frontiers in Aging Neuroscience</i> , 2022, 14, 840651. | 1.7 | 20        |
| 30 | Association of Education and Intracranial Volume With Cognitive Trajectories and Mortality Rates Across the Alzheimer Disease Continuum. <i>Neurology</i> , 2022, 98, .  | 1.5 | 17        |
| 31 | Oscillatory Activity of the Hippocampus in Prodromal Alzheimer's Disease: A Source-Space Magnetoencephalography Study. <i>Journal of Alzheimer's Disease</i> , 2022, , 1-17.   | 1.2 | 4         |
| 32 | Giving meaning to the scores of the Amsterdam instrumental activities of daily living questionnaire: a qualitative study. <i>Health and Quality of Life Outcomes</i> , 2022, 20, 47.   | 1.0 | 4         |
| 33 | New insights into the genetic etiology of Alzheimer's disease and related dementias. <i>Nature Genetics</i> , 2022, 54, 412-436.   | 9.4 | 700       |
| 34 | The protective gene dose effect of the <i>APOE</i> $\epsilon$ 2 allele on gray matter volume in cognitively unimpaired individuals. <i>Alzheimer's and Dementia</i> , 2022, 18, 1383-1395.   | 0.4 | 13        |
| 35 | Characteristics of subjective cognitive decline associated with amyloid positivity. <i>Alzheimer's and Dementia</i> , 2022, 18, 1832-1845.   | 0.4 | 22        |
| 36 | Effects of age, amyloid, sex, and <i>APOE</i> $\epsilon$ 4 on the CSF proteome in normal cognition. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2022, 14, e12286.  | 1.2 | 4         |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 37 | Subjective cognitive decline and self-reported sleep problems: The SCIENCE project. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2022, 14, .   | 1.2 | 5         |
| 38 | Determining the Minimal Important Change of Everyday Functioning in Dementia. <i>Neurology</i> , 2022, 99, .  | 1.5 | 2         |
| 39 | Association of Rare <i>APOE</i> Missense Variants V236E and R251G With Risk of Alzheimer Disease. <i>JAMA Neurology</i> , 2022, 79, 652.  | 4.5 | 31        |
| 40 | A Pragmatic, Data-Driven Method to Determine Cutoffs for CSF Biomarkers of Alzheimer Disease Based on Validation Against PET Imaging. <i>Neurology</i> , 2022, 99, .  | 1.5 | 8         |
| 41 | Changes in Brain-Health Related Modifiable Risk Factors in Older Adults After One Year of COVID-19-Restrictions. <i>Frontiers in Psychiatry</i> , 2022, 13, .   | 1.3 | 4         |
| 42 | P-tau subgroups in AD relate to distinct amyloid production and synaptic integrity profiles. <i>Alzheimer's Research and Therapy</i> , 2022, 14, .  | 3.0 | 5         |
| 43 | What Determines Cognitive Functioning in the Oldest-Old? The EMIF-AD 90+ Study. <i>Journals of Gerontology - Series B Psychological Sciences and Social Sciences</i> , 2021, 76, 1499-1511.   | 2.4 | 14        |
| 44 | Identifying Sensitive Measures of Cognitive Decline at Different Clinical Stages of Alzheimer's Disease. <i>Journal of the International Neuropsychological Society</i> , 2021, 27, 426-438.  | 1.2 | 30        |
| 45 | Kinetics and 28-day test-retest repeatability and reproducibility of [ <sup>11</sup> C]UCB-J PET brain imaging. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2021, 41, 1338-1350.   | 2.4 | 14        |
| 46 | Circulating metabolites are associated with brain atrophy and white matter hyperintensities. <i>Alzheimer's and Dementia</i> , 2021, 17, 205-214.   | 0.4 | 17        |
| 47 | Physical exercise improves quality of life, depressive symptoms, and cognition across chronic brain disorders: a transdiagnostic systematic review and meta-analysis of randomized controlled trials. <i>Journal of Neurology</i> , 2021, 268, 1222-1246. | 1.8 | 120       |
| 48 | Association of Cognitive Function Trajectories in Centenarians With Postmortem Neuropathology, Physical Health, and Other Risk Factors for Cognitive Decline. <i>JAMA Network Open</i> , 2021, 4, e2031654.   | 2.8 | 29        |
| 49 | Risk of dementia in <i>APOE</i> $\epsilon$ 4 carriers is mitigated by a polygenic risk score. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021, 13, e12229.   | 1.2 | 16        |
| 50 | Differential patterns of gray matter volumes and associated gene expression profiles in cognitively-defined Alzheimer's disease subgroups. <i>NeuroImage: Clinical</i> , 2021, 30, 102660.  | 1.4 | 13        |
| 51 | Biomarker testing in MCI patients—deciding who to test. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 14.   | 3.0 | 6         |
| 52 | Four subgroups based on tau levels in Alzheimer's disease observed in two independent cohorts. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 2.   | 3.0 | 18        |
| 53 | Amyloid $\beta$ , cortical thickness, and subsequent cognitive decline in cognitively normal oldest-old. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 348-358.  | 1.7 | 9         |
| 54 | White matter microstructure disruption in early stage amyloid pathology. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021, 13, e12124.  | 1.2 | 16        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 55 | Non-invasive Standardised Uptake Value for Verification of the Use of Previously Validated Reference Region for [18F]Flortaucipir and [18F]Florbetapir Brain PET Studies. <i>Molecular Imaging and Biology</i> , 2021, 23, 550-559.            | 1.3 | 2         |
| 56 | Routine magnetoencephalography in memory clinic patients: A machine learning approach. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021, 13, e12227.   | 1.2 | 9         |
| 57 | Aducanumab: Appropriate Use Recommendations. <i>Journal of Prevention of Alzheimer's Disease</i> , The, 2021, 8, 1-2.  | 1.5 | 4         |
| 58 | Visual assessment of [18F]flutemetamol PET images can detect early amyloid pathology and grade its extent. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2169-2182.  | 3.3 | 24        |
| 59 | In vivo tau pathology is associated with synaptic loss and altered synaptic function. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 35.  | 3.0 | 47        |
| 60 | Cerebrospinal fluid N-224 tau helps discriminate Alzheimer's disease from subjective cognitive decline and other dementias. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 38.  | 3.0 | 12        |
| 61 | The Right Temporal Variant of Frontotemporal Dementia Is Not Genetically Sporadic: A Case Series. <i>Journal of Alzheimer's Disease</i> , 2021, 79, 1195-1201.   | 1.2 | 10        |
| 62 | Serum markers glial fibrillary acidic protein and neurofilament light for prognosis and monitoring in cognitively normal older people: a prospective memory clinic-based cohort study. <i>The Lancet Healthy Longevity</i> , 2021, 2, e87-e95. | 2.0 | 85        |
| 63 | Frontotemporal dementia, music perception and social cognition share neurobiological circuits: A meta-analysis. <i>Brain and Cognition</i> , 2021, 148, 105660.  | 0.8 | 14        |
| 64 | Replication study of plasma proteins relating to Alzheimer's pathology. <i>Alzheimer's and Dementia</i> , 2021, 17, 1452-1464.   | 0.4 | 13        |
| 65 | The bvFTD phenocopy syndrome: a case study supported by repeated MRI, [18F]FDG-PET and pathological assessment. <i>Neurocase</i> , 2021, 27, 181-189.  | 0.2 | 2         |
| 66 | Onset of Preclinical Alzheimer Disease in Monozygotic Twins. <i>Annals of Neurology</i> , 2021, 89, 987-1000.  | 2.8 | 20        |
| 67 | The predictive value of normal EEGs in dementia due to Alzheimer's disease. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 1038-1048.  | 1.7 | 3         |
| 68 | Application of the ATN classification scheme in a population without dementia: Findings from the EPAD cohort. <i>Alzheimer's and Dementia</i> , 2021, 17, 1189-1204.   | 0.4 | 44        |
| 69 | Gene Expression Imputation Across Multiple Tissue Types Provides Insight Into the Genetic Architecture of Frontotemporal Dementia and Its Clinical Subtypes. <i>Biological Psychiatry</i> , 2021, 89, 825-835.                                 | 0.7 | 10        |
| 70 | Alzheimer's disease. <i>Lancet</i> , The, 2021, 397, 1577-1590.  | 6.3 | 1,530     |
| 71 | Heterogeneous distribution of tau pathology in the behavioural variant of Alzheimer's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 872-880.   | 0.9 | 17        |
| 72 | Finding Treatment Effects in Alzheimer Trials in the Face of Disease Progression Heterogeneity. <i>Neurology</i> , 2021, 96, e2673-e2684.  | 1.5 | 37        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 73 | Clinical Phenotypes of Behavioral Variant Frontotemporal Dementia by Age at Onset. <i>Journal of Alzheimer's Disease</i> , 2021, 82, 381-390.  | 1.2 | 8         |
| 74 | A phase 2 double-blind placebo-controlled 24-week treatment clinical study of the p38 alpha kinase inhibitor neflamapimod in mild Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 106.  | 3.0 | 37        |
| 75 | TMEM106B and CPOX are genetic determinants of cerebrospinal fluid Alzheimer's disease biomarker levels. <i>Alzheimer's and Dementia</i> , 2021, 17, 1628-1640.   | 0.4 | 23        |
| 76 | Highly specific and ultrasensitive plasma test detects Abeta(1-42) and Abeta(1-40) in Alzheimer's disease. <i>Scientific Reports</i> , 2021, 11, 9736.   | 1.6 | 49        |
| 77 | ADAMANT: a placebo-controlled randomized phase 2 study of AADvac1, an active immunotherapy against pathological tau in Alzheimer's disease. <i>Nature Aging</i> , 2021, 1, 521-534.  | 5.3 | 64        |
| 78 | Common variants in Alzheimer's disease and risk stratification by polygenic risk scores. <i>Nature Communications</i> , 2021, 12, 3417.  | 5.8 | 140       |
| 79 | SORL1 deficiency in human excitatory neurons causes APP-dependent defects in the endolysosome-autophagy network. <i>Cell Reports</i> , 2021, 35, 109259.   | 2.9 | 47        |
| 80 | The plasma peptides of Alzheimer's disease. <i>Clinical Proteomics</i> , 2021, 18, 17.   | 1.1 | 18        |
| 81 | Plasma amyloid- $\beta$ oligomerization assay as a pre-screening test for amyloid status. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 133.   | 3.0 | 19        |
| 82 | Rivastigmine for minor visual hallucinations in Parkinson's disease: A randomized controlled trial with 24-months follow-up. <i>Brain and Behavior</i> , 2021, 11, e2257.  | 1.0 | 11        |
| 83 | [ <sup>18</sup> F]Flortaucipir PET Across Various <i>MAPT</i> Mutations in Presymptomatic and Symptomatic Carriers. <i>Neurology</i> , 2021, 97, e1017-e1030.  | 1.5 | 16        |
| 84 | Tau PET correlates with different Alzheimer's disease-related features compared to CSF and plasma p-tau biomarkers. <i>EMBO Molecular Medicine</i> , 2021, 13, e14398.   | 3.3 | 58        |
| 85 | Rationale and study design of a randomized, placebo-controlled, double-blind phase 2b trial to evaluate efficacy, safety, and tolerability of an oral glutaminy cyclase inhibitor varoglutamstat (PQ912) in study participants with MCI and mild AD-VIVIAD. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 142. | 3.0 | 14        |
| 86 | Right temporal variant frontotemporal dementia is pathologically heterogeneous: a case-series and a systematic review. <i>Acta Neuropathologica Communications</i> , 2021, 9, 131.   | 2.4 | 16        |
| 87 | CSF Proteomic Alzheimer's Disease-Predictive Subtypes in Cognitively Intact Amyloid Negative Individuals. <i>Proteomes</i> , 2021, 9, 36.  | 1.7 | 9         |
| 88 | Genetics Contributes to Concomitant Pathology and Clinical Presentation in Dementia with Lewy Bodies. <i>Journal of Alzheimer's Disease</i> , 2021, 83, 269-279.   | 1.2 | 10        |
| 89 | Neuropsychiatric and Cognitive Symptoms Across the Alzheimer Disease Clinical Spectrum. <i>Neurology</i> , 2021, 97, e1276-e1287.  | 1.5 | 44        |
| 90 | Responding to responsive behaviour in Alzheimer's disease – Author's reply. <i>Lancet, The</i> , 2021, 398, 842.   | 6.3 | 1         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 91  | Amyloid-driven disruption of default mode network connectivity in cognitively healthy individuals. <i>Brain Communications</i> , 2021, 3, fcab201.  | 1.5 | 14        |
| 92  | Genome-wide association study of frontotemporal dementia identifies a C9ORF72 haplotype with a median of 12-G4C2 repeats that predisposes to pathological repeat expansions. <i>Translational Psychiatry</i> , 2021, 11, 451.                           | 2.4 | 6         |
| 93  | BDNF-Met polymorphism and amyloid-beta in relation to cognitive decline in cognitively normal elderly: the SCIENCE project. <i>Neurobiology of Aging</i> , 2021, 108, 146-154.  | 1.5 | 6         |
| 94  | Comparing CSF amyloid $\beta$ biomarker ratios for two automated immunoassays, Elecsys and Lumipulse, with amyloid PET status. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021, 13, e12182.                        | 1.2 | 26        |
| 95  | Identifying relevant outcomes in the progression of Alzheimer's disease; what do patients and care partners want to know about prognosis?. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2021, 7, e12189.        | 1.8 | 15        |
| 96  | Differential trajectories of hypometabolism across cognitively-defined Alzheimer $\beta$ ™s disease subgroups. <i>NeuroImage: Clinical</i> , 2021, 31, 102725.  | 1.4 | 9         |
| 97  | Dutch Brain Research Registry for study participant recruitment: Design and first results. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2021, 7, e12132.  | 1.8 | 23        |
| 98  | Polygenic Risk Score of Longevity Predicts Longer Survival Across an Age Continuum. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2021, 76, 750-759.   | 1.7 | 20        |
| 99  | Modifiable risk factors for dementia and dementia risk profiling. A user manual for Brain Health Services $\beta$ ™ part 2 of 6. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 169.   | 3.0 | 35        |
| 100 | Dementia risk communication. A user manual for Brain Health Services $\beta$ ™ part 3 of 6. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 170.  | 3.0 | 21        |
| 101 | Protocols for cognitive enhancement. A user manual for Brain Health Services $\beta$ ™ part 5 of 6. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 172.  | 3.0 | 15        |
| 102 | The Impact of Amyloid PET Disclosure on Quality of Life in Patients With Young Onset Dementia. <i>Alzheimer Disease and Associated Disorders</i> , 2021, Publish Ahead of Print, 1-6.   | 0.6 | 1         |
| 103 | Brain Health Services: organization, structure, and challenges for implementation. A user manual for Brain Health Services $\beta$ ™ part 1 of 6. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 168.  | 3.0 | 26        |
| 104 | Multidomain interventions: state-of-the-art and future directions for protocols to implement precision dementia risk reduction. A user manual for Brain Health Services $\beta$ ™ part 4 of 6. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 171. | 3.0 | 37        |
| 105 | Sex-Specific Metabolic Pathways Were Associated with Alzheimer $\beta$ ™s Disease (AD) Endophenotypes in the European Medical Information Framework for AD Multimodal Biomarker Discovery Cohort. <i>Biomedicine</i> , 2021, 9, 1610.                   | 1.4 | 7         |
| 106 | The Alzheimer $\beta$ ™s disease drug development landscape. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 186.   | 3.0 | 49        |
| 107 | Everyday Functioning in a Community-Based Volunteer Population: Differences Between Participant- and Study Partner-Report. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 761932.   | 1.7 | 4         |
| 108 | Gut Microbiota Composition Is Related to AD Pathology. <i>Frontiers in Immunology</i> , 2021, 12, 794519.   | 2.2 | 57        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 109 | Psychosocial effects of Corona virus measures on (pre-)dementia patients during 2 <sup>nd</sup> lockdown. <i>Alzheimer's and Dementia</i> , 2021, 17, e053995.                                     | 0.4 | 0         |
| 110 | Neuropsychiatric symptoms in patients with possible vascular cognitive impairment: Does sex matter?. <i>Alzheimer's and Dementia</i> , 2021, 17, .   | 0.4 | 0         |
| 111 | A stepwise approach towards diagnostic workup in dementia using online cognitive tools. <i>Alzheimer's and Dementia</i> , 2021, 17, .  | 0.4 | 0         |
| 112 | ATN classification in dementia with Lewy bodies: Association with clinical profile, cognitive decline and survival. <i>Alzheimer's and Dementia</i> , 2021, 17, .                                  | 0.4 | 1         |
| 113 | Amyloid discordance analysis in cognitively normal monozygotic twins demonstrates that the memory domain is affected first in preclinical AD. <i>Alzheimer's and Dementia</i> , 2021, 17, .        | 0.4 | 0         |
| 114 | Capturing functional change in early Alzheimer's disease: Comparing instruments and scoring techniques to detect subtle decline. <i>Alzheimer's and Dementia</i> , 2021, 17, .                     | 0.4 | 0         |
| 115 | Identifying and characterizing patterns of functional decline in memory clinic patients. <i>Alzheimer's and Dementia</i> , 2021, 17, .   | 0.4 | 0         |
| 116 | An accurate diagnosis contributes to delayed institutionalization and mortality: The ABIDE Project. <i>Alzheimer's and Dementia</i> , 2021, 17, .  | 0.4 | 0         |
| 117 | Rationale and design of the NEWTON study: A prospective cohort study of patients at risk of chronic traumatic encephalopathy. <i>Alzheimer's and Dementia</i> , 2021, 17, .                        | 0.4 | 0         |
| 118 | Genetically identical twins are highly similar in levels and spatial distribution of tau pathology: A [ <sup>18</sup> F]flortaucipir PET study. <i>Alzheimer's and Dementia</i> , 2021, 17, .      | 0.4 | 0         |
| 119 | Subjective cognitive decline and self-reported sleep at a memory clinic: The SCIENCE project. <i>Alzheimer's and Dementia</i> , 2021, 17, .  | 0.4 | 0         |
| 120 | Cognitive decline in possible vascular cognitive impairment (VCI): Does the form of vascular brain injury matter?. <i>Alzheimer's and Dementia</i> , 2021, 17, .                                   | 0.4 | 0         |
| 121 | The Effect of Alzheimer's Disease-Associated Genetic Variants on Longevity. <i>Frontiers in Genetics</i> , 2021, 12, 748781.   | 1.1 | 7         |
| 122 | Plasma $\tau_{181}$ levels predict amyloid pathology in cognitively unimpaired individuals after 10 years. <i>Alzheimer's and Dementia</i> , 2021, 17, .   | 0.4 | 0         |
| 123 | Differential gray matter connectivity correlates of CSF biomarkers: Results from the EPAD Cohort. <i>Alzheimer's and Dementia</i> , 2021, 17, .  | 0.4 | 0         |
| 124 | EEG slowing in predementia Alzheimer's disease is compatible with neuronal hyperactivity: A multiscale computational modeling study.. <i>Alzheimer's and Dementia</i> , 2021, 17 Suppl 3, e053535. | 0.4 | 0         |
| 125 | Neuropathological hallmarks of Alzheimer's disease in centenarians, in the context of aging.. <i>Alzheimer's and Dementia</i> , 2021, 17 Suppl 3, e053600.   | 0.4 | 0         |
| 126 | Neuroproteomics of cognitively healthy centenarians in the context of aging and Alzheimer's disease.. <i>Alzheimer's and Dementia</i> , 2021, 17 Suppl 3, e053681.                                 | 0.4 | 0         |



| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 127 | Immune protein levels in cerebrospinal fluid: Associations with memory scores across the AD spectrum.. Alzheimer's and Dementia, 2021, 17 Suppl 3, e055451.  | 0.4 | 0         |
| 128 | Parametric methods for [ <sup>18</sup> F]flortaucipir PET. Journal of Cerebral Blood Flow and Metabolism, 2020, 40, 365-373.   | 2.4 | 22        |
| 129 | Olfactory and gustatory functioning and food preferences of patients with Alzheimer's disease and mild cognitive impairment compared to controls: the NUDAD project. Journal of Neurology, 2020, 267, 144-152.                 | 1.8 | 21        |
| 130 | Associations of Brain Pathology Cognitive and Physical Markers With Age in Cognitively Normal Individuals Aged 60-102 Years. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2020, 75, 1609-1617. | 1.7 | 7         |
| 131 | Early restoration of parvalbumin interneuron activity prevents memory loss and network hyperexcitability in a mouse model of Alzheimer's disease. Molecular Psychiatry, 2020, 25, 3380-3398.                                   | 4.1 | 120       |
| 132 | Global Burden of Small Vessel Disease-Related Brain Changes on MRI Predicts Cognitive and Functional Decline. Stroke, 2020, 51, 170-178.   | 1.0 | 115       |
| 133 | Determinants of Cross-Sectional and Longitudinal Health-Related Quality of Life in Memory Clinic Patients Without Dementia. Journal of Geriatric Psychiatry and Neurology, 2020, 33, 256-264.                                  | 1.2 | 6         |
| 134 | Methylphenidate and galantamine in patients with vascular cognitive impairment—the proof-of-principle study STREAM-VCI. Alzheimer's Research and Therapy, 2020, 12, 10.  | 3.0 | 10        |
| 135 | Prescreening for European Prevention of Alzheimer Dementia (EPAD) trial-ready cohort: impact of AD risk factors and recruitment settings. Alzheimer's Research and Therapy, 2020, 12, 8.                                       | 3.0 | 12        |
| 136 | In pursuit of a sensitive EEG functional connectivity outcome measure for clinical trials in Alzheimer's disease. Clinical Neurophysiology, 2020, 131, 88-95.  | 0.7 | 33        |
| 137 | Hippocampal [18F]flortaucipir BPND corrected for possible spill-in of the choroid plexus retains strong clinico-pathological relationships. NeuroImage: Clinical, 2020, 25, 102113.  | 1.4 | 5         |
| 138 | Why Is Amyloid- $\beta$ PET Requested After Performing CSF Biomarkers?. Journal of Alzheimer's Disease, 2020, 73, 559-569.   | 1.2 | 8         |
| 139 | Comorbid amyloid- $\beta$ pathology affects clinical and imaging features in VCD. Alzheimer's and Dementia, 2020, 16, 354-364.   | 0.4 | 6         |
| 140 | Cross-cultural adaptation and validation of the Amsterdam Instrumental Activities of Daily Living questionnaire short version German for Switzerland. Health and Quality of Life Outcomes, 2020, 18, 323.                      | 1.0 | 5         |
| 141 | End Stage Clinical Features and Cause of Death of Behavioral Variant Frontotemporal Dementia and Young-Onset Alzheimer's Disease. Journal of Alzheimer's Disease, 2020, 77, 1169-1180.   | 1.2 | 5         |
| 142 | Immune response and endocytosis pathways are associated with the resilience against Alzheimer's disease. Translational Psychiatry, 2020, 10, 332.  | 2.4 | 33        |
| 143 | Profound regional spectral, connectivity, and network changes reflect visual deficits in posterior cortical atrophy: an EEG study. Neurobiology of Aging, 2020, 96, 1-11.  | 1.5 | 7         |
| 144 | Amyloid- $\beta$ PET and CSF in an autopsy-confirmed cohort. Annals of Clinical and Translational Neurology, 2020, 7, 2150-2160.   | 1.7 | 17        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 145 | Amyloid-PET and 18F-FDG-PET in the diagnostic investigation of Alzheimer's disease and other dementias. <i>Lancet Neurology</i> , The, 2020, 19, 951-962.   | 4.9 | 254       |
| 146 | Energy intake and expenditure in patients with Alzheimer's disease and mild cognitive impairment: the NUDAD project. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 116.   | 3.0 | 18        |
| 147 | Single-subject grey matter network trajectories over the disease course of autosomal dominant Alzheimer's disease. <i>Brain Communications</i> , 2020, 2, fcaa102.  | 1.5 | 11        |
| 148 | Multitracer model for staging cortical amyloid deposition using PET imaging. <i>Neurology</i> , 2020, 95, e1538-e1553.  | 1.5 | 55        |
| 149 | Latent atrophy factors related to phenotypical variants of posterior cortical atrophy. <i>Neurology</i> , 2020, 95, e1672-e1685.  | 1.5 | 19        |
| 150 | Diagnostic Impact of CSF Biomarkers in a Local Hospital Memory Clinic Revisited. <i>Dementia and Geriatric Cognitive Disorders</i> , 2020, 49, 2-7.   | 0.7 | 4         |
| 151 | The influence of diversity on the measurement of functional impairment: An international validation of the Amsterdam IADL Questionnaire in eight countries. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12021. | 1.2 | 15        |
| 152 | Psychosocial Effects of Corona Measures on Patients With Dementia, Mild Cognitive Impairment and Subjective Cognitive Decline. <i>Frontiers in Psychiatry</i> , 2020, 11, 585686.   | 1.3 | 52        |
| 153 | Investigating the clinico-anatomical dissociation in the behavioral variant of Alzheimer disease. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 148.  | 3.0 | 17        |
| 154 | Associations Between Caffeine Consumption, Cognitive Decline, and Dementia: A Systematic Review. <i>Journal of Alzheimer's Disease</i> , 2020, 78, 1519-1546.   | 1.2 | 27        |
| 155 | Genome-wide association study of Alzheimer's disease CSF biomarkers in the EMIF-AD Multimodal Biomarker Discovery dataset. <i>Translational Psychiatry</i> , 2020, 10, 403.   | 2.4 | 42        |
| 156 | Mendelian randomization implies no direct causal association between leukocyte telomere length and amyotrophic lateral sclerosis. <i>Scientific Reports</i> , 2020, 10, 12184.  | 1.6 | 4         |
| 157 | Small vessel disease lesion type and brain atrophy: The role of co-occurring amyloid. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12060.   | 1.2 | 7         |
| 158 | Prediction of poor clinical outcome in vascular cognitive impairment: TRACE-VCI study. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12077.  | 1.2 | 5         |
| 159 | cCOG: A web-based cognitive test tool for detecting neurodegenerative disorders. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12083.  | 1.2 | 9         |
| 160 | Association of amyloid- $\beta$ CSF/PET discordance and tau load 5 years later. <i>Neurology</i> , 2020, 95, e2648-e2657.   | 1.5 | 33        |
| 161 | Dickkopf-1 Overexpression in vitro Nominates Candidate Blood Biomarkers Relating to Alzheimer's Disease Pathology. <i>Journal of Alzheimer's Disease</i> , 2020, 77, 1353-1368.   | 1.2 | 7         |
| 162 | Sex differences in CSF biomarkers vary by Alzheimer disease stage and APOE $\epsilon$ 4 genotype. <i>Neurology</i> , 2020, 95, e2378-e2388.   | 1.5 | 48        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 163 | Precision prevention of Alzheimer's and other dementias: Anticipating future needs in the control of risk factors and implementation of disease-modifying therapies. <i>Alzheimer's and Dementia</i> , 2020, 16, 1457-1468.                | 0.4 | 43        |
| 164 | Nutritional status and structural brain changes in Alzheimer's disease: The NUDAD project. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12063.   | 1.2 | 9         |
| 165 | A clinical-radiological framework of the right temporal variant of frontotemporal dementia. <i>Brain</i> , 2020, 143, 2831-2843.   | 3.7 | 76        |
| 166 | Identification of plasma proteome signatures associated with ATN framework using SOMAscan. <i>Alzheimer's and Dementia</i> , 2020, 16, e036954.  | 0.4 | 1         |
| 167 | Amyloid $\beta$ CSF/PET discordance vs tau load 5 years later: It takes two to tangle. <i>Alzheimer's and Dementia</i> , 2020, 16, e037246.  | 0.4 | 0         |
| 168 | Operationalization of the ATN classification scheme in preclinical AD: Findings from EPAD V500.0 data release. <i>Alzheimer's and Dementia</i> , 2020, 16, e037912.  | 0.4 | 0         |
| 169 | Relationship between clinical symptomatology and disease burden in dementia with Lewy bodies: An overview of the DEvELOP baseline results. <i>Alzheimer's and Dementia</i> , 2020, 16, e039306.  | 0.4 | 0         |
| 170 | Associations of nutritional parameters with clinical progression in patients with subjective cognitive decline, mild cognitive impairment and Alzheimer's disease: The NUDAD project. <i>Alzheimer's and Dementia</i> , 2020, 16, e039848. | 0.4 | 0         |
| 171 | Gait disturbances are associated with increased CSF tau levels in a memory clinic cohort. <i>Alzheimer's and Dementia</i> , 2020, 16, e040152.   | 0.4 | 0         |
| 172 | Neuronal network hyperactivity in computational models of AD. <i>Alzheimer's and Dementia</i> , 2020, 16, e040407.   | 0.4 | 0         |
| 173 | MEG detects abnormal hippocampal activity in amyloid-positive MCI. <i>Alzheimer's and Dementia</i> , 2020, 16, e040796.  | 0.4 | 2         |
| 174 | Interneuron hyperexcitability as both causal factor and risk factor in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e040877.   | 0.4 | 3         |
| 175 | Impact of the disclosure of amyloid-PET results to patients with subjective cognitive decline: the AMYPAD Diagnostic and Patient Management Study (DPMS). <i>Alzheimer's and Dementia</i> , 2020, 16, e040952.                             | 0.4 | 0         |
| 176 | Tau pathology, relative cerebral flow and cognition in dementia with Lewy bodies. <i>Alzheimer's and Dementia</i> , 2020, 16, e041048.   | 0.4 | 2         |
| 177 | Early-onset Alzheimer's disease is related to differential spatial patterns of tau pathology and cognitive impairment. <i>Alzheimer's and Dementia</i> , 2020, 16, e042041.  | 0.4 | 0         |
| 178 | Beyond aphasia: Natural history of the aphasia onset dementia syndromes. <i>Alzheimer's and Dementia</i> , 2020, 16, e042105.  | 0.4 | 0         |
| 179 | Polygenic risk score for Alzheimer's disease is related to amyloid positivity in subjective cognitive decline: The SCIENCE project. <i>Alzheimer's and Dementia</i> , 2020, 16, e042116.   | 0.4 | 0         |
| 180 | Energy intake and expenditure in patients with Alzheimer's disease and mild cognitive impairment: The NUDAD project. <i>Alzheimer's and Dementia</i> , 2020, 16, e042429.  | 0.4 | 1         |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 181 | Pronounced regional spectral, connectivity and network changes reflect visual deficits in posterior cortical atrophy: An EEG study on PCA. <i>Alzheimer's and Dementia</i> , 2020, 16, e042561.                            | 0.4 | 0         |
| 182 | Immune response and endocytosis pathways are associated with the resilience against Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e042614.  | 0.4 | 0         |
| 183 | Differential diagnosis of dementia combining web-based cognitive testing and MRI. <i>Alzheimer's and Dementia</i> , 2020, 16, e042626.   | 0.4 | 0         |
| 184 | Baseline features of the AMYPAD Diagnostic and Patient Management Study (DPMS) participants. <i>Alzheimer's and Dementia</i> , 2020, 16, e042628.  | 0.4 | 1         |
| 185 | Examining centiloid quantification against visual assessment using [18F]flutemetamol PET. <i>Alzheimer's and Dementia</i> , 2020, 16, e042653.   | 0.4 | 0         |
| 186 | Computerized decision support to select memory clinic patients for amyloid PET: Which patient to test?. <i>Alzheimer's and Dementia</i> , 2020, 16, e042687.   | 0.4 | 0         |
| 187 | BDNF polymorphism on top of amyloid pathology predisposes for faster cognitive decline in cognitively normal elderly: The SCIENCe Project. <i>Alzheimer's and Dementia</i> , 2020, 16, e042728.                            | 0.4 | 0         |
| 188 | Biomarker testing in MCI patients: Deciding who to tap. <i>Alzheimer's and Dementia</i> , 2020, 16, e042735.   | 0.4 | 0         |
| 189 | Neurofilament light and cognitive performance: Associations with amyloid and vascular pathologies in individuals with mild cognitive impairment. <i>Alzheimer's and Dementia</i> , 2020, 16, e042739.                      | 0.4 | 0         |
| 190 | A loss of neuronal inhibition best explains EEG abnormalities in preclinical Alzheimer's disease: A multiscale computational modeling study. <i>Alzheimer's and Dementia</i> , 2020, 16, e043262.                          | 0.4 | 0         |
| 191 | Current status and quantitative results of the AMYPAD prognostic and natural history study. <i>Alzheimer's and Dementia</i> , 2020, 16, e044711.   | 0.4 | 0         |
| 192 | Dutch Brain Research Registry for online study participant recruitment: Design and first results. <i>Alzheimer's and Dementia</i> , 2020, 16, e044738.   | 0.4 | 0         |
| 193 | An RCT to identify best practices for disclosure of amyloid imaging results in mild cognitive impairment: The ABIDE simulation study. <i>Alzheimer's and Dementia</i> , 2020, 16, e044761.                                 | 0.4 | 0         |
| 194 | Serum glial fibrillary acidic protein and neurofilament light as prognostic biomarkers for clinical progression in subjective cognitive decline: The SCIENCe project. <i>Alzheimer's and Dementia</i> , 2020, 16, e044783. | 0.4 | 1         |
| 195 | Trajectories of decline in cognitively complex everyday activities across the Alzheimer's disease continuum. <i>Alzheimer's and Dementia</i> , 2020, 16, e044787.  | 0.4 | 1         |
| 196 | Heterogeneous distribution of pathology in behavioral variant Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e044830.  | 0.4 | 1         |
| 197 | Amyloid aggregation and subsequent memory decline over time in cognitively intact older identical twins. <i>Alzheimer's and Dementia</i> , 2020, 16, e045112.  | 0.4 | 0         |
| 198 | Using cerebrospinal fluid amyloid-beta (1-42) in the memory clinic: Concordance with PET and use of biomarker ratios across immunoassays. <i>Alzheimer's and Dementia</i> , 2020, 16, e045128.                             | 0.4 | 3         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 199 | Serum neurofilament light in memory clinic practice. <i>Alzheimer's and Dementia</i> , 2020, 16, e045155.   | 0.4 | 0         |
| 200 | Amyloid pathology, but not vascular pathology, is associated with risk of incident dementia in non-demented memory clinic participants. <i>Alzheimer's and Dementia</i> , 2020, 16, e045196.  | 0.4 | 0         |
| 201 | Grey zone amyloid burden heralds future memory decline: The SCIENCE Project. <i>Alzheimer's and Dementia</i> , 2020, 16, e045210.   | 0.4 | 0         |
| 202 | Cerebrospinal fluid proteomic profiles predict progression to dementia in prodromal AD. <i>Alzheimer's and Dementia</i> , 2020, 16, e045230.  | 0.4 | 1         |
| 203 | The evolution of neuropsychiatric symptoms in atypical variants of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e045236.  | 0.4 | 2         |
| 204 | Plasma biomarkers predict amyloid pathology in cognitively unimpaired individuals. <i>Alzheimer's and Dementia</i> , 2020, 16, e045470.   | 0.4 | 0         |
| 205 | A mixed-methods approach to establish clinically meaningful categories of impairment in instrumental activities of daily living. <i>Alzheimer's and Dementia</i> , 2020, 16, e045693.   | 0.4 | 2         |
| 206 | Plasma amyloid $\beta$ oligomerization assay as a screening test for abnormal amyloid status. <i>Alzheimer's and Dementia</i> , 2020, 16, e045754.  | 0.4 | 0         |
| 207 | Assessment of cortical vulnerability of the anterior cingulate cortex in the behavioral variant of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e045770.  | 0.4 | 0         |
| 208 | Regional tau pathology is associated with loss of synapses and reduced synaptic activity: A combined [ $^{18}$ F]flortaucipir, [ $^{11}$ C]UCB-J and magnetoencephalography study. <i>Alzheimer's and Dementia</i> , 2020, 16, e045806. | 0.4 | 0         |
| 209 | Identifying and predicting heterogeneity in cognitive decline among individuals with prodromal Alzheimer's disease using a latent class analysis. <i>Alzheimer's and Dementia</i> , 2020, 16, e045829.                                  | 0.4 | 1         |
| 210 | DNA methylation differences associated with peripheral biomarkers in the EMIF-AD cohort. <i>Alzheimer's and Dementia</i> , 2020, 16, e045853.   | 0.4 | 0         |
| 211 | Regional distribution of tau pathology in cognitively unimpaired, genetically identical twins. <i>Alzheimer's and Dementia</i> , 2020, 16, e045876.   | 0.4 | 0         |
| 212 | Increased $^{18}$ F-flortaucipir load correlates with changes in MEG functional connectivity and network topology, as well as oscillatory slowing. <i>Alzheimer's and Dementia</i> , 2020, 16, e045911.                                 | 0.4 | 0         |
| 213 | Synaptic proteins relate to memory scores in preclinical Alzheimer's disease and cognitively healthy controls depending on amyloid. <i>Alzheimer's and Dementia</i> , 2020, 16, e046102.  | 0.4 | 0         |
| 214 | Decline in cognitively complex everyday activities accelerates along the Alzheimer's disease continuum. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 138.  | 3.0 | 14        |
| 215 | CDH6 and HACH protein levels in plasma associate with Alzheimer's disease in APOE $\epsilon$ 4 carriers. <i>Scientific Reports</i> , 2020, 10, 8233.  | 1.6 | 17        |
| 216 | Validation of Plasma Proteomic Biomarkers Relating to Brain Amyloid Burden in the EMIF-Alzheimer's Disease Multimodal Biomarker Discovery Cohort. <i>Journal of Alzheimer's Disease</i> , 2020, 74, 213-225.                            | 1.2 | 13        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 217 | A decade of Alzheimer's Research & Therapy: reflections on the past, present, and future. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 67.  | 3.0 | 2         |
| 218 | Tau pathology and relative cerebral blood flow are independently associated with cognition in Alzheimer's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 3165-3175.                    | 3.3 | 28        |
| 219 | APOE $\epsilon$ 4 genotype-dependent cerebrospinal fluid proteomic signatures in Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 65.  | 3.0 | 28        |
| 220 | ATN classification and clinical progression in subjective cognitive decline. <i>Neurology</i> , 2020, 95, e46-e58.   | 1.5 | 97        |
| 221 | Education as Proxy for Cognitive Reserve in a Large Elderly Memory Clinic: â€˜Window of Benefitâ€™. <i>Journal of Alzheimer's Disease</i> , 2020, 76, 671-679.   | 1.2 | 20        |
| 222 | Pre-trained MRI-based Alzheimer's disease classification models to classify memory clinic patients. <i>NeuroImage: Clinical</i> , 2020, 27, 102303.  | 1.4 | 4         |
| 223 | Reproducibility of EEG functional connectivity in Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 68.   | 3.0 | 73        |
| 224 | A Suboptimal Diet Is Associated with Poorer Cognition: The NUDAD Project. <i>Nutrients</i> , 2020, 12, 703.  | 1.7 | 21        |
| 225 | Degree of genetic liability for Alzheimer's disease associated with specific proteomic profiles in cerebrospinal fluid. <i>Neurobiology of Aging</i> , 2020, 93, 144.e1-144.e15.   | 1.5 | 7         |
| 226 | PLCG2 protective variant p.P522R modulates tau pathology and disease progression in patients with mild cognitive impairment. <i>Acta Neuropathologica</i> , 2020, 139, 1025-1044.  | 3.9 | 40        |
| 227 | Effectiveness of Pharmacological Interventions for Symptoms of Behavioral Variant Frontotemporal Dementia: A Systematic Review. <i>Cognitive and Behavioral Neurology</i> , 2020, 33, 1-15.                                    | 0.5 | 21        |
| 228 | Gait Disturbances are Associated with Increased Cognitive Impairment and Cerebrospinal Fluid Tau Levels in a Memory Clinic Cohort. <i>Journal of Alzheimer's Disease</i> , 2020, 76, 1061-1070.                                | 1.2 | 13        |
| 229 | Associations Between Nutrient Intake and Corresponding Nutritional Biomarker Levels in Blood in a Memory Clinic Cohort: The NUDAD Project. <i>Journal of the American Medical Directors Association</i> , 2020, 21, 1436-1438. | 1.2 | 1         |
| 230 | Diagnostic and prognostic value of EEG in prodromal dementia with Lewy bodies. <i>Neurology</i> , 2020, 95, e662-e670.   | 1.5 | 28        |
| 231 | Worldwide FINGERS Network: A global approach to risk reduction and prevention of dementia. <i>Alzheimer's and Dementia</i> , 2020, 16, 1078-1094.  | 0.4 | 257       |
| 232 | Longitudinal Maintenance of Cognitive Health in Centenarians in the 100-plus Study. <i>JAMA Network Open</i> , 2020, 3, e200094.   | 2.8 | 26        |
| 233 | Fingerprinting Alzheimer's Disease by <sup>1</sup> H Nuclear Magnetic Resonance Spectroscopy of Cerebrospinal Fluid. <i>Journal of Proteome Research</i> , 2020, 19, 1696-1705.  | 1.8 | 32        |
| 234 | Plasma amyloid is associated with the rate of cognitive decline in cognitively normal elderly: the SCIENCe project. <i>Neurobiology of Aging</i> , 2020, 89, 99-107.   | 1.5 | 34        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 235 | Selection of memory clinic patients for CSF biomarker assessment can be restricted to a quarter of cases by using computerized decision support, without compromising diagnostic accuracy. PLoS ONE, 2020, 15, e0226784.                              | 1.1 | 7         |
| 236 | Regional [ <sup>18</sup> F]flortaucipir PET is more closely associated with disease severity than CSF p-tau in Alzheimer's disease. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 2866-2878.                                  | 3.3 | 29        |
| 237 | Quantitative amyloid PET in Alzheimer's disease: the AMYPAD prognostic and natural history study. Alzheimer's and Dementia, 2020, 16, 750-758.  | 0.4 | 29        |
| 238 | The Cognitive-Functional Composite is sensitive to clinical progression in early dementia: Longitudinal findings from the Catch-Cog study cohort. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2020, 6, e12020.       | 1.8 | 18        |
| 239 | Evaluating severity of white matter lesions from computed tomography images with convolutional neural network. Neuroradiology, 2020, 62, 1257-1263.   | 1.1 | 8         |
| 240 | Specific Nutritional Biomarker Profiles in Mild Cognitive Impairment and Subjective Cognitive Decline Are Associated With Clinical Progression: The NUDAD Project. Journal of the American Medical Directors Association, 2020, 21, 1513.e1-1513.e17. | 1.2 | 17        |
| 241 | Single-subject gray matter networks predict future cortical atrophy in preclinical Alzheimer's disease. Neurobiology of Aging, 2020, 94, 71-80.   | 1.5 | 14        |
| 242 | Understanding multifactorial brain changes in type 2 diabetes: a biomarker perspective. Lancet Neurology, The, 2020, 19, 699-710.   | 4.9 | 96        |
| 243 | Pathophysiological subtypes of Alzheimer's disease based on cerebrospinal fluid proteomics. Brain, 2020, 143, 3776-3792.  | 3.7 | 89        |
| 244 | Grey matter network trajectories across the Alzheimer's disease continuum and relation to cognition. Brain Communications, 2020, 2, fcaa177.  | 1.5 | 10        |
| 245 | Combination of plasma amyloid beta(1-42/1-40) and glial fibrillary acidic protein strongly associates with cerebral amyloid pathology. Alzheimer's Research and Therapy, 2020, 12, 118.   | 3.0 | 129       |
| 246 | Amyloid- $\beta^2$ misfolding as a plasma biomarker indicates risk for future clinical Alzheimer's disease in individuals with subjective cognitive decline. Alzheimer's Research and Therapy, 2020, 12, 169.   | 3.0 | 31        |
| 247 | Evaluation of a novel immunoassay to detect p-tau Thr217 in the CSF to distinguish Alzheimer disease from other dementias. Neurology, 2020, 95, e3026-e3035.  | 1.5 | 31        |
| 248 | LDL cholesterol and uridine levels in blood are potential nutritional biomarkers of AD progression: The NUDAD project. Alzheimer's and Dementia, 2020, 16, .  | 0.4 | 2         |
| 249 | White matter integrity disruption in early amyloid accumulators. Alzheimer's and Dementia, 2020, 16, e043021.   | 0.4 | 0         |
| 250 | LDL cholesterol and uridine levels in blood are potential nutritional biomarkers for clinical progression in Alzheimer's disease: The NUDAD project. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12120.        | 1.2 | 7         |
| 251 | TARGETING LIFESTYLE BEHAVIOR TO IMPROVE BRAIN HEALTH: USER-EXPERIENCES OF AN ONLINE PROGRAM FOR INDIVIDUALS WITH SUBJECTIVE COGNITIVE DECLINE. journal of prevention of Alzheimer's disease, The, 2020, 7, 1-11.                                      | 1.5 | 2         |
| 252 | An Operational Definition of "Abnormal Cognition" to Optimize the Prediction of Progression to Dementia: What Are Optimal Cut-Off Points for Univariate and Multivariate Normative Comparisons?. Journal of Alzheimer's Disease, 2020, 77, 1693-1703. | 1.2 | 2         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 253 | Title is missing!. , 2020, 15, e0226784.  |     | 0         |
| 254 | Title is missing!. , 2020, 15, e0226784.  |     | 0         |
| 255 | Title is missing!. , 2020, 15, e0226784.  |     | 0         |
| 256 | Title is missing!. , 2020, 15, e0226784.  |     | 0         |
| 257 | Medial temporal lobe atrophy relates more strongly to sleep-wake rhythm fragmentation than to age or any other known risk. <i>Neurobiology of Learning and Memory</i> , 2019, 160, 132-138.                             | 1.0 | 49        |
| 258 | Survival in memory clinic cohort is short, even in young-onset dementia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 726-728.  | 0.9 | 22        |
| 259 | Quantification of [ <sup>18</sup> F]florbetapir: A test-retest tracer kinetic modelling study. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2019, 39, 2172-2180.  | 2.4 | 22        |
| 260 | Added value of amyloid PET in individualized risk predictions for MCI patients. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019, 11, 529-537.                                      | 1.2 | 8         |
| 261 | Cerebral amyloid burden is associated with white matter hyperintensity location in specific posterior white matter regions. <i>Neurobiology of Aging</i> , 2019, 84, 225-234.   | 1.5 | 42        |
| 262 | Clinician-patient communication during the diagnostic workup: The ABIDE project. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019, 11, 520-528.                                     | 1.2 | 23        |
| 263 | Retinal thickness as potential biomarker in posterior cortical atrophy and typical Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 62.   | 3.0 | 40        |
| 264 | Cognitive and functional progression of dementia in two longitudinal studies. <i>International Journal of Geriatric Psychiatry</i> , 2019, 34, 1623-1632.   | 1.3 | 6         |
| 265 | Retinal thickness as a potential biomarker in patients with amyloid-proven early and late-onset Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019, 11, 463-471. | 1.2 | 25        |
| 266 | Cognitive reserve and clinical progression in Alzheimer disease. <i>Neurology</i> , 2019, 93, e334-e346.  | 1.5 | 85        |
| 267 | Prognostic value of Alzheimer's biomarkers in mild cognitive impairment: the effect of age at onset. <i>Journal of Neurology</i> , 2019, 266, 2535-2545.  | 1.8 | 11        |
| 268 | Associations between quantitative [18F]florbetapir tau PET and atrophy across the Alzheimer's disease spectrum. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 60.   | 3.0 | 40        |
| 269 | Applying the ATN scheme in a memory clinic population. <i>Neurology</i> , 2019, 93, e1635-e1646.  | 1.5 | 51        |
| 270 | Assessment of the appropriate use criteria for amyloid PET in an unselected memory clinic cohort: The ABIDE project. <i>Alzheimer's and Dementia</i> , 2019, 15, 1458-1467.   | 0.4 | 18        |



| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 271 | Amyloid- $\beta$ peptides in cerebrospinal fluid of patients with dementia with Lewy bodies. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 83.   | 3.0 | 23        |
| 272 | Cerebrospinal Fluid Amyloid- $\beta$ Subtypes in Confirmed Frontotemporal Lobar Degeneration Cases: A Pilot Study. <i>Journal of Alzheimer's Disease</i> , 2019, 71, 15-20.  | 1.2 | 2         |
| 273 | Exploring effects of Souvenaid on cerebral glucose metabolism in Alzheimer's disease. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2019, 5, 492-500.   | 1.8 | 5         |
| 274 | "Alzheimer's disease" is neither "Alzheimer's clinical syndrome" nor "dementia". <i>Alzheimer's and Dementia</i> , 2019, 15, 153-157.  | 0.4 | 23        |
| 275 | Use of mild cognitive impairment and prodromal AD/MCI due to AD in clinical care: a European survey. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 74.   | 3.0 | 28        |
| 276 | The "rights" of precision drug development for Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 76.  | 3.0 | 148       |
| 277 | Discovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assay. <i>Alzheimer's and Dementia</i> , 2019, 15, 1478-1488.   | 0.4 | 46        |
| 278 | Re-aligning scientific and lay narratives of Alzheimer's disease. <i>Lancet Neurology</i> , The, 2019, 18, 918-919.  | 4.9 | 31        |
| 279 | Discordant amyloid- $\beta$ PET and CSF biomarkers and its clinical consequences. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 78.  | 3.0 | 40        |
| 280 | Biomarker-based prognosis for people with mild cognitive impairment (ABIDE): a modelling study. <i>Lancet Neurology</i> , The, 2019, 18, 1034-1044.  | 4.9 | 85        |
| 281 | Testing Episodic Memory in Elderly Subjects: Not as Simple as It Looks. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2019, 9, 207-216.  | 0.6 | 1         |
| 282 | Amyloid- $\beta$ Load Is Related to Worries, but Not to Severity of Cognitive Complaints in Individuals With Subjective Cognitive Decline: The SCIENCE Project. <i>Frontiers in Aging Neuroscience</i> , 2019, 11, 7.                  | 1.7 | 37        |
| 283 | Associations of AD Biomarkers and Cognitive Performance with Nutritional Status: The NUDAD Project. <i>Nutrients</i> , 2019, 11, 1161.   | 1.7 | 25        |
| 284 | A nonsynonymous mutation in <i>PLCG2</i> reduces the risk of Alzheimer's disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity. <i>Acta Neuropathologica</i> , 2019, 138, 237-250. | 3.9 | 87        |
| 285 | Cerebrospinal fluid collection: An informative animation video for patients and caregivers. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019, 11, 435-438.   | 1.2 | 4         |
| 286 | White Matter Hyperintensities and Hippocampal Atrophy in Relation to Cognition: The 90+ Study. <i>Journal of the American Geriatrics Society</i> , 2019, 67, 1827-1834.  | 1.3 | 28        |
| 287 | Duration of preclinical, prodromal, and dementia stages of Alzheimer's disease in relation to age, sex, and <i>APOE</i> genotype. <i>Alzheimer's and Dementia</i> , 2019, 15, 888-898.   | 0.4 | 290       |
| 288 | Gray matter T1w/T2w ratios are higher in Alzheimer's disease. <i>Human Brain Mapping</i> , 2019, 40, 3900-3909.  | 1.9 | 33        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 289 | A $\beta$ 234 is a BACE1-derived degradation intermediate associated with amyloid clearance and Alzheimer's disease progression. <i>Nature Communications</i> , 2019, 10, 2240.  | 5.8 | 39        |
| 290 | Early recognition and treatment of neuropsychiatric symptoms to improve quality of life in early Alzheimer's disease: protocol of the BEAT-IT study. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 48.   | 3.0 | 14        |
| 291 | Primary fatty amides in plasma associated with brain amyloid burden, hippocampal volume, and memory in the European Medical Information Framework for Alzheimer's Disease biomarker discovery cohort. <i>Alzheimer's and Dementia</i> , 2019, 15, 817-827. | 0.4 | 62        |
| 292 | Alzheimer disease biomarkers may aid in the prognosis of MCI cases initially reverted to normal. <i>Neurology</i> , 2019, 92, e2699-e2705.   | 1.5 | 10        |
| 293 | High amyloid burden is associated with fewer specific words during spontaneous speech in individuals with subjective cognitive decline. <i>Neuropsychologia</i> , 2019, 131, 184-192.  | 0.7 | 22        |
| 294 | Dietary Patterns Are Related to Clinical Characteristics in Memory Clinic Patients with Subjective Cognitive Decline: The SCIENCE Project. <i>Nutrients</i> , 2019, 11, 1057.  | 1.7 | 10        |
| 295 | Is retinal vasculature a biomarker in amyloid proven Alzheimer's disease?. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019, 11, 383-391.  | 1.2 | 53        |
| 296 | Assessing cognition and daily function in early dementia using the cognitive-functional composite: findings from the Catch-Cog study cohort. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 45.   | 3.0 | 19        |
| 297 | Driving Difficulties Among Patients with Alzheimer's Disease and Other Neurodegenerative Disorders. <i>Journal of Alzheimer's Disease</i> , 2019, 69, 1019-1030.   | 1.2 | 15        |
| 298 | Inflammatory biomarkers in Alzheimer's disease plasma. <i>Alzheimer's and Dementia</i> , 2019, 15, 776-787.  | 0.4 | 134       |
| 299 | Personalized risk for clinical progression in cognitively normal subjects—the ABIDE project. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 33.   | 3.0 | 30        |
| 300 | How Do Different Forms of Vascular Brain Injury Relate to Cognition in a Memory Clinic Population: The TRACE-VCI Study. <i>Journal of Alzheimer's Disease</i> , 2019, 68, 1273-1286.   | 1.2 | 4         |
| 301 | ApoE and clusterin CSF levels influence associations between APOE genotype and changes in CSF tau, but not CSF A $\beta$ 42, levels in non-demented elderly. <i>Neurobiology of Aging</i> , 2019, 79, 101-109.   | 1.5 | 12        |
| 302 | Modeling grey matter atrophy as a function of time, aging or cognitive decline show different anatomical patterns in Alzheimer's disease. <i>NeuroImage: Clinical</i> , 2019, 22, 101786.  | 1.4 | 27        |
| 303 | Cerebrospinal fluid biomarkers of neurodegeneration, synaptic integrity, and astroglial activation across the clinical Alzheimer's disease spectrum. <i>Alzheimer's and Dementia</i> , 2019, 15, 644-654.  | 0.4 | 90        |
| 304 | Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer's disease continuum in the BIOMARKAPD study. <i>Alzheimer's and Dementia</i> , 2019, 15, 742-753.  | 0.4 | 82        |
| 305 | Amyloid PET and cognitive decline in cognitively normal individuals: the SCIENCE project. <i>Neurobiology of Aging</i> , 2019, 79, 50-58.  | 1.5 | 41        |
| 306 | Automatically computed rating scales from MRI for patients with cognitive disorders. <i>European Radiology</i> , 2019, 29, 4937-4947.  | 2.3 | 23        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 307 | Association of amyloid pathology with memory performance and cognitive complaints in cognitively normal older adults: a monozygotic twin study. <i>Neurobiology of Aging</i> , 2019, 77, 58-65.   | 1.5 | 14        |
| 308 | The Clinical Phenotype of Vascular Cognitive Impairment in Patients with Type 2 Diabetes Mellitus. <i>Journal of Alzheimer's Disease</i> , 2019, 68, 311-322.   | 1.2 | 16        |
| 309 | F3â€1â€01: THE DIAGNOSTIC FRAMEWORK FOR ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2019, 15, P863.  | 0.4 | 0         |
| 310 | ICâ€Pâ€100: A LONGITUDINAL STUDY OF THE EFFECTS OF EDUCATION AND INTRACRANIAL VOLUME ON COGNITIVE CHANGES AND MORTALITY RATES IN ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2019, 15, P87.  | 0.4 | 0         |
| 311 | Can post-mortem MRI be used as a proxy for in vivo? A case study. <i>Brain Communications</i> , 2019, 1, fcz030.  | 1.5 | 17        |
| 312 | The plasma peptides of breast versus ovarian cancer. <i>Clinical Proteomics</i> , 2019, 16, 43.   | 1.1 | 16        |
| 313 | P4â€525: ASSOCIATION OF CSF TAU WITH HYPERPLASTICITY IN ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2019, 15, P1515.  | 0.4 | 0         |
| 314 | F2â€01â€01: NEURODEVELOPMENTAL DIFFERENCES AND ENVIRONMENTAL INSULTS INVERSELY CORRELATE WITH AGE OF ONSET IN ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2019, 15, P515.  | 0.4 | 0         |
| 315 | ICâ€Pâ€025: GREY MATTER CONNECTIVITY TRAJECTORIES ACROSS THE ALZHEIMER'S DISEASE CONTINUUM AND ASSOCIATIONS WITH COGNITIVE DECLINE. <i>Alzheimer's and Dementia</i> , 2019, 15, P32.  | 0.4 | 0         |
| 316 | ICâ€02â€01: GREY MATTER CONNECTIVITY TRAJECTORIES ACROSS THE ALZHEIMER'S DISEASE CONTINUUM AND ASSOCIATIONS WITH COGNITIVE DECLINE. <i>Alzheimer's and Dementia</i> , 2019, 15, P1.   | 0.4 | 0         |
| 317 | ICâ€Pâ€076: FDGâ€PET REVEALS DISTINCT HYPOMETABOLIC TRAJECTORIES IN COGNITIVELYâ€DEFINED SUBGROUPS OF ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2019, 15, P68.   | 0.4 | 0         |
| 318 | A metaboliteâ€based machine learning approach to diagnose Alzheimerâ€type dementia in blood: Results from the European Medicalâ€Information Framework for Alzheimer disease biomarker discovery cohort. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2019, 5, 933-938. | 1.8 | 70        |
| 319 | ICâ€Pâ€015: VOXELâ€BASED AMYLOID PET STAGING FOR THE WHOLE ALZHEIMER'S DISEASE <i>CONTINUUM</i>. <i>Alzheimer's and Dementia</i> , 2019, 15, P24.  | 0.4 | 0         |
| 320 | ICâ€Pâ€097: DIFFERENTIATING THE BEHAVIOURAL VARIANT OF ALZHEIMER'S DISEASE FROM BEHAVIOURAL VARIANT FRONTOTEMPORAL DEMENTIA AND TYPICAL ALZHEIMER'S DISEASE: THE VALUE OF NEUROIMAGING. <i>Alzheimer's and Dementia</i> , 2019, 15, P84.  | 0.4 | 0         |
| 321 | PET and CSF amyloid- $\beta^2$ status are differently predicted by patient features: information from discordant cases. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 100.  | 3.0 | 21        |
| 322 | Subjective cognitive decline and rates of incident Alzheimer's disease and nonâ€Alzheimer's disease dementia. <i>Alzheimer's and Dementia</i> , 2019, 15, 465-476.   | 0.4 | 232       |
| 323 | Neuropsychological Test Performance of Cognitively Healthy Centenarians: Normative Data From the Dutch 100â€Plus Study. <i>Journal of the American Geriatrics Society</i> , 2019, 67, 759-767.   | 1.3 | 19        |
| 324 | Decision tree supports the interpretation of CSF biomarkers in Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019, 11, 1-9.  | 1.2 | 14        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 325 | Impairment in complex activities of daily living is related to neurodegeneration in Alzheimer's disease-specific regions. <i>Neurobiology of Aging</i> , 2019, 75, 109-116.   | 1.5 | 22        |
| 326 | AMYPAD Diagnostic and Patient Management Study: Rationale and design. <i>Alzheimer's and Dementia</i> , 2019, 15, 388-399.  | 0.4 | 37        |
| 327 | Data-driven approaches for tau-PET imaging biomarkers in Alzheimer's disease. <i>Human Brain Mapping</i> , 2019, 40, 638-651.   | 1.9 | 27        |
| 328 | Predicting progression in the late onset frontal lobe syndrome. <i>International Psychogeriatrics</i> , 2019, 31, 743-748.  | 0.6 | 6         |
| 329 | Assessing Amyloid Pathology in Cognitively Normal Subjects Using <sup>18</sup> F-Flutemetamol PET: Comparing Visual Reads and Quantitative Methods. <i>Journal of Nuclear Medicine</i> , 2019, 60, 541-547.   | 2.8 | 47        |
| 330 | Repeat length variations in ATXN1 and AR modify disease expression in Alzheimer's disease. <i>Neurobiology of Aging</i> , 2019, 73, 230.e9-230.e17.   | 1.5 | 7         |
| 331 | Centenarian controls increase variant effect sizes by an average twofold in an extreme case extreme control analysis of Alzheimer's disease. <i>European Journal of Human Genetics</i> , 2019, 27, 244-253.   | 1.4 | 46        |
| 332 | Auditory hallucinations in adults with hearing impairment: a large prevalence study. <i>Psychological Medicine</i> , 2019, 49, 132-139.   | 2.7 | 30        |
| 333 | Impact of white matter hyperintensity location on depressive symptoms in memory-clinic patients: a lesion-symptom mapping study. <i>Journal of Psychiatry and Neuroscience</i> , 2019, 44, E1-E10.  | 1.4 | 9         |
| 334 | Development and Usability of ADappt: Web-Based Tool to Support Clinicians, Patients, and Caregivers in the Diagnosis of Mild Cognitive Impairment and Alzheimer Disease. <i>JMIR Formative Research</i> , 2019, 3, e13417.                                    | 0.7 | 38        |
| 335 | Neurogranin as Cerebrospinal Fluid Biomarker for Alzheimer Disease: An Assay Comparison Study. <i>Clinical Chemistry</i> , 2018, 64, 927-937.   | 1.5 | 37        |
| 336 | White matter hyperintensities and vascular risk factors in monozygotic twins. <i>Neurobiology of Aging</i> , 2018, 66, 40-48.   | 1.5 | 20        |
| 337 | Understanding hallucinations in probable Alzheimer's disease: Very low prevalence rates in a tertiary memory clinic. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018, 10, 358-362.                                       | 1.2 | 13        |
| 338 | An exploratory clinical study of p38 kinase inhibition in Alzheimer's disease. <i>Annals of Clinical and Translational Neurology</i> , 2018, 5, 464-473.  | 1.7 | 43        |
| 339 | EEG-based neurophysiological indicators of hallucinations in Alzheimer's disease: Comparison with dementia with Lewy bodies. <i>Neurobiology of Aging</i> , 2018, 67, 75-83.  | 1.5 | 21        |
| 340 | Plasma Amyloid- $\beta^2$ (A $\beta^2$ ) Correlates with Cerebrospinal Fluid A $\beta^2$ in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2018, 62, 1857-1863.   | 1.2 | 100       |
| 341 | Single Subject Classification of Alzheimer's Disease and Behavioral Variant Frontotemporal Dementia Using Anatomical, Diffusion Tensor, and Resting-State Functional Magnetic Resonance Imaging. <i>Journal of Alzheimer's Disease</i> , 2018, 62, 1827-1839. | 1.2 | 33        |
| 342 | NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2018, 14, 535-562.  | 0.4 | 5,861     |

| #   | ARTICLE  | IF   | CITATIONS |
|-----|--|------|-----------|
| 343 | A more randomly organized grey matter network is associated with deteriorating language and global cognition in individuals with subjective cognitive decline. <i>Human Brain Mapping</i> , 2018, 39, 3143-3151.                                 | 1.9  | 40        |
| 344 | Social Cognition Differentiates Behavioral Variant Frontotemporal Dementia From Other Neurodegenerative Diseases and Psychiatric Disorders. <i>American Journal of Geriatric Psychiatry</i> , 2018, 26, 569-579.                                 | 0.6  | 31        |
| 345 | Biomarker pattern of ARIA-E participants in phase 3 randomized clinical trials with bapineuzumab. <i>Neurology</i> , 2018, 90, e877-e886.  | 1.5  | 28        |
| 346 | Vascular cognitive impairment. <i>Nature Reviews Disease Primers</i> , 2018, 4, 18003.   | 18.1 | 358       |
| 347 | Subjective Cognitive Decline Is Associated With Altered Default Mode Network Connectivity in Individuals With a Family History of Alzheimer's Disease. <i>Biological Psychiatry: Cognitive Neuroscience and Neuroimaging</i> , 2018, 3, 463-472. | 1.1  | 41        |
| 348 | A novel cognitive-functional composite measure to detect changes in early Alzheimer's disease: Test-retest reliability and feasibility. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018, 10, 153-160.       | 1.2  | 12        |
| 349 | Microbleeds are associated with depressive symptoms in Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018, 10, 112-120.   | 1.2  | 7         |
| 350 | Circulating metabolites and general cognitive ability and dementia: Evidence from 11 cohort studies. <i>Alzheimer's and Dementia</i> , 2018, 14, 707-722.  | 0.4  | 143       |
| 351 | Disease-related determinants are associated with mortality in dementia due to Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 23.   | 3.0  | 20        |
| 352 | Cerebral White Matter Lesions have Low Impact on Cognitive Function in a Large Elderly Memory Clinic Population. <i>Journal of Alzheimer's Disease</i> , 2018, 63, 1129-1139.  | 1.2  | 9         |
| 353 | European Prevention of Alzheimer's Dementia Registry: Recruitment and prescreening approach for a longitudinal cohort and prevention trials. <i>Alzheimer's and Dementia</i> , 2018, 14, 837-842.  | 0.4  | 20        |
| 354 | Prevalence of the apolipoprotein E $\epsilon$ 4 allele in amyloid $\beta$ positive subjects across the spectrum of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2018, 14, 913-924.   | 0.4  | 58        |
| 355 | Upward drift in cerebrospinal fluid amyloid $\beta$ 42 assay values for more than 10 years. <i>Alzheimer's and Dementia</i> , 2018, 14, 62-70.   | 0.4  | 50        |
| 356 | Thinner cortex in patients with subjective cognitive decline is associated with steeper decline of memory. <i>Neurobiology of Aging</i> , 2018, 61, 238-244.   | 1.5  | 23        |
| 357 | Gray matter networks and clinical progression in subjects with predementia Alzheimer's disease. <i>Neurobiology of Aging</i> , 2018, 61, 75-81.  | 1.5  | 52        |
| 358 | Gray matter network measures are associated with cognitive decline in mild cognitive impairment. <i>Neurobiology of Aging</i> , 2018, 61, 198-206.   | 1.5  | 44        |
| 359 | Association of Cerebral Amyloid- $\beta$ Aggregation With Cognitive Functioning in Persons Without Dementia. <i>JAMA Psychiatry</i> , 2018, 75, 84.  | 6.0  | 133       |
| 360 | Unbiased Approach to Counteract Upward Drift in Cerebrospinal Fluid Amyloid- $\beta$ 1-42 Analysis Results. <i>Clinical Chemistry</i> , 2018, 64, 576-585.   | 1.5  | 126       |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 361 | Retinal thickness correlates with parietal cortical atrophy in early-onset Alzheimer's disease and controls. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018, 10, 49-55.                    | 1.2 | 77        |
| 362 | Differential effects of cognitive reserve and brain reserve on cognition in Alzheimer disease. <i>Neurology</i> , 2018, 90, e149-e156.   | 1.5 | 103       |
| 363 | Assessing Fitness to Drive in Patients With Different Types of Dementia. <i>Alzheimer Disease and Associated Disorders</i> , 2018, 32, 70-75.  | 0.6 | 26        |
| 364 | P3-403: LOSS OF GREY MATTER CONNECTIVITY IN THE PRECLINICAL IS ASSOCIATED WITH FASTER ATROPHY RATES IN PRECLINICAL ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2018, 14, P1257.                                       | 0.4 | 0         |
| 365 | O3-13-01: PATTERNS OF GLUCOSE HYPOMETABOLISM, SUBCORTICAL ATROPHY AND WHITE MATTER HYPERINTENSITIES IN THE BEHAVIORAL VARIANT OF ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2018, 14, P1054.                         | 0.4 | 0         |
| 366 | P1-476: CORTICAL T1W/T2W RATIO VALUES ARE HIGHER IN ALZHEIMER'S DISEASE COMPARED TO CONTROLS. <i>Alzheimer's and Dementia</i> , 2018, 14, P506.  | 0.4 | 0         |
| 367 | O1-14-04: IMPACT OF WHITE MATTER HYPERINTENSITY LOCATION ON DEPRESSIVE SYMPTOMS IN MEMORY CLINIC PATIENTS: A LESION-SYMP TOM MAPPING STUDY. <i>Alzheimer's and Dementia</i> , 2018, 14, P259.                                    | 0.4 | 0         |
| 368 | P2-470: DIFFERENT CO-LOCALIZATION OF NEUROINFLAMMATORY MARKERS IN PLAQUES OF ATYPICAL COMPARED TO TYPICAL ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2018, 14, P903.   | 0.4 | 0         |
| 369 | P3-216: IS THE RELATION BETWEEN BLOOD PRESSURE AND COGNITION DEPENDENT ON AMYLOID PATHOLOGY OR PHYSICAL PERFORMANCE? RESULTS OF THE EMIF-AD 90+ STUDY. <i>Alzheimer's and Dementia</i> , 2018, 14, P1153.                        | 0.4 | 0         |
| 370 | IC-PA-222: [18F]AV1451 PET IN RELATION TO ATROPHY ACROSS THE ALZHEIMER'S DISEASE SPECTRUM. <i>Alzheimer's and Dementia</i> , 2018, 14, P180.   | 0.4 | 0         |
| 371 | P2-270: INCREASED CSF AMYLOID $\beta$ 1-38 AND 1-40 CONCENTRATIONS IN INDIVIDUALS WITH MILD COGNITIVE IMPAIRMENT WITH TAU BUT WITHOUT AMYLOID PATHOPHYSIOLOGY. <i>Alzheimer's and Dementia</i> , 2018, 14, P780.                 | 0.4 | 0         |
| 372 | P1-333: DETECTING CLINICALLY RELEVANT CHANGES IN DEMENTIA USING INSTRUMENTAL ACTIVITIES OF DAILY LIVING: A LONGITUDINAL VALIDATION STUDY WITH 3, 6, 9 AND 12 MONTHS FOLLOW-UP. <i>Alzheimer's and Dementia</i> , 2018, 14, P420. | 0.4 | 0         |
| 373 | IC-PA-066: WHITE MATTER MICROSTRUCTURE AND AMYLOID AGGREGATION IN COGNITIVELY HEALTHY, ELDERLY IDENTICAL TWINS. <i>Alzheimer's and Dementia</i> , 2018, 14, P59.   | 0.4 | 0         |
| 374 | IC-PA-182: EVENT-BASED MODELING OF THE TEMPORAL ORDERING OF REGIONAL $\beta$ -AMYLOID DEPOSITION IN THE BRAIN. <i>Alzheimer's and Dementia</i> , 2018, 14, P152.   | 0.4 | 1         |
| 375 | P4-113: COMPARING THE COGNITIVE-FUNCTIONAL COMPOSITE WITH TRADITIONAL TESTS OF COGNITION AND FUNCTION: FINDINGS FROM THE CATCH-COG STUDY COHORT. <i>Alzheimer's and Dementia</i> , 2018, 14, P1482.                              | 0.4 | 0         |
| 376 | P3-233: PLASMA PRIMARY FATTY AMIDES ASSOCIATE TO CSF AMYLOID LEVELS AND ALZHEIMER'S DISEASE PROGRESSION IN THE EMIF-AD BIOMARKER DISCOVERY COHORT. <i>Alzheimer's and Dementia</i> , 2018, 14, P1161.                            | 0.4 | 0         |
| 377 | P1-357: MEDIAN SURVIVAL IN MEMORY CLINIC COHORT IS SHORT, EVEN IN YOUNG-ONSET DEMENTIA. <i>Alzheimer's and Dementia</i> , 2018, 14, P431.  | 0.4 | 0         |
| 378 | P1-016: METHYLPHENIDATE IMPROVES EXECUTIVE FUNCTIONING IN PATIENTS WITH VASCULAR COGNITIVE IMPAIRMENT: FIRST RESULTS OF THE STREAM-VCI STUDY. <i>Alzheimer's and Dementia</i> , 2018, 14, P270.                                  | 0.4 | 0         |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 379 | P1â€259: SEX DIFFERENCES IN CEREBROSPINAL FLUID BIOMARKER CONCENTRATIONS ACROSS CLINICAL STAGES OF ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2018, 14, P380.  | 0.4 | 0         |
| 380 | O2â€06â€03: AMYLOIDâ€12 LOAD IS RELATED TO WORRIES IN INDIVIDUALS WITH SUBJECTIVE COGNITIVE DECLINE. <i>Alzheimer's and Dementia</i> , 2018, 14, P632.   | 0.4 | 0         |
| 381 | P2â€248: CONTACTINâ€2 AS A POTENTIAL BIOMARKER FOR MILD COGNITIVE IMPAIRMENT. <i>Alzheimer's and Dementia</i> , 2018, 14, P768.  | 0.4 | 0         |
| 382 | ICâ€06â€05: LOSS OF GREY MATTER CONNECTIVITY IN THE PRECUNEUS IS ASSOCIATED WITH FASTER ATROPHY RATES IN PRECLINICAL ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2018, 14, P13.                               | 0.4 | 0         |
| 383 | O2â€04â€02: LONGITUDINAL COGNITIVE TRAJECTORIES OF PATIENTS WITH DISCORDANT CSF AND PET AMYLOID BIOMARKERS. <i>Alzheimer's and Dementia</i> , 2018, 14, P621.  | 0.4 | 0         |
| 384 | P1â€418: WHITE MATTER MICROSTRUCTURE AND AMYLOID AGGREGATION IN COGNITIVELY HEALTHY, ELDERLY IDENTICAL TWINS. <i>Alzheimer's and Dementia</i> , 2018, 14, P465.  | 0.4 | 0         |
| 385 | ICâ€Pâ€092: COGNITIVELY DEFINED SUBTYPES OF ALZHEIMER'S DISEASE ARE ASSOCIATED WITH DISTINCT PATTERNS OF ATROPHY. <i>Alzheimer's and Dementia</i> , 2018, 14, P76.   | 0.4 | 1         |
| 386 | P1â€525: AMYLOID AGGREGATION IS ASSOCIATED WITH DECLINE ON DIGIT SPAN BACKWARD IN COGNITIVELY NORMAL ELDERLY MONOZYGOTIC TWINS. <i>Alzheimer's and Dementia</i> , 2018, 14, P533.  | 0.4 | 0         |
| 387 | P4â€106: DECLINE IN GREY MATTER CONNECTIVITY OVER TIME IS RELATED TO CLINICAL PROGRESSION IN MCI DUE TO AD. <i>Alzheimer's and Dementia</i> , 2018, 14, P1479.   | 0.4 | 1         |
| 388 | P1â€297: METABOLIC BLOODâ€BASED BIOMARKERS RELATE TO BRAIN ATROPHY AND WHITE MATTER HYPERINTENSITIES IN ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2018, 14, P401.   | 0.4 | 0         |
| 389 | P2â€153: DIFFERENT CORTICAL NEURONAL VULNERABILITY IN DEMENTIA WITH AND WITHOUT PREDOMINANT BEHAVIOURAL SYMPTOMS. <i>Alzheimer's and Dementia</i> , 2018, 14, P726.  | 0.4 | 0         |
| 390 | P3â€438: PARAMETRIC IMAGING OF [ <sup>18</sup> F]FLORBETAPIR: A TESTâ€RETEST STUDY IN HEALTHY SUBJECTS AND PATIENTS WITH ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2018, 14, P1281.                         | 0.4 | 0         |
| 391 | P2â€349: DIFFERENT COMBINATIONS OF DIAGNOSTIC TESTS DISCRIMINATE SPECIFIC SUBTYPES OF DEMENTIA. <i>Alzheimer's and Dementia</i> , 2018, 14, P820.  | 0.4 | 0         |
| 392 | P1â€627: AMYLOID BURDEN IMPACTS EVERYDAY FUNCTIONING INDEPENDENT OF COGNITION AND AWARENESS IN SUBJECTIVE COGNITIVE DECLINE: FINDINGS FROM THE INSIGHT PREâ€AD COHORT. <i>Alzheimer's and Dementia</i> , 2018, 14, P581. | 0.4 | 0         |
| 393 | P2â€363: LATENT ATROPHY FACTORS IN POSTERIOR CORTICAL ATROPHY RELATE TO SPECIFIC COGNITIVE IMPAIRMENTS. <i>Alzheimer's and Dementia</i> , 2018, 14, P830.  | 0.4 | 0         |
| 394 | F1â€02â€04: GENOMICS AND EPIGENOMICS ANALYSES IN THE EMIFâ€AD MULTIMODAL BIOMARKER DISCOVERY STUDY. <i>Alzheimer's and Dementia</i> , 2018, 14, P204.  | 0.4 | 0         |
| 395 | P2â€134: THE ADDED VALUE OF EXTREME PHENOTYPES IN ALZHEIMER'S DISEASE CASEâ€CONTROL STUDIES. <i>Alzheimer's and Dementia</i> , 2018, 14, P719.   | 0.4 | 0         |
| 396 | P2â€360: [ <sup>18</sup> F]AV1451 PET IN RELATION TO ATROPHY ACROSS THE ALZHEIMER'S DISEASE SPECTRUM. <i>Alzheimer's and Dementia</i> , 2018, 14, P827.  | 0.4 | 0         |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 397 | P3â€264: UNBIASED METHOD TO DETERMINE CUTâ€POINTS FOR CSF TOTAL TAU LEVELS REVEALS PRESENCE OF BIOLOGICAL SUBTYPES IN A LARGE ALZHEIMER'S DISEASE POPULATION. <i>Alzheimer's and Dementia</i> , 2018, 14, P1176.                     | 0.4 | 0         |
| 398 | O2â€03â€03: COGNITIVELY DEFINED SUBTYPES OF ALZHEIMER'S DISEASE ARE ASSOCIATED WITH DISTINCT PATTERNS OF ATROPHY. <i>Alzheimer's and Dementia</i> , 2018, 14, P615.  | 0.4 | 0         |
| 399 | P4â€038: IS <i>SORL1</i> AN AUTOSOMAL DOMINANT ALZHEIMER GENE?. <i>Alzheimer's and Dementia</i> , 2018, 14, P1447.   | 0.4 | 0         |
| 400 | O5â€04â€01: A RARE GENETIC VARIANT IN THE <i>PLCG2</i> GENE IS ASSOCIATED WITH A REDUCED RISK OF ALL MAJOR TYPES OF DEMENTIA AND AN INCREASED RISK TO REACH AN EXTREMELY OLD AGE. <i>Alzheimer's and Dementia</i> , 2018, 14, P1648. | 0.4 | 0         |
| 401 | O2â€14â€04: IDENTIFYING BEHAVIORAL VARIANT FRONTOTEMPORAL DEMENTIA AMONG PATIENTS WITH A LATEâ€ONSET FRONTAL LOBE SYNDROME: SUMMARY RESULTS OF THE LOF STUDY. <i>Alzheimer's and Dementia</i> , 2018, 14, P657.                      | 0.4 | 0         |
| 402 | ICâ€Pâ€093: LATENT ATROPHY FACTORS IN POSTERIOR CORTICAL ATROPHY RELATE TO SPECIFIC COGNITIVE IMPAIRMENTS. <i>Alzheimer's and Dementia</i> , 2018, 14, P79.  | 0.4 | 0         |
| 403 | ICâ€Pâ€033: LONGITUDINAL CHANGES IN GREY MATTER CONNECTIVITY ARE RELATED TO COGNITIVE DECLINE IN PRODROMAL ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2018, 14, P37.   | 0.4 | 0         |
| 404 | P3â€342: INFLUENCE OF NETWORK CONSTRUCTION METHODS ON PATH LENGTH VALUES IN ALZHEIMER'S DISEASE: A MULTIâ€STUDY ANALYSIS OF MRI CONNECTIVITY STUDIES. <i>Alzheimer's and Dementia</i> , 2018, 14, P1214.                             | 0.4 | 0         |
| 405 | ICâ€Pâ€032: INFLUENCE OF NETWORK CONSTRUCTION METHODS ON PATH LENGTH VALUES IN ALZHEIMER'S DISEASE: A MULTIâ€STUDY ANALYSIS OF MRI CONNECTIVITY STUDIES. <i>Alzheimer's and Dementia</i> , 2018, 14, P36.                            | 0.4 | 0         |
| 406 | P3â€272: A COMPARISON OF EEG CONNECTIVITY OUTCOME MEASURES FOR ALZHEIMER'S DISEASE IN A DOUBLEâ€BLINDED RANDOMIZED CLINICAL TRIAL OF PQ912. <i>Alzheimer's and Dementia</i> , 2018, 14, P1181.                                       | 0.4 | 0         |
| 407 | ICâ€Pâ€192: DISEASEâ€STAGE SPECIFIC RELATIONSHIP BETWEEN COGNITIVE RESERVE AND CLINICAL PROGRESSION IN ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2018, 14, P158.  | 0.4 | 2         |
| 408 | P3â€277: IMPAIRMENT IN COMPLEX ACTIVITIES OF DAILY LIVING IS RELATED TO NEURODEGENERATION IN ALZHEIMER'S DISEASE SPECIFIC REGIONS. <i>Alzheimer's and Dementia</i> , 2018, 14, P1183.  | 0.4 | 0         |
| 409 | P3â€445: FACTORS PREDICTING MORTALITY AT THE MEMORY CLINIC AT SIRIRAJ HOSPITAL: 815 THAI COHORT. <i>Alzheimer's and Dementia</i> , 2018, 14, P1286.  | 0.4 | 0         |
| 410 | P1â€291: BINDING PROPERTIES OF CURCUMIN IN POSTMORTEM BRAIN TISSUE: TOWARD AMYLOID IMAGING IN THE RETINA?. <i>Alzheimer's and Dementia</i> , 2018, 14, P397.   | 0.4 | 0         |
| 411 | ICâ€Pâ€110: PATTERNS OF GLUCOSE HYPOMETABOLISM, SUBCORTICAL ATROPHY AND WHITE MATTER HYPERINTENSITIES IN THE BEHAVIORAL VARIANT OF ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2018, 14, P94.                             | 0.4 | 0         |
| 412 | F5â€05â€04: THE USE OF RESIDUAL METHODS TO CAPTURE COGNITIVE RESERVE AND STUDY CLINICAL PROGRESSION IN ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2018, 14, P1633.   | 0.4 | 0         |
| 413 | P1â€467: DISEASEâ€STAGEâ€SPECIFIC RELATIONSHIP BETWEEN COGNITIVE RESERVE AND CLINICAL PROGRESSION IN ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2018, 14, P500.  | 0.4 | 0         |
| 414 | O3â€13â€06: TAKING AMYLOID PET INTO THE CLINIC: INDIVIDUALIZED RISK PREDICTION IN MCI PATIENTS â€” THE ABIDE PROJECT. <i>Alzheimer's and Dementia</i> , 2018, 14, P1058.   | 0.4 | 0         |



| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 415 | O2â€09â€05: EXTENSION AND VALIDATION OF AN AMYLOID STAGING MODEL: ASSOCIATIONS WITH CLINICAL MEASURES. Alzheimer's and Dementia, 2018, 14, P643.  | 0.4 | 0         |
| 416 | O2â€15â€04: ROBUST INDIVIDUALIZED PREDICTION MODELS WHICH ARE APPLICABLE ACROSS DIFFERENT COHORTS. Alzheimer's and Dementia, 2018, 14, P661.  | 0.4 | 0         |
| 417 | O5â€01â€03: ATROPHY SUBTYPES IN ALZHEIMER'S DISEASE IDENTIFIED THROUGH NONâ€NEGATIVE MATRIX FACTORIZATION. Alzheimer's and Dementia, 2018, 14, P1638.   | 0.4 | 0         |
| 418 | ICâ€Pâ€005: ASSESSMENT OF EARLY AMYLOID PATHOLOGY USING [ <sup>18</sup> F]FLUTEMETAMOL POSITRON EMISSION TOMOGRAPHY: COMPARING VISUAL READ, SEMIâ€QUANTITATIVE AND QUANTITATIVE METHODS. Alzheimer's and Dementia, 2018, 14, P16. | 0.4 | 0         |
| 419 | P2â€284: NUTRITIONAL MARKERS ASSOCIATED WITH CLINICAL PROGRESSION IN PATIENTS WITH MILD COGNITIVE IMPAIRMENT AND SUBJECTIVE COGNITIVE DECLINE: THE NUDAD STUDY. Alzheimer's and Dementia, 2018, 14, P789.                         | 0.4 | 0         |
| 420 | FTS3â€01â€02: EUROPEAN PERSPECTIVE ON CLINICAL AMYLOID IMAGING. Alzheimer's and Dementia, 2018, 14, P1004.  | 0.4 | 0         |
| 421 | P2â€445: EVENTâ€BASED MODELING OF THE TEMPORAL ORDERING OF REGIONAL Î²â€AMYLOID DEPOSITION IN THE BRAIN. Alzheimer's and Dementia, 2018, 14, P887.  | 0.4 | 1         |
| 422 | P1â€602: DUTCH ONLINE REGISTRY FOR RECRUITMENT OF PARTICIPANTS FOR DEMENTIA STUDIES: HERSENONDERZOEK.NL AND BRAIN HEALTH REGISTRY. Alzheimer's and Dementia, 2018, 14, P569.  | 0.4 | 1         |
| 423 | WHAT HAVE WE LEARNED FROM EXPEDITION III AND EPOCH TRIALS? PERSPECTIVE OF THE CTAD TASK FORCE. journal of prevention of Alzheimer's disease, The, 2018, 5, 1-4.   | 1.5 | 7         |
| 424 | P3â€617: NUTRITIONAL INTAKE IN SUBJECTIVE COGNITIVE DECLINE: ROOM FOR IMPROVEMENT?. Alzheimer's and Dementia, 2018, 14, P1366.  | 0.4 | 0         |
| 425 | A novel partial volume correction method for accurate quantification of [18F] flortaucipir in the hippocampus. EJNMMI Research, 2018, 8, 79.  | 1.1 | 19        |
| 426 | P3â€568: PROGNOSIS OF INDIVIDUALS WITH MILD COGNITIVE IMPAIRMENT REVERTING TO NORMAL COGNITION. Alzheimer's and Dementia, 2018, 14, P1341.  | 0.4 | 0         |
| 427 | F4â€08â€01: PLASMA AMYLOID AS A PREâ€SCREENING TOOL FOR AMYLOID POSITIVITY IN SUBJECTIVE COGNITIVE DECLINE. Alzheimer's and Dementia, 2018, 14, P1394.  | 0.4 | 0         |
| 428 | F1â€02â€02: DISCOVERY, REPLICATION AND EXTENSION STUDY OF PLASMA PROTEOMIC BIOMARKERS RELATING TO BRAIN AMYLOID BURDEN AND ALZHEIMER'S DISEASE PROGRESSION. Alzheimer's and Dementia, 2018, 14, P201.                             | 0.4 | 0         |
| 429 | P2â€251: NEUROPATHOLOGICAL HALLMARKS OF ALZHEIMER'S DISEASE IN POSTMORTEM AD RETINAS. Alzheimer's and Dementia, 2018, 14, P770.   | 0.4 | 0         |
| 430 | Resilience to cognitive impairment in the oldest-old: design of the EMIF-AD 90+ study. BMC Geriatrics, 2018, 18, 289.   | 1.1 | 25        |
| 431 | Heterogeneity of Alzheimerâ€™s disease: consequence for drug trials?. Alzheimer's Research and Therapy, 2018, 10, 122.  | 3.0 | 75        |
| 432 | O1â€10â€05: ELECTROâ€ENCEPHALOGRAPHY AS A PRODROMAL MARKER OF DEMENTIA WITH LEWY BODIES. Alzheimer's and Dementia, 2018, 14, P245.  | 0.4 | 0         |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 433 | Computer-assisted prediction of clinical progression in the earliest stages of AD. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018, 10, 726-736.  | 1.2 | 8         |
| 434 | P355: ASSESSMENT OF EARLY AMYLOID PATHOLOGY USING [ <sup>18</sup> F]FLUTEMETAMOL POSITRON EMISSION TOMOGRAPHY: COMPARING VISUAL READ, SEMI-QUANTITATIVE AND QUANTITATIVE METHODS. <i>Alzheimer's and Dementia</i> , 2018, 14, P1221.   | 0.4 | 0         |
| 435 | Amyloid-beta and phosphorylated tau in post-mortem Alzheimer's disease retinas. <i>Acta Neuropathologica Communications</i> , 2018, 6, 147.  | 2.4 | 138       |
| 436 | Angiopoietin like-4 as a novel vascular mediator in capillary cerebral amyloid angiopathy. <i>Brain</i> , 2018, 141, 3377-3388.  | 3.7 | 32        |
| 437 | The plasma peptides of ovarian cancer. <i>Clinical Proteomics</i> , 2018, 15, 41.  | 1.1 | 33        |
| 438 | The plasma peptidome. <i>Clinical Proteomics</i> , 2018, 15, 39.   | 1.1 | 22        |
| 439 | Plasma Protein Biomarkers for the Prediction of CSF Amyloid and Tau and [18F]-Flutemetamol PET Scan Result. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 409.  | 1.7 | 28        |
| 440 | Current state of Alzheimer's fluid biomarkers. <i>Acta Neuropathologica</i> , 2018, 136, 821-853.  | 3.9 | 370       |
| 441 | F101: RELATING CSF MARKERS NEUROGRANIN, NEUROFILAMENT LIGHT AND YKL40 TO A $\beta$ , APOE $\epsilon$ 4 AND COGNITION: RESULTS FROM THE EMIF-AD MULTIMODAL BIOMARKER DISCOVERY STUDY. <i>Alzheimer's and Dementia</i> , 2018, 14, P201. | 0.4 | 0         |
| 442 | A C6orf10/LOC101929163 locus is associated with age of onset in C9orf72 carriers. <i>Brain</i> , 2018, 141, 2895-2907.   | 3.7 | 39        |
| 443 | Prevalence of amyloid $\beta$ pathology in distinct variants of primary progressive aphasia. <i>Annals of Neurology</i> , 2018, 84, 729-740.   | 2.8 | 132       |
| 444 | MRI predictors of amyloid pathology: results from the EMIF-AD Multimodal Biomarker Discovery study. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 100.   | 3.0 | 64        |
| 445 | The 100-plus Study of cognitively healthy centenarians: rationale, design and cohort description. <i>European Journal of Epidemiology</i> , 2018, 33, 1229-1249.   | 2.5 | 43        |
| 446 | Secondary prevention of Alzheimer's dementia: neuroimaging contributions. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 112.   | 3.0 | 46        |
| 447 | O306: A PROTOTYPE SIMOA ASSAY QUANTIFYING PLASMA AMYLOID BETA 1 $\beta$ 42 AND 1 $\beta$ 40 ISOFORMS CAN DIFFERENTIATE PARTICIPANTS WITH AD FROM HEALTHY CONTROL SUBJECTS. <i>Alzheimer's and Dementia</i> , 2018, 14, P1039.          | 0.4 | 4         |
| 448 | P2458: PREDICTING COGNITIVE DECLINE THROUGH STRUCTURAL MRI BIOMARKERS: RESULTS FROM THE EMIF-AD BIOMARKER DISCOVERY STUDY. <i>Alzheimer's and Dementia</i> , 2018, 14, P895.   | 0.4 | 0         |
| 449 | F103: MRI PREDICTORS OF AMYLOID PATHOLOGY: RESULTS FROM THE EMIF-AD BIOMARKER DISCOVERY STUDY. <i>Alzheimer's and Dementia</i> , 2018, 14, P202.   | 0.4 | 0         |
| 450 | Atrophy subtypes in prodromal Alzheimer's disease are associated with cognitive decline. <i>Brain</i> , 2018, 141, 3443-3456.  | 3.7 | 102       |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 451 | Safety, tolerability and efficacy of the glutamyl cyclase inhibitor PQ912 in Alzheimer's disease: results of a randomized, double-blind, placebo-controlled phase 2a study. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 107. | 3.0 | 80        |
| 452 | ICA-187: CORTICAL T1 $\rho$ /T2 $\rho$ RATIO VALUES ARE HIGHER IN ALZHEIMER'S DISEASE COMPARED TO CONTROLS. <i>Alzheimer's and Dementia</i> , 2018, 14, P156.  | 0.4 | 0         |
| 453 | Clinical phenotype, atrophy, and small vessel disease in $\epsilon$ APOE $\epsilon$ 2 carriers with Alzheimer disease. <i>Neurology</i> , 2018, 91, e1851-e1859.   | 1.5 | 46        |
| 454 | Plasma Amyloid as Prescreener for the Earliest Alzheimer Pathological Changes. <i>Annals of Neurology</i> , 2018, 84, 648-658.   | 2.8 | 230       |
| 455 | The EMIF-AD PreclinAD study: study design and baseline cohort overview. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 75.  | 3.0 | 48        |
| 456 | Hypometabolism of the posterior cingulate cortex is not restricted to Alzheimer's disease. <i>NeuroImage: Clinical</i> , 2018, 19, 625-632.  | 1.4 | 23        |
| 457 | Disclosure of amyloid positron emission tomography results to individuals without dementia: a systematic review. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 72.   | 3.0 | 34        |
| 458 | Vascular Endothelial Growth Factor remains unchanged in cerebrospinal fluid of patients with Alzheimer's disease and vascular dementia. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 58.                                      | 3.0 | 21        |
| 459 | EEG Characteristics of Dementia With Lewy Bodies, Alzheimer's Disease and Mixed Pathology. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 190.   | 1.7 | 48        |
| 460 | Pre-amyloid stage of Alzheimer's disease in cognitively normal individuals. <i>Annals of Clinical and Translational Neurology</i> , 2018, 5, 1037-1047.  | 1.7 | 23        |
| 461 | Amsterdam Dementia Cohort: Performing Research to Optimize Care. <i>Journal of Alzheimer's Disease</i> , 2018, 62, 1091-1111.  | 1.2 | 228       |
| 462 | Brain-Area Specific White Matter Hyperintensities: Associations to Falls in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2018, 8, 455-462.   | 1.5 | 6         |
| 463 | Quantitative PET and Histology of Brain Biopsy Reveal Lack of Selective Pittsburgh Compound-B Binding to Intracerebral Amyloidoma. <i>Journal of Alzheimer's Disease</i> , 2018, 65, 71-77.  | 1.2 | 2         |
| 464 | Neuropathology and cognitive performance in self-reported cognitively healthy centenarians. <i>Acta Neuropathologica Communications</i> , 2018, 6, 64.   | 2.4 | 36        |
| 465 | An intervention programme for caregivers of dementia patients with frontal behavioural changes: an explorative study with controlled effect on sense of competence. <i>Psychogeriatrics</i> , 2018, 18, 451-459.                     | 0.6 | 10        |
| 466 | Data-Driven Differential Diagnosis of Dementia Using Multiclass Disease State Index Classifier. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 111.  | 1.7 | 29        |
| 467 | The EMIF-AD Multimodal Biomarker Discovery study: design, methods and cohort characteristics. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 64.  | 3.0 | 62        |
| 468 | Gray matter atrophy in dementia with Lewy bodies with and without concomitant Alzheimer's disease pathology. <i>Neurobiology of Aging</i> , 2018, 71, 171-178.   | 1.5 | 25        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 469 | Gray Matter Network Disruptions and Regional Amyloid Beta in Cognitively Normal Adults. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 67.   | 1.7 | 29        |
| 470 | Synaptic proteins in CSF as potential novel biomarkers for prognosis in prodromal Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 5.  | 3.0 | 94        |
| 471 | Evaluating combinations of diagnostic tests to discriminate different dementia types. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018, 10, 509-518.                                 | 1.2 | 19        |
| 472 | Prominent Non-Memory Deficits in Alzheimer's Disease Are Associated with Faster Disease Progression. <i>Journal of Alzheimer's Disease</i> , 2018, 65, 1029-1039.  | 1.2 | 14        |
| 473 | Neuroinflammation is increased in the parietal cortex of atypical Alzheimer's disease. <i>Journal of Neuroinflammation</i> , 2018, 15, 170.  | 3.1 | 30        |
| 474 | Subjective Cognitive Impairment Cohort (SCIENCE): study design and first results. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 76.  | 3.0 | 87        |
| 475 | Association of Amyloid Positron Emission Tomography With Changes in Diagnosis and Patient Treatment in an Unselected Memory Clinic Cohort. <i>JAMA Neurology</i> , 2018, 75, 1062.                                       | 4.5 | 102       |
| 476 | Symptomatic Treatment of Vascular Cognitive Impairment (STREAM-VCI): Protocol for a Cross-Over Trial. <i>JMIR Research Protocols</i> , 2018, 7, e80.   | 0.5 | 3         |
| 477 | Diagnostiek en classificatie van dementie. , 2018, , 15-29.  |     | 1         |
| 478 | Patients to learn from: on the need for systematic integration of research and care in academic health care. <i>Journal of Clinical and Translational Research</i> , 2018, 3, 401-406.                                   | 0.3 | 1         |
| 479 | Genome-wide significant risk factors for Alzheimer's disease: role in progression to dementia due to Alzheimer's disease among subjects with mild cognitive impairment. <i>Molecular Psychiatry</i> , 2017, 22, 153-160. | 4.1 | 102       |
| 480 | Early-Onset Dementia. <i>Alzheimer Disease and Associated Disorders</i> , 2017, 31, 146-151.   | 0.6 | 12        |
| 481 | Apolipoprotein A1 in Cerebrospinal Fluid and Plasma and Progression to Alzheimer's Disease in Non-Demented Elderly. <i>Journal of Alzheimer's Disease</i> , 2017, 56, 687-697.   | 1.2 | 60        |
| 482 | Active A $\beta$ 2 immunotherapy CAD106 in Alzheimer's disease: A phase 2b study. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2017, 3, 10-22.                                   | 1.8 | 102       |
| 483 | Improved Cerebrospinal Fluid-Based Discrimination between Alzheimer's Disease Patients and Controls after Correction for Ventricular Volumes. <i>Journal of Alzheimer's Disease</i> , 2017, 56, 543-555.                 | 1.2 | 10        |
| 484 | Practical use of visual medial temporal lobe atrophy cut-off scores in Alzheimer's disease: Validation in a large memory clinic population. <i>European Radiology</i> , 2017, 27, 3147-3155.                             | 2.3 | 48        |
| 485 | Alzheimer's biomarkers in daily practice (ABIDE) project: Rationale and design. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017, 6, 143-151.  | 1.2 | 57        |
| 486 | Predicting progression to dementia in persons with mild cognitive impairment using cerebrospinal fluid markers. <i>Alzheimer's and Dementia</i> , 2017, 13, 903-912.   | 0.4 | 32        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 487 | A composite measure of cognitive and functional progression in Alzheimer's disease: Design of the Capturing Changes in Cognition study. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2017, 3, 130-138.  | 1.8 | 26        |
| 488 | A multinational study distinguishing Alzheimer's and healthy patients using cerebrospinal fluid tau/A $\beta$ 42 cutoff with concordance to amyloid positron emission tomography imaging. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017, 6, 201-209.   | 1.2 | 19        |
| 489 | Unbiased estimates of cerebrospinal fluid $\beta$ -amyloid 1 $\beta$ 42 cutoffs in a large memory clinic population. <i>Alzheimer's Research and Therapy</i> , 2017, 9, 8.  | 3.0 | 60        |
| 490 | Consensus classification of posterior cortical atrophy. <i>Alzheimer's and Dementia</i> , 2017, 13, 870-884.  | 0.4 | 423       |
| 491 | Gait Speed and Grip Strength Reflect Cognitive Impairment and Are Modestly Related to Incident Cognitive Decline in Memory Clinic Patients With Subjective Cognitive Decline and Mild Cognitive Impairment: Findings From the 4C Study. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2017, 72, 846-854. | 1.7 | 69        |
| 492 | Quantification of Tau Load Using [18F]AV1451 PET. <i>Molecular Imaging and Biology</i> , 2017, 19, 963-971.   | 1.3 | 42        |
| 493 | Cognitive subtypes of probable Alzheimer's disease robustly identified in four cohorts. <i>Alzheimer's and Dementia</i> , 2017, 13, 1226-1236.  | 0.4 | 59        |
| 494 | CSF ApoE predicts clinical progression in nondemented APOE $\epsilon$ 4 carriers. <i>Neurobiology of Aging</i> , 2017, 57, 186-194.   | 1.5 | 26        |
| 495 | Patterns of atrophy in pathologically confirmed dementias: a voxelwise analysis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, 908-916.  | 0.9 | 78        |
| 496 | Rare Genetic Variant in SORL1 May Increase Penetrance of Alzheimer's Disease in a Family with Several Generations of APOE $\epsilon$ 4 Homozygosity. <i>Journal of Alzheimer's Disease</i> , 2017, 56, 63-74.   | 1.2 | 32        |
| 497 | A neuroimaging approach to capture cognitive reserve: Application to Alzheimer's disease. <i>Human Brain Mapping</i> , 2017, 38, 4703-4715.   | 1.9 | 59        |
| 498 | Nutrients required for phospholipid synthesis are lower in blood and cerebrospinal fluid in mild cognitive impairment and Alzheimer's disease dementia. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017, 8, 139-146.   | 1.2 | 19        |
| 499 | Alzheimer's disease: The state of the art in resting-state magnetoencephalography. <i>Clinical Neurophysiology</i> , 2017, 128, 1426-1437.  | 0.7 | 76        |
| 500 | Characterization of pathogenic SORL1 genetic variants for association with Alzheimer's disease: a clinical interpretation strategy. <i>European Journal of Human Genetics</i> , 2017, 25, 973-981.  | 1.4 | 102       |
| 501 | Effect of Long-Term Vascular Care on Progression of Cerebrovascular Lesions. <i>Stroke</i> , 2017, 48, 1842-1848.   | 1.0 | 32        |
| 502 | Consensus guidelines for lumbar puncture in patients with neurological diseases. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017, 8, 111-126.  | 1.2 | 197       |
| 503 | Glutamyl cyclase activity correlates with levels of A $\beta$ peptides and mediators of angiogenesis in cerebrospinal fluid of Alzheimer's disease patients. <i>Alzheimer's Research and Therapy</i> , 2017, 9, 38.   | 3.0 | 24        |
| 504 | Selective impairment of hippocampus and posterior hub areas in Alzheimer's disease: an MEG-based multiplex network study. <i>Brain</i> , 2017, 140, 1466-1485.  | 3.7 | 132       |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 505 | The frequency and influence of dementia risk factors in prodromal Alzheimer's disease. <i>Neurobiology of Aging</i> , 2017, 56, 33-40.  | 1.5 | 27        |
| 506 | Cerebrospinal fluid biomarker examination as a tool to discriminate behavioral variant frontotemporal dementia from primary psychiatric disorders. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017, 7, 99-106.   | 1.2 | 32        |
| 507 | Cognitive functioning of individuals aged 90 years and older without dementia: A systematic review. <i>Ageing Research Reviews</i> , 2017, 36, 42-49.   | 5.0 | 10        |
| 508 | Clinical validity of medial temporal atrophy as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework. <i>Neurobiology of Aging</i> , 2017, 52, 167-182.e1.  | 1.5 | 60        |
| 509 | Low normal cerebrospinal fluid A $\beta$ 42 levels predict clinical progression in nondemented subjects. <i>Annals of Neurology</i> , 2017, 81, 749-753.  | 2.8 | 20        |
| 510 | From corticocentrism to leucocentrism or both. <i>Brain</i> , 2017, 140, 247-250.   | 3.7 | 0         |
| 511 | 24-month intervention with a specific multinutrient in people with prodromal Alzheimer's disease (LipiDiDiet): a randomised, double-blind, controlled trial. <i>Lancet Neurology</i> , The, 2017, 16, 965-975.  | 4.9 | 175       |
| 512 | The Pitfall of Behavioral Variant Frontotemporal Dementia Mimics Despite Multidisciplinary Application of the FTDC Criteria. <i>Journal of Alzheimer's Disease</i> , 2017, 60, 959-975.   | 1.2 | 34        |
| 513 | Interpreting Biomarker Results in Individual Patients With Mild Cognitive Impairment in the Alzheimer's Biomarkers in Daily Practice (ABIDE) Project. <i>JAMA Neurology</i> , 2017, 74, 1481.   | 4.5 | 77        |
| 514 | Association Between Later Life Lifestyle Factors and Alzheimer's Disease Biomarkers in Non-Demented Individuals: A Longitudinal Descriptive Cohort Study. <i>Journal of Alzheimer's Disease</i> , 2017, 60, 1387-1395.  | 1.2 | 24        |
| 515 | A novel quantification-driven proteomic strategy identifies an endogenous peptide of pleiotrophin as a new biomarker of Alzheimer's disease. <i>Scientific Reports</i> , 2017, 7, 13333.  | 1.6 | 45        |
| 516 | [P1â€“30]: MRI-BASED CLASSIFICATION ACCURACY OF DEMENTIA TYPE IS DETERMINED BY MRI MODALITY. <i>Alzheimer's and Dementia</i> , 2017, 13, P98.   | 0.4 | 0         |
| 517 | [P1â€“392]: AUTOMATED SELECTION OF MULTIMODAL MRI BIOMARKERS FOR DIAGNOSIS OF DEMENTIA. <i>Alzheimer's and Dementia</i> , 2017, 13, P417.   | 0.4 | 0         |
| 518 | Blood-based metabolic signatures in Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017, 8, 196-207.  | 1.2 | 56        |
| 519 | Directional information flow in patients with Alzheimer's disease. A source-space resting-state MEC study. <i>NeuroImage: Clinical</i> , 2017, 15, 673-681.   | 1.4 | 33        |
| 520 | Lumbar puncture in patients with neurologic conditions. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017, 8, 108-110.   | 1.2 | 12        |
| 521 | Lower cerebral blood flow in subjects with Alzheimer's dementia, mild cognitive impairment, and subjective cognitive decline using two-dimensional phase-contrast magnetic resonance imaging. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017, 9, 76-83. | 1.2 | 39        |
| 522 | [P2â€“245]: AMYLOID VISUALIZATION IN THE RETINA OF ALZHEIMER'S DISEASE PATIENTS WITH CURCUMIN. <i>Alzheimer's and Dementia</i> , 2017, 13, P705.  | 0.4 | 0         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 523 | The effect of diagnostic criteria on outcome measures in preclinical and prodromal Alzheimer's disease: Implications for trial design. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2017, 3, 513-523. | 1.8 | 17        |
| 524 | EEG spectral analysis as a putative early prognostic biomarker in nondemented, amyloid positive subjects. <i>Neurobiology of Aging</i> , 2017, 57, 133-142.   | 1.5 | 91        |
| 525 | Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers. <i>Lancet Neurology</i> , The, 2017, 16, 661-676.  | 4.9 | 464       |
| 526 | Diagnostic impact of [18F]flutemetamol PET in early-onset dementia. <i>Alzheimer's Research and Therapy</i> , 2017, 9, 2.   | 3.0 | 98        |
| 527 | Lower cerebral blood flow is associated with impairment in multiple cognitive domains in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2017, 13, 531-540.  | 0.4 | 99        |
| 528 | Lower cerebral blood flow is associated with faster cognitive decline in Alzheimer's disease. <i>European Radiology</i> , 2017, 27, 1169-1175.  | 2.3 | 97        |
| 529 | A novel <i>CCM2</i> variant in a family with nonprogressive cognitive complaints and cerebral microbleeds. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2017, 174, 220-226.                                | 1.1 | 6         |
| 530 | Gray matter network differences between behavioral variant frontotemporal dementia and Alzheimer's disease. <i>Neurobiology of Aging</i> , 2017, 50, 77-86.   | 1.5 | 6         |
| 531 | Assessing fitness to drive: A validation study on patients with mild cognitive impairment. <i>Traffic Injury Prevention</i> , 2017, 18, 145-149.  | 0.6 | 27        |
| 532 | [P1â€“244]: DISCRIMINATION BETWEEN DEMENTIA WITH LEWY BODIES (DLB), ALZHEIMER'S DISEASE (AD) AND MIXED PATHOLOGY USING ELECTROENCEPHALOGRAPHY (EEG). <i>Alzheimer's and Dementia</i> , 2017, 13, P338.  | 0.4 | 0         |
| 533 | [P2â€“399]: CORRELATION OF GREY MATTER NETWORK MEASURES IN COGNITIVELY HEALTHY ELDERLY MONOZYGOTIC TWIN PAIRS. <i>Alzheimer's and Dementia</i> , 2017, 13, P783.  | 0.4 | 0         |
| 534 | [P2â€“473]: THE EFFECTS OF AMYLOID ON SEMANTIC COMPLEXITY IN SPONTANEOUS SPEECH IN SUBJECTIVE COGNITIVE DECLINE. <i>Alzheimer's and Dementia</i> , 2017, 13, P821.  | 0.4 | 0         |
| 535 | [P3â€“161]: GRANULOCYTES: KEY PLAYERS IN PERIPHERAL A $\beta$ CLEARANCE?. <i>Alzheimer's and Dementia</i> , 2017, 13, P995.   | 0.4 | 0         |
| 536 | [P3â€“226]: PROFILING PERIPHERAL METABOLIC DYSREGULATION IN ALZHEIMER'S DISEASE: THE ADDED VALUE OF MULTIPLE SIGNATURES. <i>Alzheimer's and Dementia</i> , 2017, 13, P1024.   | 0.4 | 0         |
| 537 | [P3â€“375]: GREY MATTER CONNECTIVITY IS ASSOCIATED WITH THE RATE OF COGNITIVE DECLINE IN MILD COGNITIVE IMPAIRMENT. <i>Alzheimer's and Dementia</i> , 2017, 13, P1102.  | 0.4 | 0         |
| 538 | [P3â€“386]: COMPUTED RATING SCALES FOR COGNITIVE DISORDERS FROM MRI. <i>Alzheimer's and Dementia</i> , 2017, 13, P1108.   | 0.4 | 1         |
| 539 | [P3â€“407]: SUBJECTIVE COGNITIVE DECLINE IS ASSOCIATED WITH ALTERED POSTERIOR CINGULATE CONNECTIVITY IN ELDERLY WITH A FAMILIAL HISTORY OF ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2017, 13, P1120.                            | 0.4 | 0         |
| 540 | [P3â€“422]: CLINICAL AND RADIOLOGICAL FINDINGS IN PATIENTS WITH PATHOLOGICALLY CONFIRMED CAA. <i>Alzheimer's and Dementia</i> , 2017, 13, P1127.  | 0.4 | 0         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 541 | [P3â€“427]: NONâ€“AMNESTIC ALZHEIMER'S DISEASE: A POSSIBLE ROLE FOR NEUROINFLAMMATION?. Alzheimer's and Dementia, 2017, 13, P1131.  | 0.4 | 0         |
| 542 | [P4â€“219]: [ <sup>18</sup> F]AV1451 BINDING POTENTIAL IN RELATION TO AMYLOID STATUS AND COGNITION IN SUBJECTS WITH SUBJECTIVE COGNITIVE DECLINE. Alzheimer's and Dementia, 2017, 13, P1352.                                  | 0.4 | 0         |
| 543 | [P4â€“235]: PARAMETRIC IMAGING OF TAU LOAD IN ALZHEIMER'S PATIENTS AND CONTROLS USING FLORTAUCIPIR. Alzheimer's and Dementia, 2017, 13, P1364.  | 0.4 | 0         |
| 544 | [P4â€“302]: DOES BRAIN AMYLOID DEPOSITION IMPACT EVERYDAY FUNCTIONING IN SUBJECTS WITH COGNITIVE COMPLAINTS? RESULTS FROM THE INSIGHT COHORT. Alzheimer's and Dementia, 2017, 13, P1406.                                      | 0.4 | 0         |
| 545 | [ICâ€“Pâ€“005]: CONCORDANCE BETWEEN CEREBROSPINAL FLUID AMYLOIDâ€“ $\beta$ 2 AND [ <sup>18</sup> F]FLORBETABEN PET IN AN UNSELECTED COHORT OF MEMORY CLINIC PATIENTS. Alzheimer's and Dementia, 2017, 13, P13.                | 0.4 | 1         |
| 546 | [ICâ€“Pâ€“036]: CORRELATION OF GREY MATTER NETWORK MEASURES IN COGNITIVELY HEALTHY ELDERLY MONOZYGOTIC TWIN PAIRS. Alzheimer's and Dementia, 2017, 13, P32.   | 0.4 | 0         |
| 547 | [ICâ€“Pâ€“037]: SUBJECTIVE COGNITIVE DECLINE IS ASSOCIATED WITH ALTERED POSTERIOR CINGULATE CONNECTIVITY IN ELDERLY WITH A FAMILIAL HISTORY OF ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2017, 13, P33.                  | 0.4 | 0         |
| 548 | [ICâ€“Pâ€“053]: EARLY ALTERATIONS IN RESTINGâ€“STATE FUNCTIONAL CONNECTIVITY IS ASSOCIATED WITH AMYLOID PATHOLOGY IN COGNITIVELY HEALTHY ELDERLY MONOZYGOTIC TWINS. Alzheimer's and Dementia, 2017, 13, P43.                  | 0.4 | 0         |
| 549 | [ICâ€“Pâ€“055]: EFFECT OF APOEâ€“ $\epsilon$ 2 ON REGIONAL GRAY MATTER ATROPHY AND CLINICAL PHENOTYPE IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2017, 13, P45.  | 0.4 | 0         |
| 550 | [ICâ€“Pâ€“058]: TWIN CORRELATIONS FOR AMYLOID PATHOLOGY MEASURED WITH POSITRON EMISSION TOMOGRAPHY AND IN CEREBROSPINAL FLUID IN COGNITIVELY HEALTHY ELDERLY MONOZYGOTIC TWIN PAIRS. Alzheimer's and Dementia, 2017, 13, P47. | 0.4 | 0         |
| 551 | [ICâ€“Pâ€“065]: WHITE MATTER HYPERINTENSITIES AND VASCULAR RISK FACTORS IN COGNITIVELY HEALTHY ELDERLY MONOZYGOTIC TWIN PAIRS. Alzheimer's and Dementia, 2017, 13, P53.   | 0.4 | 0         |
| 552 | [ICâ€“Pâ€“085]: GREY MATTER CONNECTIVITY IS ASSOCIATED WITH THE RATE OF COGNITIVE DECLINE IN MILD COGNITIVE IMPAIRMENT. Alzheimer's and Dementia, 2017, 13, P69.  | 0.4 | 0         |
| 553 | [ICâ€“Pâ€“095]: MICROBLEEDS ARE ASSOCIATED WITH DEPRESSIVE SYMPTOMS IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2017, 13, P74.  | 0.4 | 0         |
| 554 | [ICâ€“Pâ€“106]: PREDICTING PROGRESSION IN PREâ€“DEMEMENTIA STAGES OF ALZHEIMER'S DISEASE WITH A NEUROIMAGING MEASURE OF COGNITIVE RESERVE. Alzheimer's and Dementia, 2017, 13, P81.   | 0.4 | 0         |
| 555 | [ICâ€“Pâ€“110]: GREY MATTER CONNECTIVITY IS RELATED TO A STEEPER LOSS OF MEMORY AND LANGUAGE FUNCTIONING OVER TIME IN PATIENTS WITH SUBJECTIVE COGNITIVE DECLINE. Alzheimer's and Dementia, 2017, 13, P87.                    | 0.4 | 0         |
| 556 | [ICâ€“Pâ€“203]: [ <sup>18</sup> F]AV1451 BINDING POTENTIAL IN RELATION TO AMYLOID STATUS AND COGNITION IN SUBJECTS WITH SUBJECTIVE COGNITIVE DECLINE. Alzheimer's and Dementia, 2017, 13, P148.                               | 0.4 | 0         |
| 557 | [ICâ€“Pâ€“206]: PARAMETRIC IMAGING OF TAU LOAD IN ALZHEIMER'S PATIENTS AND CONTROLS USING FLORTAUCIPIR. Alzheimer's and Dementia, 2017, 13, P150.   | 0.4 | 0         |
| 558 | [P1â€“250]: DECISION TREE ANALYSIS REVEALS TWO CUTâ€“OFF LEVELS FOR AMYLOID BETA IN EARLY AD DIAGNOSIS. Alzheimer's and Dementia, 2017, 13, P342.   | 0.4 | 0         |



| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 559 | [P1â€™276]: BRI2 DEMENTIA PATHWAY IN CSF, IMPROVING DETECTION THROUGH ULTRASENSITIVE SIMOA TECHNOLOGY. Alzheimer's and Dementia, 2017, 13, P355.   | 0.4 | 0         |
| 560 | [P1â€™283]: RETINAL THICKNESS CORRELATES WITH PARIETAL CORTICAL ATROPHY ON MRI. Alzheimer's and Dementia, 2017, 13, P359.  | 0.4 | 0         |
| 561 | [P1â€™289]: DISCOVERY, REPLICATION AND EXTENSION STUDY OF PLASMA PROTEOMIC BIOMARKERS RELATING TO BRAIN AMYLOID BURDEN (CSF AÎ² OR AMYLOIDâ€™PET) IN THE EMIFâ€™AD BIOMARKER DISCOVERY COHORT. Alzheimer's and Dementia, 2017, 13, P361. | 0.4 | 0         |
| 562 | [P1â€™387]: CHARACTERIZATION OF SUSPECTED NONâ€™ALZHEIMER'S DISEASE PATHOPHYSIOLOGY (SNAP) IN INDIVIDUALS WITH MILD COGNITIVE IMPAIRMENT USING NEUROIMAGING. Alzheimer's and Dementia, 2017, 13, P414.                                   | 0.4 | 0         |
| 563 | [P1â€™404]: EARLY ALTERATIONS IN RESTINGâ€™STATE FUNCTIONAL CONNECTIVITY IS ASSOCIATED WITH AMYLOID PATHOLOGY IN COGNITIVELY HEALTHY ELDERLY MONOZYGOTIC TWINS. Alzheimer's and Dementia, 2017, 13, P429.                                | 0.4 | 0         |
| 564 | [P1â€™411]: WHITE MATTER HYPERINTENSITIES AND VASCULAR RISK FACTORS IN COGNITIVELY HEALTHY ELDERLY MONOZYGOTIC TWIN PAIRS. Alzheimer's and Dementia, 2017, 13, P433.   | 0.4 | 0         |
| 565 | [P1â€™440]: GREY MATTER CONNECTIVITY IS RELATED TO A STEEPER LOSS OF MEMORY AND LANGUAGE FUNCTIONING OVER TIME IN PATIENTS WITH SUBJECTIVE COGNITIVE DECLINE. Alzheimer's and Dementia, 2017, 13, P451.                                  | 0.4 | 0         |
| 566 | [P2â€™052]: THE DUTCH BRAIN HEALTH REGISTRY: OPTIMIZING RECRUITMENT FOR DEMENTIA RESEARCH. Alzheimer's and Dementia, 2017, 13, P624.   | 0.4 | 3         |
| 567 | [P2â€™207]: CONCORDANCE BETWEEN CEREBROSPINAL FLUID AMYLOIDâ€™Î² AND [ <sup>18</sup> F]FLORBETABEN PET IN AN UNSELECTED COHORT OF MEMORY CLINIC PATIENTS. Alzheimer's and Dementia, 2017, 13, P688.                                      | 0.4 | 0         |
| 568 | [P2â€™212]: EUROPEAN MEDICAL INFORMATION FRAMEWORK FOR ALZHEIMER'S DISEASE (EMIFâ€™AD): THE BIOMARKER DISCOVERY STUDY. Alzheimer's and Dementia, 2017, 13, P691.   | 0.4 | 1         |
| 569 | [P2â€™335]: EFFECT OF APOE Î²2 ON REGIONAL GRAY MATTER ATROPHY AND CLINICAL PHENOTYPE IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2017, 13, P748.  | 0.4 | 0         |
| 570 | [F1â€™03â€™04]: BIOMARKERâ€™BASED PERSONALIZED RISK ESTIMATES FOR PATIENTS WITH SUBJECTIVE COGNITIVE DECLINE. Alzheimer's and Dementia, 2017, 13, P177.  | 0.4 | 0         |
| 571 | [P1â€™01â€™02â€™01]: BIOMARKERS FOR THE DIAGNOSIS OF ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2017, 13, P180.  | 0.4 | 0         |
| 572 | [O1â€™01â€™02]: MICROBLEEDS ARE ASSOCIATED WITH DEPRESSIVE SYMPTOMS IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2017, 13, P182.  | 0.4 | 0         |
| 573 | [O1â€™05â€™03]: CSF AMYLOID BETA 1â€™42 LEVELS OBTAINED OVER 15 YEARS SHOW A DIAGNOSISâ€™DEPENDENT UPWARD DRIFT. Alzheimer's and Dementia, 2017, 13, P198.   | 0.4 | 0         |
| 574 | [O2â€™01â€™01]: CHARACTERIZING INDIVIDUALS WITH SUBJECTIVE COGNITIVE DECLINE: THE SUBJECTIVE COGNITIVE IMPAIRMENT COHORT (SCIENCE). Alzheimer's and Dementia, 2017, 13, P547.  | 0.4 | 0         |
| 575 | [O2â€™05â€™01]: TWIN CORRELATIONS FOR AMYLOID PATHOLOGY MEASURED WITH POSITRON EMISSION TOMOGRAPHY AND IN CEREBROSPINAL FLUID IN COGNITIVELY HEALTHY ELDERLY MONOZYGOTIC TWIN PAIRS. Alzheimer's and Dementia, 2017, 13, P559.           | 0.4 | 0         |
| 576 | [O2â€™10â€™06]: PROGNOSIS OF CLINICAL PROGRESSION IN SUBJECTIVE COGNITIVE DECLINE USING A CLINICAL DECISION SUPPORT SYSTEM. Alzheimer's and Dementia, 2017, 13, P579.  | 0.4 | 0         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 577 | [O2â€™11â€™03]: PREDICTING PROGRESSION IN PREâ€DEMENTIA STAGES OF ALZHEIMER'S DISEASE WITH A NEUROIMAGING MEASURE OF COGNITIVE RESERVE. <i>Alzheimer's and Dementia</i> , 2017, 13, P581.   | 0.4 | 0         |
| 578 | [O2â€™12â€™03]: DURATION OF ALZHEIMER'S DISEASE IN THE PRECLINICAL, PRODROMAL AND DEMENTIA STAGE: A MULTIâ€STATE MODEL ANALYSIS. <i>Alzheimer's and Dementia</i> , 2017, 13, P585.  | 0.4 | 4         |
| 579 | [O3â€™06â€™04]: PROMINENT NONâ€MEMORY DEFICITS IN AD ARE ASSOCIATED WITH A FASTER DISEASE PROGRESSION. <i>Alzheimer's and Dementia</i> , 2017, 13, P912.  | 0.4 | 0         |
| 580 | [O3â€™10â€™03]: LONGITUDINAL CEREBROSPINAL FLUID BIOMARKER TRAJECTORIES ALONG THE ALZHEIMER'S DISEASE CONTINUUM: A MULTICENTRE EUROPEAN STUDY. <i>Alzheimer's and Dementia</i> , 2017, 13, P924.                                  | 0.4 | 3         |
| 581 | [O5â€™07â€™04]: COGNITIVE PERFORMANCE AND ALZHEIMERâ€ASSOCIATED PATHOLOGY IN THE CONTEXT OF EXTREME AGING. <i>Alzheimer's and Dementia</i> , 2017, 13, P1472.   | 0.4 | 0         |
| 582 | [DTâ€™01â€™02]: THE IMPACT OF AMYLOID PET ON DIAGNOSIS AND PATIENT MANAGEMENT IN AN UNSELECTED MEMORY CLINIC COHORT: THE ABIDE PROJECT. <i>Alzheimer's and Dementia</i> , 2017, 13, P1474.  | 0.4 | 0         |
| 583 | [P2â€™194]: USING EMERGING CEREBROSPINAL FLUID MARKERS TO CHARACTERIZE SUSPECTED NONâ€ALZHEIMER'S DISEASE PATHOPHYSIOLOGY (SNAP) IN INDIVIDUALS WITH MILD COGNITIVE IMPAIRMENT. <i>Alzheimer's and Dementia</i> , 2017, 13, P680. | 0.4 | 0         |
| 584 | [P3â€™075]: PLEIOTROPHIN, A NEW BIOMARKER FOR AD, IDENTIFIED USING A NOVEL STRATEGY IN CLINICAL PROTEOMICS. <i>Alzheimer's and Dementia</i> , 2017, 13, P960.   | 0.4 | 0         |
| 585 | Psychosis in behavioral variant frontotemporal dementia. <i>Neuropsychiatric Disease and Treatment</i> , 2017, Volume 13, 1099-1106.  | 1.0 | 24        |
| 586 | MEG Beamformer-Based Reconstructions of Functional Networks in Mild Cognitive Impairment. <i>Frontiers in Aging Neuroscience</i> , 2017, 9, 107.  | 1.7 | 34        |
| 587 | MRI Visual Ratings of Brain Atrophy and White Matter Hyperintensities across the Spectrum of Cognitive Decline Are Differently Affected by Age and Diagnosis. <i>Frontiers in Aging Neuroscience</i> , 2017, 9, 117.              | 1.7 | 71        |
| 588 | White Matter Changes-Related Gait and Executive Function Deficits: Associations with Age and Parkinson's Disease. <i>Frontiers in Aging Neuroscience</i> , 2017, 9, 213.  | 1.7 | 12        |
| 589 | Current Approaches and Clinician Attitudes to the Use of Cerebrospinal Fluid Biomarkers in Diagnostic Evaluation of Dementia in Europe. <i>Journal of Alzheimer's Disease</i> , 2017, 60, 201-210.                                | 1.2 | 11        |
| 590 | On the path to 2025: understanding the Alzheimerâ€™s disease continuum. <i>Alzheimer's Research and Therapy</i> , 2017, 9, 60.  | 3.0 | 316       |
| 591 | Amyloid-independent atrophy patterns predict time to progression to dementia in mild cognitive impairment. <i>Alzheimer's Research and Therapy</i> , 2017, 9, 73.   | 3.0 | 25        |
| 592 | A phase III randomized trial of gantenerumab in prodromal Alzheimerâ€™s disease. <i>Alzheimer's Research and Therapy</i> , 2017, 9, 95.   | 3.0 | 396       |
| 593 | Cerebrovascular and amyloid pathology in predementia stages: the relationship with neurodegeneration and cognitive decline. <i>Alzheimer's Research and Therapy</i> , 2017, 9, 101.   | 3.0 | 43        |
| 594 | Cognitive Decline in Patients with Chronic Hydrocephalus and Normal Aging: â€Growing into Deficits'. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2017, 6, 500-507.  | 0.6 | 12        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 595 | Imaging biomarkers in Alzheimer's disease: added value in the clinical setting. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2017, 61, 360-371.  | 0.4 | 10        |
| 596 | Detecting functional decline from normal aging to dementia: Development and validation of a short version of the Amsterdam IADL Questionnaire. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 8, 26-35.                       | 1.2 | 58        |
| 597 | CLINICAL EFFECTS OF TRAMIPROSATE IN APOE4/4 HOMOZYGOUS PATIENTS WITH MILD ALZHEIMER'S DISEASE SUGGEST DISEASE MODIFICATION POTENTIAL. Journal of prevention of Alzheimer's disease, The, 2017, 4, 1-8.   | 1.5 | 34        |
| 598 | Vascular Cognitive Impairment in a Memory Clinic Population: Rationale and Design of the Utrecht-Amsterdam Clinical Features and Prognosis in Vascular Cognitive Impairment (TRACE-VCI) Study. JMIR Research Protocols, 2017, 6, e60.                        | 0.5 | 29        |
| 599 | Cognitive Deficits in Patients With Neuropsychiatric Symptoms. Journal of Clinical Psychiatry, 2017, 78, e940-e946.  | 1.1 | 19        |
| 600 | The Diagnostic Challenge of the Late-Onset Frontal Lobe Syndrome. Journal of Clinical Psychiatry, 2017, 78, e1197-e1203.   | 1.1 | 18        |
| 601 | Subjective Memory Complaints in APOE ε4 Carriers are Associated with High Amyloid-β Burden. Journal of Alzheimer's Disease, 2016, 49, 1115-1122.   | 1.2 | 45        |
| 602 | Integrating Biomarkers for Underlying Alzheimer's Disease in Mild Cognitive Impairment in Daily Practice: Comparison of a Clinical Decision Support System with Individual Biomarkers. Journal of Alzheimer's Disease, 2016, 50, 261-270.                    | 1.2 | 14        |
| 603 | Protein Kinase Activity Decreases with Higher Braak Stages of Alzheimer's Disease Pathology. Journal of Alzheimer's Disease, 2016, 49, 927-943.  | 1.2 | 41        |
| 604 | Magnetoencephalography for the Detection of Intervention Effects of a Specific Nutrient Combination in Patients with Mild Alzheimer's Disease: Results from an Exploratory Double-Blind, Randomized, Controlled Study. Frontiers in Neurology, 2016, 7, 161. | 1.1 | 6         |
| 605 | Slowing of Hippocampal Activity Correlates with Cognitive Decline in Early Onset Alzheimer's Disease. An MEG Study with Virtual Electrodes. Frontiers in Human Neuroscience, 2016, 10, 238.  | 1.0 | 75        |
| 606 | A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology, 2016, 87, 539-547.   | 1.5 | 1,216     |
| 607 | Application of Machine Learning to Arterial Spin Labeling in Mild Cognitive Impairment and Alzheimer Disease. Radiology, 2016, 281, 865-875.   | 3.6 | 58        |
| 608 | White Matter Changes and Cognitive Decline in a Ten-Year Follow-Up Period: A Pilot Study on a Single-Center Cohort from the Leukoaraiosis and Disability Study. Dementia and Geriatric Cognitive Disorders, 2016, 41, 303-313.                               | 0.7 | 3         |
| 609 | A profile of The Clinical Course of Cognition and Comorbidity in Mild Cognitive Impairment and Dementia Study (The 4C study): two complementary longitudinal, clinical cohorts in the Netherlands. BMC Neurology, 2016, 16, 242.                             | 0.8 | 17        |
| 610 | Heterogeneous Language Profiles in Patients with Primary Progressive Aphasia due to Alzheimer's Disease. Journal of Alzheimer's Disease, 2016, 51, 581-590.  | 1.2 | 35        |
| 611 | Diagnostic Accuracy of MRI and Additional [18F]FDG-PET for Behavioral Variant Frontotemporal Dementia in Patients with Late Onset Behavioral Changes. Journal of Alzheimer's Disease, 2016, 53, 1287-1297.   | 1.2 | 58        |
| 612 | Dementia and Rapid Mortality: Who is at Risk?. Journal of Alzheimer's Disease, 2016, 53, 135-142.  | 1.2 | 29        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 613 | Cognitive reserve moderates long-term cognitive and functional outcome in cerebral small vessel disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 1296-1302.  | 0.9 | 45        |
| 614 | Added Prognostic Value of Cerebrospinal Fluid Biomarkers in Predicting Decline in Memory Clinic Patients in a Prospective Cohort. <i>Journal of Alzheimer's Disease</i> , 2016, 52, 875-885.  | 1.2 | 8         |
| 615 | Formal Psychiatric Disorders are not Overrepresented in Behavioral Variant Frontotemporal Dementia. <i>Journal of Alzheimer's Disease</i> , 2016, 51, 1249-1256.  | 1.2 | 12        |
| 616 | P2â€131: Applying Random Forest Machine Learning to Diagnose Alzheimer's Disease and Dementia with Lewy Bodies: A Combination of Electroencephalography (EEG), Clinical Parameters and Biomarkers. <i>Alzheimer's and Dementia</i> , 2016, 12, P661. | 0.4 | 5         |
| 617 | A Longitudinal Study on Resting State Functional Connectivity in Behavioral Variant Frontotemporal Dementia and Alzheimerâ€™s Disease. <i>Journal of Alzheimer's Disease</i> , 2016, 55, 521-537.   | 1.2 | 48        |
| 618 | P1-297: The Diagnostic Value of Amyloid Pet in an Unselected Cohort of Memory Clinic Patients. , 2016, 12, P534-P535.   |     | 0         |
| 619 | Thinner temporal and parietal cortex is related to incident clinical progression to dementia in patients with subjective cognitive decline. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2016, 5, 43-52.           | 1.2 | 42        |
| 620 | P2â€221: Cerebral Blood Flow Measured with Phaseâ€Contrast MRI in AD, MCI and Controls. <i>Alzheimer's and Dementia</i> , 2016, 12, P706.   | 0.4 | 0         |
| 621 | P4â€122: Prevalence of Vascular Risk Factors in Different Stages of Prodromal Alzheimerâ€™s Disease and Its Influence on Cognitive Decline. <i>Alzheimer's and Dementia</i> , 2016, 12, P1059.   | 0.4 | 0         |
| 622 | ICâ€Pâ€196: Quantification of TAU Load Using [ <sup>18</sup> F]AVâ€1451 and PET. <i>Alzheimer's and Dementia</i> , 2016, 12, P141.   | 0.4 | 0         |
| 623 | P1â€178: Impact of Coâ€Morbid Amyloid Pathology on Clinical Phenotype of Patients with Vascular Cognitive Disorders. <i>Alzheimer's and Dementia</i> , 2016, 12, P472.  | 0.4 | 0         |
| 624 | ICâ€Pâ€017: Concordance of [18F]Flutemetamol Amyloid Deposition in Cognitively Healthy Elderly Monozygotic Twin Pairs. <i>Alzheimer's and Dementia</i> , 2016, 12, P23.   | 0.4 | 0         |
| 625 | IC-02-04: Correlation of Cortical Thickness in Cognitively Healthy Elderly Monozygotic Twin Pairs. , 2016, 12, P7-P8.   |     | 0         |
| 626 | IC-03-05: EEG Directed Connectivity from Posterior Brain Regions is Decreased in Dementia with Lewy Bodies: A Comparison with Alzheimerâ€™s Disease And Controls. , 2016, 12, P12-P12.  |     | 0         |
| 627 | P1â€298: The Influence of Concomitant Alzheimer Pathology on Atrophy in Dementia with Lewy Bodies (DLB): A Comparative MRI Study. <i>Alzheimer's and Dementia</i> , 2016, 12, P535.  | 0.4 | 0         |
| 628 | P1â€339: Different Pathological Distribution Pattern of Phosphorylated TAU and Microglia in Amnestic and Nonâ€Amnestic Alzheimerâ€™s Disease. <i>Alzheimer's and Dementia</i> , 2016, 12, P558.   | 0.4 | 0         |
| 629 | P2â€015: Pooled Amyloid Pet Baseline Data from The Bapineuzumab IV Phase III Trials. <i>Alzheimer's and Dementia</i> , 2016, 12, P614.   | 0.4 | 0         |
| 630 | ICâ€Pâ€097: A Novel Neuroimaging Approach to Capture Cognitive Reserve. <i>Alzheimer's and Dementia</i> , 2016, 12, P74.  | 0.4 | 0         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 631 | ICâ€Pâ€103: Active and Passive Reserve Differentially Mitigate Cognitive Symptoms in Demented and Nonâ€Demented Stages of Alzheimerâ€™s Disease. Alzheimer's and Dementia, 2016, 12, P78.                 | 0.4 | 0         |
| 632 | P2-165: Resilience to Clinical Dementia at Old Age: The European Medical Information Framework (EMIF) 90+ Study. , 2016, 12, P678-P678.   |     | 0         |
| 633 | ICâ€Pâ€108: Cerebral Blood Flow Measured With Phaseâ€Contrast MRI in AD, MCI and Controls. Alzheimer's and Dementia, 2016, 12, P82.   | 0.4 | 0         |
| 634 | P2-237: Concordance of [18F] Flutemetamol Amyloid Deposition in Cognitively Healthy Elderly Monozygotic Twin Pairs. , 2016, 12, P714-P715.  |     | 0         |
| 635 | P2â€282: EEGâ€Directed Connectivity from Posterior Brain Regions is Decreased in Dementia with Lewy Bodies: A Comparison with Alzheimer's Disease and Controls. Alzheimer's and Dementia, 2016, 12, P738. | 0.4 | 0         |
| 636 | P2-300: Capturing Changes in Cognition: The Needs and Wishes of Dementia Researchers and Clinicians. , 2016, 12, P748-P748.   |     | 0         |
| 637 | ICâ€Pâ€147: Atrophy Patterns Predicting Cognitive Decline in Nonâ€Demented Subjects are Independent of Amyloid Pathology. Alzheimer's and Dementia, 2016, 12, P109.                                       | 0.4 | 0         |
| 638 | P3â€144: Cognitive Subtypes Identified Using Nonnegative Matrix Factorisation in Four Large Alzheimer's Disease Dementia Cohorts. Alzheimer's and Dementia, 2016, 12, P873.                               | 0.4 | 0         |
| 639 | IC-P-153: Thinner Cortical Thickness in Patients With Subjective Cognitive Decline is Related to Poor Memory Performance and Faster Decline of Executive Function. , 2016, 12, P113-P114.                 |     | 1         |
| 640 | P3â€269: Correlation of Cortical Thickness in Cognitively Healthy Elderly Monozygotic Twin Pairs. Alzheimer's and Dementia, 2016, 12, P935.   | 0.4 | 0         |
| 641 | P4â€112: Amyloid Levels in the Normal Range are Predictive for Incident Dementia in Nonâ€Demented Elderly. Alzheimer's and Dementia, 2016, 12, P1055.   | 0.4 | 0         |
| 642 | P4â€146: Largeâ€Vessel Disease and [18F]Flutemetamolâ€Amyloid Deposition in Cognitively Healthy Elderly Twins. Alzheimer's and Dementia, 2016, 12, P1069.   | 0.4 | 0         |
| 643 | P4â€153: Subjective Cognitive Decline and Progression to Dementia Due to AD and Nonâ€AD in Memory Clinic and Communityâ€Based Cohorts. Alzheimer's and Dementia, 2016, 12, P1073.                         | 0.4 | 1         |
| 644 | P4â€191: A Novel Neuroimaging Approach to Capture Cognitive Reserve. Alzheimer's and Dementia, 2016, 12, P1095.   | 0.4 | 0         |
| 645 | P4â€215: Quantification of Tau Load Using [ <sup>18</sup> F]AVâ€1451 and Pet. Alzheimer's and Dementia, 2016, 12, P1109.  | 0.4 | 0         |
| 646 | P4â€224: Alzheimerâ€™s Disease Patients With Osas History Have Higher CSF Tau Levels. Alzheimer's and Dementia, 2016, 12, P1115.  | 0.4 | 3         |
| 647 | FTS3â€01â€03: Biomarkers for Vascular Contributions to Dementia. Alzheimer's and Dementia, 2016, 12, P276.  | 0.4 | 0         |
| 648 | O1-01-01: Active and Passive Reserve Differentially Mitigate Cognitive Symptoms in Demented and Non-Demented Stages of Alzheimerâ€™s Disease. , 2016, 12, P169-P170.                                      |     | 0         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 649 | O1â€10â€01: Gantenerumab Treatment Reduces Biomarkers of Neuronal and Synaptic Degeneration in Alzheimerâ€™s Disease. <i>Alzheimer's and Dementia</i> , 2016, 12, P198.   | 0.4 | 3         |
| 650 | FTS2-01-04: The Dutch Dementia Delta Plan (DDDP). , 2016, 12, P220-P220.  |     | 0         |
| 651 | O4â€02â€04: Atrophy Patterns Predicting Cognitive Decline in Nonâ€Demented Subjects are Independent of Amyloid Pathology. <i>Alzheimer's and Dementia</i> , 2016, 12, P335.   | 0.4 | 0         |
| 652 | F5-05-01: THE PAST, PRESENT, AND FUTURE OF INSTRUMENTAL ACTIVITIES OF DAILY LIVING ASSESSMENTS IN ALZHEIMER'S DISEASE. , 2016, 12, P372-P373.   |     | 2         |
| 653 | P1â€238: When Less is More: Detecting Functional Decline Using a Short Version of the Amsterdam Iadl Questionnaire. <i>Alzheimer's and Dementia</i> , 2016, 12, P498.   | 0.4 | 0         |
| 654 | The Diagnostic and Prognostic Value ofâ€Neuropsychological Assessment inâ€Memory Clinic Patients. <i>Journal of Alzheimer's Disease</i> , 2016, 55, 679-689.  | 1.2 | 20        |
| 655 | Low Prevalence of Mixed Dementia in a Cohort of 2,000 Elderly Patients in a Memory Clinic Setting. <i>Journal of Alzheimer's Disease</i> , 2016, 50, 797-806.   | 1.2 | 24        |
| 656 | Genetic risk factors for the posterior cortical atrophy variant of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2016, 12, 862-871.  | 0.4 | 93        |
| 657 | Increased occurrence of protein kinase CK2 in astrocytes in Alzheimerâ€™s disease pathology. <i>Journal of Neuroinflammation</i> , 2016, 13, 4.   | 3.1 | 54        |
| 658 | Efficacy, Safety and Biomarker Data from SCarlet RoADâ€™a Global Phase 3 Study of Gantenerumab in Patients with Prodromal AD. <i>American Journal of Geriatric Psychiatry</i> , 2016, 24, S161-S162.                                  | 0.6 | 2         |
| 659 | CSF and amyloid pet biomarker data from scarlet roadâ€ a global Phase 3 study of gantenerumab in patients with prodromal AD. <i>Neurobiology of Aging</i> , 2016, 39, S28-S29.  | 1.5 | 2         |
| 660 | Combinations of Service Use Types of People With Early Cognitive Disorders. <i>Journal of the American Medical Directors Association</i> , 2016, 17, 620-625.   | 1.2 | 7         |
| 661 | Design of the NLâ€ENIGMA study: Exploring the effect of Souvenaid on cerebral glucose metabolism in early Alzheimer's disease. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2016, 2, 233-240. | 1.8 | 4         |
| 662 | Random forest to differentiate dementia with Lewy bodies from Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2016, 4, 99-106.   | 1.2 | 50        |
| 663 | Drug development in Alzheimerâ€™s disease: the path to 2025. <i>Alzheimer's Research and Therapy</i> , 2016, 8, 39.   | 3.0 | 323       |
| 664 | Diagnostic Accuracy of the Frontotemporal Dementia Consensus Criteria in the Late-Onset Frontal Lobe Syndrome. <i>Dementia and Geriatric Cognitive Disorders</i> , 2016, 41, 210-219.   | 0.7 | 29        |
| 665 | Pseudo-healthy Image Synthesis for White Matter Lesion Segmentation. <i>Lecture Notes in Computer Science</i> , 2016, , 87-96.  | 1.0 | 19        |
| 666 | S4-01-01: Cross-Sectional Studies of Plasma Proteomic Biomarkers Relating to Pet Amyloid and CSF Amyloid and Tau. , 2016, 12, P321-P321.  |     | 0         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 667 | O4â€09â€05: Risk Factors for Cognitive Decline are Age Dependent. Alzheimer's and Dementia, 2016, 12, P356.   | 0.4 | 0         |
| 668 | ICâ€Pâ€011: The Diagnostic Value of Amyloid Pet in an Unselected Cohort of Memory Clinic Patients. Alzheimer's and Dementia, 2016, 12, P19.   | 0.4 | 0         |
| 669 | P2â€342: Thinner Cortical Thickness in Patients with Subjective Cognitive Decline is Related to Poor Memory Performance and Faster Decline of Executive Function. Alzheimer's and Dementia, 2016, 12, P774.                 | 0.4 | 0         |
| 670 | O5-07-02: Personalized Risk Estimates for Mci Patients: Taking Biomarkers Into the Clinic. , 2016, 12, P393-P393.   |     | 1         |
| 671 | Effect Size Analyses of Souvenaid in Patients with Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2016, 55, 1131-1139.  | 1.2 | 34        |
| 672 | Bapineuzumab for mild to moderate Alzheimerâ€™s disease in two global, randomized, phase 3 trials. Alzheimer's Research and Therapy, 2016, 8, 18.   | 3.0 | 208       |
| 673 | Does MRI Increase the Diagnostic Confidence of Physicians in an Outpatient Memory Clinic. Dementia and Geriatric Cognitive Disorders Extra, 2016, 6, 242-251.   | 0.6 | 5         |
| 674 | Validation of soluble amyloidâ€12 precursor protein assays as diagnostic <scp>CSF</scp> biomarkers for neurodegenerative diseases. Journal of Neurochemistry, 2016, 137, 112-121.   | 2.1 | 17        |
| 675 | Schizophrenia as a mimic of behavioral variant frontotemporal dementia. Neurocase, 2016, 22, 285-288.   | 0.2 | 12        |
| 676 | ABCA7 p.G215S as potential protective factor for Alzheimer's disease. Neurobiology of Aging, 2016, 46, 235.e1-235.e9.   | 1.5 | 37        |
| 677 | Differences in structural covariance brain networks between behavioral variant frontotemporal dementia and Alzheimer's disease. Human Brain Mapping, 2016, 37, 978-988.   | 1.9 | 48        |
| 678 | Disrupted subjectâ€specific gray matter network properties and cognitive dysfunction in type 1 diabetes patients with and without proliferative retinopathy. Human Brain Mapping, 2016, 37, 1194-1208.                      | 1.9 | 25        |
| 679 | Cortical phase changes measured using 7â€T MRI in subjects with subjective cognitive impairment, and their association with cognitive function. NMR in Biomedicine, 2016, 29, 1289-1294.                                    | 1.6 | 12        |
| 680 | Impact of Imaging and Cerebrospinal Fluid Biomarkers on Behavioral Variant Frontotemporal Dementia Diagnosis within a Late-Onset Frontal Lobe Syndrome Cohort. Dementia and Geriatric Cognitive Disorders, 2016, 41, 16-26. | 0.7 | 12        |
| 681 | The effect of physical activity on cognitive function in patients with dementia: A meta-analysis of randomized control trials. Ageing Research Reviews, 2016, 25, 13-23.  | 5.0 | 455       |
| 682 | Alzheimer Disease and Behavioral Variant Frontotemporal Dementia: Automatic Classification Based on Cortical Atrophy for Single-Subject Diagnosis. Radiology, 2016, 279, 838-848.   | 3.6 | 79        |
| 683 | Cerebral perfusion in the predementia stages of Alzheimerâ€™s disease. European Radiology, 2016, 26, 506-514.   | 2.3 | 99        |
| 684 | Genome-wide analysis of genetic correlation in dementia with Lewy bodies, Parkinson's and Alzheimer's diseases. Neurobiology of Aging, 2016, 38, 214.e7-214.e10.  | 1.5 | 78        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 685 | Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria. <i>Alzheimer's and Dementia</i> , 2016, 12, 292-323.   | 0.4 | 1,318     |
| 686 | MRI visual rating scales in the diagnosis of dementia: evaluation in 184 post-mortem confirmed cases. <i>Brain</i> , 2016, 139, 1211-1225.  | 3.7 | 174       |
| 687 | Different patterns of cortical gray matter loss over time in behavioral variant frontotemporal dementia and Alzheimer's disease. <i>Neurobiology of Aging</i> , 2016, 38, 21-31.  | 1.5 | 40        |
| 688 | Defeating Alzheimer's disease and other dementias: a priority for European science and society. <i>Lancet Neurology</i> , The, 2016, 15, 455-532.   | 4.9 | 1,242     |
| 689 | Alzheimer's disease. <i>Lancet</i> , The, 2016, 388, 505-517.   | 6.3 | 2,430     |
| 690 | EEG-directed connectivity from posterior brain regions is decreased in dementia with Lewy bodies: a comparison with Alzheimer's disease and controls. <i>Neurobiology of Aging</i> , 2016, 41, 122-129.                                   | 1.5 | 52        |
| 691 | Alzheimer's disease risk variants modulate endophenotypes in mild cognitive impairment. <i>Alzheimer's and Dementia</i> , 2016, 12, 872-881.  | 0.4 | 50        |
| 692 | Role of Vascular Disease in Alzheimer-Like Progressive Cognitive Impairment. <i>Stroke</i> , 2016, 47, 577-580.   | 1.0 | 7         |
| 693 | Gray matter network disruptions and amyloid beta in cognitively normal adults. <i>Neurobiology of Aging</i> , 2016, 37, 154-160.  | 1.5 | 51        |
| 694 | Performance and complications of lumbar puncture in memory clinics: Results of the multicenter lumbar puncture feasibility study. <i>Alzheimer's and Dementia</i> , 2016, 12, 154-163.  | 0.4 | 179       |
| 695 | The Association of Glucose Metabolism and Eigenvector Centrality in Alzheimer's Disease. <i>Brain Connectivity</i> , 2016, 6, 1-8.  | 0.8 | 18        |
| 696 | Relation between subcortical grey matter atrophy and conversion from mild cognitive impairment to Alzheimer's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 425-432.                                      | 0.9 | 88        |
| 697 | The identification of cognitive subtypes in Alzheimer's disease dementia using latent class analysis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 235-243.   | 0.9 | 89        |
| 698 | A Semi-supervised Large Margin Algorithm for White Matter Hyperintensity Segmentation. <i>Lecture Notes in Computer Science</i> , 2016, , 104-112.  | 1.0 | 2         |
| 699 | Atrophy, hypometabolism and clinical trajectories in patients with amyloid-negative Alzheimer's disease. <i>Brain</i> , 2016, 139, 2528-2539.   | 3.7 | 58        |
| 700 | IC-P-115: Longitudinal white matter alterations of MCI patients in WP5 PharmaCog/E-ADNI study: Preliminary data. , 2015, 11, P79-P79.   |     | 0         |
| 701 | P3-158: Grey matter network disruptions are related to amyloid beta in cognitively healthy elderly. , 2015, 11, P689-P689.  |     | 0         |
| 702 | P4-040: Use of recent research criteria for inclusion and use of biomarkers as endpoint in preclinical and prodromal Alzheimer's disease (AD) trials: An Alzheimer's disease neuroimaging initiative (ADNI) study. , 2015, 11, P780-P781. |     | 0         |



| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 703 | P1-174: Diagnostic impact of [18 F]flutemetamol amyloid imaging in young onset dementia. , 2015, 11, P411-P412.  |     | 0         |
| 704 | P3-072: Are relations between ApoE genotype and ad-related pathology in nondemented elderly mediated by CSF apolipoproteins?. , 2015, 11, P644-P644.   |     | 0         |
| 705 | O4-05-04: A four-center study on the effect of polygenic risk score on cerebrospinal fluid markers and memory decline in mild cognitive impairment patients. , 2015, 11, P279-P279.  |     | 0         |
| 706 | Discriminative and prognostic potential of cerebrospinal fluid phosphoTau/tau ratio and neurofilaments for frontotemporal dementia subtypes. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2015, 1, 505-512. | 1.2 | 81        |
| 707 | IC-P-116: Hippocampal subfield changes in mild cognitive impairment patients with Alzheimer's disease pathology. , 2015, 11, P79-P80.  |     | 0         |
| 708 | IC-04-05: Multisite hippocampal subfields reproducibility: A european 3T study. , 2015, 11, P12-P12.   |     | 0         |
| 709 | IC-P-124: Classification of resting-state cerebral perfusion maps from patients with Alzheimer's disease and patients with frontotemporal dementia. , 2015, 11, P85-P85.   |     | 0         |
| 710 | P4-088: Lower cerebral blood flow is associated with cognitive decline in patients with Alzheimer's disease. , 2015, 11, P806-P806.  |     | 0         |
| 711 | P1-093: Dementia and rapid mortality: Who's at risk?. , 2015, 11, P374-P374.   |     | 0         |
| 712 | P2-298: Altered plasma and CSF levels of nutrients that enhance neuronal phospholipid synthesis in Alzheimer's disease: A retrospective cohort study. , 2015, 11, P606-P607.   |     | 0         |
| 713 | Differential Expression of microRNA in Cerebrospinal Fluid as a Potential Novel Biomarker for Alzheimer's Disease. Journal of Alzheimer's Disease, 2015, 47, 243-252.  | 1.2 | 35        |
| 714 | Amyloid- $\beta^2$ Oligomers Relate to Cognitive Decline in Alzheimer's Disease. Journal of Alzheimer's Disease, 2015, 45, 35-43.  | 1.2 | 52        |
| 715 | Matrix Metalloproteinases in Alzheimer's Disease and Concurrent Cerebral Microbleeds. Journal of Alzheimer's Disease, 2015, 48, 711-720.   | 1.2 | 71        |
| 716 | Serum Leptin is not Altered nor Related to Cognitive Decline in Alzheimer's Disease. Journal of Alzheimer's Disease, 2015, 44, 809-813.  | 1.2 | 42        |
| 717 | More Atrophy of Deep Gray Matter Structures in Frontotemporal Dementia Compared to Alzheimer's Disease. Journal of Alzheimer's Disease, 2015, 44, 635-647.   | 1.2 | 46        |
| 718 | Hypertensive Disorders of Pregnancy Appear Not to Be Associated with Alzheimer's Disease Later in Life. Dementia and Geriatric Cognitive Disorders Extra, 2015, 5, 375-385.  | 0.6 | 21        |
| 719 | P1-180: Hypometabolism of the posterior cingulate cortex is not restricted to Alzheimer's disease. , 2015, 11, P414-P414.  |     | 0         |
| 720 | Correcting for the Absence of a Gold Standard Improves Diagnostic Accuracy of Biomarkers in Alzheimer's Disease. Journal of Alzheimer's Disease, 2015, 46, 889-899.  | 1.2 | 11        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 721 | IC-P-079: Lower cerebral blood flow is associated with cognitive decline in patients with Alzheimer's disease. , 2015, 11, P57-P57.  |     | 0         |
| 722 | O4-10-02: Cross-cultural differences in instrumental activities of daily living (IADL): Translations and adaptations of the amsterdam iadl questionnaire. , 2015, 11, P293-P293.   |     | 0         |
| 723 | P4-089: Lower cerebral blood flow is related to more severe cognitive impairment in patients with dementia due to Alzheimer's disease. , 2015, 11, P806-P807.  |     | 1         |
| 724 | IC-04-03: Grey matter network disruptions are related to amyloid-beta in cognitively healthy elderly. , 2015, 11, P11-P11.   |     | 0         |
| 725 | IC-P-092: Visual assessment in postmortem-proven dementias: Clinical expertise versus machine learning. , 2015, 11, P64-P64.   |     | 0         |
| 726 | P3-182: Hippocampal subfield changes in mild cognitive impairment patients with Alzheimer's disease pathology. , 2015, 11, P700-P701.  |     | 0         |
| 727 | IC-P-062: Lower cerebral blood flow is related to more severe cognitive impairment in patients with dementia due to Alzheimer's disease. , 2015, 11, P46-P47.  |     | 0         |
| 728 | O3-09-02: An eeg study into functional connectivity and hubs in Alzheimer's disease: What's going on in the posterior regions?. , 2015, 11, P237-P238.   |     | 0         |
| 729 | Can agrin cerebrospinal fluid concentration be used as an early biomarker for Alzheimer's disease?. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2015, 1, 75-80.  | 1.2 | 4         |
| 730 | P2-174: Multi-site hippocampal subfields reproducibility: A european 3T study. , 2015, 11, P558-P558.  |     | 0         |
| 731 | O4-11-04: Performance and complications of lumbar puncture in memory clinics: Results of the multicenter lp feasibility study. , 2015, 11, P297-P297.  |     | 1         |
| 732 | Effects of Souvenaid on plasma micronutrient levels and fatty acid profiles in mild and mild-to-moderate Alzheimer's disease. Alzheimer's Research and Therapy, 2015, 7, 51.   | 3.0 | 38        |
| 733 | Loss of <sc>EEG</sc><sc>N</sc>etwork <sc>E</sc>fficiency <sc>I</sc>s <sc>R</sc>elated to <sc>C</sc>ognitive <sc>I</sc>mpairment in <sc>D</sc>ementia <sc>W</sc>ith <sc>L</sc>ewy <sc>B</sc>odies. Movement Disorders, 2015, 30, 1785-1793. | 2.2 | 65        |
| 734 | Timely Diagnosis for Alzheimer's Disease: A Literature Review on Benefits and Challenges. Journal of Alzheimer's Disease, 2015, 49, 617-631.   | 1.2 | 330       |
| 735 | Predicting Progression from Cognitive Impairment to Alzheimer's Disease with the Disease State Index. Current Alzheimer Research, 2015, 12, 69-79.   | 0.7 | 22        |
| 736 | The Central Biobank and Virtual Biobank of BIOMARKAPD: A Resource for Studies on Neurodegenerative Diseases. Frontiers in Neurology, 2015, 6, 216.   | 1.1 | 36        |
| 737 | Resting state functional connectivity differences between behavioral variant frontotemporal dementia and Alzheimer's disease. Frontiers in Human Neuroscience, 2015, 9, 474.   | 1.0 | 64        |
| 738 | Trajectories of cognitive decline in different types of dementia. Psychological Medicine, 2015, 45, 1051-1059.   | 2.7 | 85        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 739 | Prediction of AD dementia by biomarkers following the NIA&AA and&AWG diagnostic criteria in MCI patients from three European memory clinics. <i>Alzheimer's and Dementia</i> , 2015, 11, 1191-1201. | 0.4 | 71        |
| 740 | The role of the orbitofrontal cortex in cognition and behavior. <i>Reviews in the Neurosciences</i> , 2015, 26, 1-11.   | 1.4 | 49        |
| 741 | P4-242: A case-control cohort study to define a threshold for the tau/abeta42 ratio in cerebrospinal fluid optimized for diagnosis of Alzheimer's disease. , 2015, 11, P873-P873.                   |     | 0         |
| 742 | Atrophy patterns in early clinical stages across distinct phenotypes of Alzheimer's disease. <i>Human Brain Mapping</i> , 2015, 36, 4421-4437.  | 1.9 | 196       |
| 743 | O2-02-06: Slow gait speed and low grip strength are related to worse attention and mental speed in patients with subjective cognitive decline and mild cognitive impairment. , 2015, 11, P177-P177. |     | 0         |
| 744 | Joint assessment of white matter integrity, cortical and subcortical atrophy to distinguish AD from behavioral variant FTD: A two-center study. <i>NeuroImage: Clinical</i> , 2015, 9, 418-429.     | 1.4 | 38        |
| 745 | F2-03-03: Characterization of the behavioral and dysexecutive variants of Alzheimer's disease. , 2015, 11, P168-P168.   |     | 0         |
| 746 | DT-01-02: Biomarker data from scarlet road: A global phase 3 study of gantenerumab in patients with prodromal Alzheimer's disease. , 2015, 11, P331-P331.   |     | 4         |
| 747 | IC-01-04: Diagnostic impact of [18 F]flutemetamol amyloid imaging in young-onset dementia. , 2015, 11, P3-P4.   |     | 2         |
| 748 | P3-142: Alzheimer's biomarkers in daily practice (ABIDE): Study design. , 2015, 11, P679-P680.  |     | 0         |
| 749 | IC-P-093: Distinct patterns of atrophy in postmortem confirmed dementias. , 2015, 11, P64-P65.  |     | 0         |
| 750 | P4-087: Longitudinal white matter alterations of MCI patients in WP5 PharmaCog/E-ADNI study: Preliminary data. , 2015, 11, P805-P806.   |     | 0         |
| 751 | O1-07-02: Alzheimer's disease core biomarkers and prediction of dementia in MCI: The effect of age at onset. , 2015, 11, P140-P142.   |     | 0         |
| 752 | F2-03-02: Early onset APOE-É4-negative Alzheimer's disease patients show faster cognitive decline on non-memory domains. , 2015, 11, P168-P168.   |     | 1         |
| 753 | F2-03-04: Genetic risk factors for posterior cortical atrophy. , 2015, 11, P168-P169.   |     | 2         |
| 754 | O3-11-02: Prevalence and diagnostic procedures in early-onset dementia in tertiary referral center patients in denmark, sweden, and the netherlands. , 2015, 11, P244-P245.                         |     | 0         |
| 755 | O3-14-02: Assessing underlying Alzheimer's disease pathology in MCI patients from the amsterdam dementia cohort by use of the predictad software tool. , 2015, 11, P254-P255.                       |     | 0         |
| 756 | O3-14-04: The relation between eeg spectral analysis and clinical progression in non-demented, amyloid-positive subjects. , 2015, 11, P255-P256.  |     | 1         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 757 | F4-02-02: The influence of severity of total comorbidity on cognitive decline and conversion to dementia in memory clinic visitors. , 2015, 11, P260-P261.                              |     | 0         |
| 758 | FTS-04-01: Diagnostic impact of biomarkers including CSF and PET in a tertiary memory clinic. , 2015, 11, P263-P263.  |     | 0         |
| 759 | O4-08-05: Distinct patterns of atrophy in postmortem-confirmed dementias. , 2015, 11, P288-P289.  |     | 0         |
| 760 | O4-08-06: Visual assessment in postmortem-proven dementias: Clinical expertise versus machine learning. , 2015, 11, P289-P289.  |     | 0         |
| 761 | O5-02-03: Reduced cortical thickness in patients with subjective cognitive decline is related to clinical progression. , 2015, 11, P317-P317.   |     | 0         |
| 762 | O5-05-03: Neurogranin, a CSF biomarker for synaptic loss, predicts decline to dementia due to Alzheimer's disease. , 2015, 11, P326-P326.   |     | 0         |
| 763 | DTâ€1â€03: Efficacy and safety of gantenerumab in prodromal Alzheimer's disease: Results from scarlet roadâ€a global, multicenter trial. Alzheimer's and Dementia, 2015, 11, P331.   | 0.4 | 14        |
| 764 | The influence of genetic variants in SORL1 gene on the manifestation of Alzheimer's disease. Neurobiology of Aging, 2015, 36, 1605.e13-1605.e20.  | 1.5 | 27        |
| 765 | Standardized evaluation of algorithms for computer-aided diagnosis of dementia based on structural MRI: The CADDementia challenge. NeuroImage, 2015, 111, 562-579.                      | 2.1 | 266       |
| 766 | Temporal evolution of biomarkers and cognitive markers in the asymptomatic, MCI, and dementia stage of Alzheimer's disease. Alzheimer's and Dementia, 2015, 11, 511-522.                | 0.4 | 55        |
| 767 | White matter hyperintensities, cognitive impairment and dementia: an update. Nature Reviews Neurology, 2015, 11, 157-165.   | 4.9 | 811       |
| 768 | Diagnostic impact of CSF biomarkers for Alzheimer's disease in a tertiary memory clinic. Alzheimer's and Dementia, 2015, 11, 523-532.   | 0.4 | 59        |
| 769 | Prevalence and prognosis of Alzheimer's disease at the mild cognitive impairment stage. Brain, 2015, 138, 1327-1338.  | 3.7 | 284       |
| 770 | The EADCâ€ADNI Harmonized Protocol for manual hippocampal segmentation on magnetic resonance: Evidence of validity. Alzheimer's and Dementia, 2015, 11, 111-125.                       | 0.4 | 162       |
| 771 | Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer's disease. Alzheimer's and Dementia, 2015, 11, 1180-1190.       | 0.4 | 254       |
| 772 | Cerebrospinal fluid biomarkers and cerebral atrophy in distinct clinical variants of probable Alzheimer's disease. Neurobiology of Aging, 2015, 36, 2340-2347.                          | 1.5 | 49        |
| 773 | Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects. Brain, 2015, 138, 2701-2715.  | 3.7 | 109       |
| 774 | Rethinking biobanking and translational medicine in the Netherlands: how the research process stands to matter for patient care. European Journal of Human Genetics, 2015, 23, 736-738. | 1.4 | 7         |

| #   | ARTICLE  | IF   | CITATIONS |
|-----|--|------|-----------|
| 775 | Clinico-Pathological Correlations of the Frontal Lobe Syndrome: Results of a Large Brain Bank Study. <i>Dementia and Geriatric Cognitive Disorders</i> , 2015, 40, 121-129.                              | 0.7  | 4         |
| 776 | The trajectory of cognitive decline in the pre-dementia phase in memory clinic visitors: findings from the 4C-MCI study. <i>Psychological Medicine</i> , 2015, 45, 1509-1519.                            | 2.7  | 39        |
| 777 | The behavioural/dysexecutive variant of Alzheimer's disease: clinical, neuroimaging and pathological features. <i>Brain</i> , 2015, 138, 2732-2749.  | 3.7  | 397       |
| 778 | Tolerability and Safety of Souvenaid in Patients with Mild Alzheimer's Disease: Results of Multi-Center, 24-Week, Open-Label Extension Study. <i>Journal of Alzheimer's Disease</i> , 2015, 44, 471-480. | 1.2  | 44        |
| 779 | DNMT3A moderates cognitive decline in subjects with mild cognitive impairment: replicated evidence from two mild cognitive impairment cohorts. <i>Epigenomics</i> , 2015, 7, 533-537.                    | 1.0  | 23        |
| 780 | Cerebral perfusion and glucose metabolism in Alzheimer's disease and frontotemporal dementia: two sides of the same coin?. <i>European Radiology</i> , 2015, 25, 3050-3059.                              | 2.3  | 80        |
| 781 | The metabolic syndrome in a memory clinic population: Relation with clinical profile and prognosis. <i>Journal of the Neurological Sciences</i> , 2015, 351, 18-23.                                      | 0.3  | 19        |
| 782 | Early onset APOE E4-negative Alzheimer's disease patients show faster cognitive decline on non-memory domains. <i>European Neuropsychopharmacology</i> , 2015, 25, 1010-1017.                            | 0.3  | 43        |
| 783 | Angiotensin-Converting Enzyme in Cerebrospinal Fluid and Risk of Brain Atrophy. <i>Journal of Alzheimer's Disease</i> , 2015, 44, 153-162.   | 1.2  | 18        |
| 784 | EFNS-EANS-EAN Guideline on concomitant use of cholinesterase inhibitors and memantine in moderate to severe Alzheimer's disease. <i>European Journal of Neurology</i> , 2015, 22, 889-898.               | 1.7  | 110       |
| 785 | Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 1924.   | 3.8  | 1,166     |
| 786 | Prevalence of Amyloid PET Positivity in Dementia Syndromes. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 1939.   | 3.8  | 501       |
| 787 | Arterial stiffness and progression of structural brain changes. <i>Neurology</i> , 2015, 84, 448-455.  | 1.5  | 36        |
| 788 | Mild cognitive impairment with suspected nonamyloid pathology (SNAP). <i>Neurology</i> , 2015, 84, 508-515.  | 1.5  | 122       |
| 789 | The Rest-Activity Rhythm and Physical Activity in Early-Onset Dementia. <i>Alzheimer Disease and Associated Disorders</i> , 2015, 29, 45-49.   | 0.6  | 36        |
| 790 | Microbleeds, Mortality, and Stroke in Alzheimer Disease. <i>JAMA Neurology</i> , 2015, 72, 539.  | 4.5  | 48        |
| 791 | PLD3 variants in population studies. <i>Nature</i> , 2015, 520, E2-E3.   | 13.7 | 49        |
| 792 | Cerebrospinal fluid VILIP-1 and YKL-40, candidate biomarkers to diagnose, predict and monitor Alzheimer's disease in a memory clinic cohort. <i>Alzheimer's Research and Therapy</i> , 2015, 7, 59.      | 3.0  | 101       |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 793 | Declining functional connectivity and changing hub locations in Alzheimer's disease: an EEG study. <i>BMC Neurology</i> , 2015, 15, 145.  | 0.8 | 133       |
| 794 | Identifying bvFTD Within the Wide Spectrum of Late Onset Frontal Lobe Syndrome: A Clinical Approach. <i>American Journal of Geriatric Psychiatry</i> , 2015, 23, 1056-1066.                                   | 0.6 | 26        |
| 795 | White Matter Hyperintensities Relate to Clinical Progression in Subjective Cognitive Decline. <i>Stroke</i> , 2015, 46, 2661-2664.  | 1.0 | 73        |
| 796 | The sensitivity to change over time of the Amsterdam IADL Questionnaire. <i>Alzheimer's and Dementia</i> , 2015, 11, 1231-1240.   | 0.4 | 40        |
| 797 | Brain Health: The Importance of Recognizing Cognitive Impairment: An IAGG Consensus Conference. <i>Journal of the American Medical Directors Association</i> , 2015, 16, 731-739.                             | 1.2 | 222       |
| 798 | Neurogranin as a Cerebrospinal Fluid Biomarker for Synaptic Loss in Symptomatic Alzheimer Disease. <i>JAMA Neurology</i> , 2015, 72, 1275.  | 4.5 | 183       |
| 799 | 7T T2*-weighted magnetic resonance imaging reveals cortical phase differences between early- and late-onset Alzheimer's disease. <i>Neurobiology of Aging</i> , 2015, 36, 20-26.                              | 1.5 | 43        |
| 800 | The Two-Year Incidence of Depression and Anxiety Disorders in Spousal Caregivers of Persons with Dementia: Who is at the Greatest Risk?. <i>American Journal of Geriatric Psychiatry</i> , 2015, 23, 293-303. | 0.6 | 126       |
| 801 | Physical activity in the elderly is associated with improved executive function and processing speed: the LADIS Study. <i>International Journal of Geriatric Psychiatry</i> , 2015, 30, 744-750.              | 1.3 | 51        |
| 802 | Variability of CSF Alzheimer's Disease Biomarkers: Implications for Clinical Practice. <i>PLoS ONE</i> , 2014, 9, e100784.  | 1.1 | 72        |
| 803 | Widespread Disruption of Functional Brain Organization in Early-Onset Alzheimer's Disease. <i>PLoS ONE</i> , 2014, 9, e102995.  | 1.1 | 56        |
| 804 | SUCLG2 identified as both a determinant of CSF A $\beta$ 1-42 levels and an attenuator of cognitive decline in Alzheimer's disease. <i>Human Molecular Genetics</i> , 2014, 23, 6644-6658.                    | 1.4 | 45        |
| 805 | Single-Subject Gray Matter Graph Properties and Their Relationship with Cognitive Impairment in Early- and Late-Onset Alzheimer's Disease. <i>Brain Connectivity</i> , 2014, 4, 337-346.                      | 0.8 | 69        |
| 806 | Mutation frequency of PRKAR1B and the major familial dementia genes in a Dutch early onset dementia cohort. <i>Journal of Neurology</i> , 2014, 261, 2085-2092.   | 1.8 | 10        |
| 807 | Genetic analysis implicates APOE, SNCA and suggests lysosomal dysfunction in the etiology of dementia with Lewy bodies. <i>Human Molecular Genetics</i> , 2014, 23, 6139-6146.                                | 1.4 | 178       |
| 808 | Long-term effects of amyloid, hypometabolism, and atrophy on neuropsychological functions. <i>Neurology</i> , 2014, 82, 1768-1775.  | 1.5 | 51        |
| 809 | Prevalence of cortical superficial siderosis in a memory clinic population. <i>Neurology</i> , 2014, 82, 698-704.   | 1.5 | 71        |
| 810 | THE COMBINATION OF HIPPOCAMPAL ATROPHY ON MRI AND CSF IS A BIOMARKER FOR FRONTOTEMPORAL DEMENTIA IN EARLY ONSET DEMENTIA. , 2014, 10, P287-P288.  |     | 0         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 811 | Increased Number of Microinfarcts in Alzheimer Disease at 7-T MR Imaging. <i>Radiology</i> , 2014, 270, 205-211.  | 3.6 | 72        |
| 812 | Medial temporal lobe atrophy scores translated to clinical practice: Editorial comment on 'Influence of age, disease onset and ApoE4 on visual medial temporal lobe atrophy cutoffs'. <i>Journal of Internal Medicine</i> , 2014, 275, 331-333. | 2.7 | 13        |
| 813 | Amyloid and its association with default network integrity in Alzheimer's disease. <i>Human Brain Mapping</i> , 2014, 35, 779-791.  | 1.9 | 37        |
| 814 | Brain volume and white matter hyperintensities as determinants of cerebral blood flow in Alzheimer's disease. <i>Neurobiology of Aging</i> , 2014, 35, 2665-2670.   | 1.5 | 28        |
| 815 | Eyes-closed task-free electroencephalography in clinical trials for Alzheimer's disease: an emerging method based upon brain dynamics. <i>Alzheimer's Research and Therapy</i> , 2014, 6, 86.   | 3.0 | 44        |
| 816 | Diagnostic Criteria for Vascular Cognitive Disorders. <i>Alzheimer Disease and Associated Disorders</i> , 2014, 28, 206-218.  | 0.6 | 529       |
| 817 | O3-06-02: A RE-EVALUATION OF EARLY ALZHEIMER'S DISEASE BIOMARKERS ACCOUNTING FOR INACCURACY OF THE CLINICAL DIAGNOSIS. , 2014, 10, P219-P219.   |     | 0         |
| 818 | Associations Between Cerebral Small-Vessel Disease and Alzheimer Disease Pathology as Measured by Cerebrospinal Fluid Biomarkers. <i>JAMA Neurology</i> , 2014, 71, 855.  | 4.5 | 140       |
| 819 | Using Magnetic Resonance Imaging in Diagnosing Dementia: A Dutch Outpatient Memory Clinics Survey. <i>Dementia and Geriatric Cognitive Disorders</i> , 2014, 38, 281-285.   | 0.7 | 2         |
| 820 | Building a New Paradigm for the Early Recognition of Behavioral Variant Frontotemporal Dementia: Late Onset Frontal Lobe Syndrome Study. <i>American Journal of Geriatric Psychiatry</i> , 2014, 22, 735-740.                                   | 0.6 | 30        |
| 821 | Quantitative regional validation of the visual rating scale for posterior cortical atrophy. <i>European Radiology</i> , 2014, 24, 397-404.  | 2.3 | 27        |
| 822 | The effect of amyloid pathology and glucose metabolism on cortical volume loss over time in Alzheimer's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 1190-8.  | 3.3 | 7         |
| 823 | An algorithmic approach to structural imaging in dementia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014, 85, 692-698.  | 0.9 | 98        |
| 824 | Apraxia in Mild Cognitive Impairment and Alzheimer's Disease: Validity and Reliability of the Van Heugten Test for Apraxia. <i>Dementia and Geriatric Cognitive Disorders</i> , 2014, 38, 55-64.  | 0.7 | 33        |
| 825 | A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2014, 10, 844-852.  | 0.4 | 1,863     |
| 826 | Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. <i>Lancet Neurology</i> , 2014, 13, 614-629.  | 4.9 | 2,657     |
| 827 | Neurological abnormalities predict disability: the LADIS (Leukoaraiosis And DISability) study. <i>Journal of Neurology</i> , 2014, 261, 1160-1169.  | 1.8 | 16        |
| 828 | White Matter Hyperintensities and Cognitive Impairment During Electroconvulsive Therapy in Severely Depressed Elderly Patients. <i>American Journal of Geriatric Psychiatry</i> , 2014, 22, 157-166.  | 0.6 | 25        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 829 | Cerebrospinal fluid levels of Alzheimer's disease biomarkers in middle-aged patients with type 1 diabetes. <i>Diabetologia</i> , 2014, 57, 2208-2214.   | 2.9 | 40        |
| 830 | The association of angiotensin-converting enzyme with biomarkers for Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2014, 6, 27.  | 3.0 | 63        |
| 831 | Altered distribution of the EphA4 kinase in hippocampal brain tissue of patients with Alzheimer's disease correlates with pathology. <i>Acta Neuropathologica Communications</i> , 2014, 2, 79.   | 2.4 | 25        |
| 832 | Brain network alterations in Alzheimer's disease measured by Eigenvector centrality in fMRI are related to cognition and CSF biomarkers. <i>Human Brain Mapping</i> , 2014, 35, 2383-2393.  | 1.9 | 108       |
| 833 | Frontotemporal dementia and its subtypes: a genome-wide association study. <i>Lancet Neurology</i> , The, 2014, 13, 686-699.  | 4.9 | 302       |
| 834 | Comparison of Simplified Parametric Methods for Visual Interpretation of <sup>11</sup> C-Pittsburgh Compound-B PET Images. <i>Journal of Nuclear Medicine</i> , 2014, 55, 1305-1307.  | 2.8 | 24        |
| 835 | Distinct perfusion patterns in Alzheimer's disease, frontotemporal dementia and dementia with Lewy bodies. <i>European Radiology</i> , 2014, 24, 2326-2333.   | 2.3 | 50        |
| 836 | Automatic temporal lobe atrophy assessment in prodromal AD: Data from the DESCRIPA study. <i>Alzheimer's and Dementia</i> , 2014, 10, 456-467.  | 0.4 | 16        |
| 837 | No mutations in hnRNPA1 and hnRNPA2B1 in Dutch patients with amyotrophic lateral sclerosis, frontotemporal dementia, and inclusion body myopathy. <i>Neurobiology of Aging</i> , 2014, 35, 1956.e9-1956.e11.  | 1.5 | 26        |
| 838 | BRI2-BRICHOS is increased in human amyloid plaques in early stages of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2014, 35, 1596-1604.  | 1.5 | 46        |
| 839 | Regional atrophy is associated with impairment in distinct cognitive domains in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2014, 10, S299-305.  | 0.4 | 31        |
| 840 | The structure of the geriatric depressed brain and response to electroconvulsive therapy. <i>Psychiatry Research - Neuroimaging</i> , 2014, 222, 1-9.   | 0.9 | 25        |
| 841 | The cerebrospinal fluid 'Alzheimer profile': Easily said, but what does it mean?. <i>Alzheimer's and Dementia</i> , 2014, 10, 713.  | 0.4 | 249       |
| 842 | Dysglycemia, brain volume and vascular lesions on MRI in a memory clinic population. <i>Journal of Diabetes and Its Complications</i> , 2014, 28, 85-90.  | 1.2 | 17        |
| 843 | A Nutritional Approach to Ameliorate Altered Phospholipid Metabolism in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2014, 41, 715-717.   | 1.2 | 30        |
| 844 | Optimizing Patient Care and Research: The Amsterdam Dementia Cohort. <i>Journal of Alzheimer's Disease</i> , 2014, 41, 313-327.   | 1.2 | 307       |
| 845 | Concordance Between Cerebrospinal Fluid Biomarkers and [ <sup>11</sup> C]PIB PET in a Memory Clinic Cohort. <i>Journal of Alzheimer's Disease</i> , 2014, 41, 801-807.  | 1.2 | 109       |
| 846 | The effect of galantamine on brain atrophy rate in subjects with mild cognitive impairment is modified by apolipoprotein E genotype: post-hoc analysis of data from a randomized controlled trial. <i>Alzheimer's Research and Therapy</i> , 2014, 6, 47. | 3.0 | 24        |



| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 847 | Differences in Nutritional Status Between Very Mild Alzheimer's Disease Patients and Healthy Controls. <i>Journal of Alzheimer's Disease</i> , 2014, 41, 261-271.   | 1.2 | 75        |
| 848 | P1-258: CORTICAL PHASE CHANGES AT 7T MRI IN SUBJECTIVE COGNITIVE IMPAIRMENT AND THEIR ASSOCIATION WITH COGNITIVE FUNCTION. , 2014, 10, P402-P402.   |     | 1         |
| 849 | O2-13-05: APOLIPOPROTEIN A-1 IS ASSOCIATED WITH DECLINE IN PRECLINICAL AD. , 2014, 10, P195-P196.   |     | 0         |
| 850 | O5-02-02: LOBAR MICROBLEEDS PREDICT STROKE IN PATIENTS WITH ALZHEIMER'S DISEASE: THE MISTRAL STUDY. , 2014, 10, P291-P292.  |     | 0         |
| 851 | P1-135: DIRECTED ANTERIOR-TO-POSTERIOR COMMUNICATION IN THE BRAIN IS REVERSED IN DEMENTIA WITH LEWY BODIES AND IS RELATED TO ATTENTION DEFICITS. , 2014, 10, P349-P349.   |     | 1         |
| 852 | O2-13-03: MILD COGNITIVE IMPAIRMENT WITH SUSPECTED NON AD PATHOLOGY (SNAP): PREDICTION OF PROGRESSION TO DEMENTIA. , 2014, 10, P194-P195.   |     | 0         |
| 853 | P3-031: AMYLOID-BETA DEGRADATION BY HUMAN ASTROCYTES IS IMPAIRED BY APOJ AND APOE. , 2014, 10, P638-P638.   |     | 1         |
| 854 | P1-223: MORE ATROPHY OF DEEP GRAY MATTER STRUCTURES IN BEHAVIORAL VARIANT FRONTOTEMPORAL DEMENTIA COMPARED TO ALZHEIMER'S DISEASE. , 2014, 10, P385-P386.   |     | 0         |
| 855 | O4-06-02: CSF AD-PROFILE IN DEMENTIA WITH LEWY BODIES: EFFECT ON CLINICAL PARAMETERS AND COGNITIVE DECLINE. , 2014, 10, P261-P262.  |     | 0         |
| 856 | IC-P-085: COMPARING ATROPHY PATTERNS IN EARLY CLINICAL STAGES ACROSS DISTINCT PHENOTYPES OF ALZHEIMER'S DISEASE. , 2014, 10, P48-P49.   |     | 0         |
| 857 | O2-08-06: THE FUTURE OF CARE: THE DIGITAL ALZHEIMER CENTER-EVALUATION OF AN ONLINE PORTAL FOR PATIENTS WITH DEMENTIA AND THEIR INFORMAL CAREGIVERS. , 2014, 10, P181-P182.  |     | 0         |
| 858 | O4-01-05: CLINICALLY DIAGNOSED PROBABLE AD CASES WITH A NEGATIVE AMYLOID PET SCAN: CLINICAL FINDINGS. , 2014, 10, P250-P250.  |     | 1         |
| 859 | O4-11-04: ACTIVE A $\beta$ <sup>2</sup> IMMUNOTHERAPY CAD106 PHASE II DOSE-ADJUVANT FINDING STUDY: SAFETY AND CNS BIOMARKERS. , 2014, 10, P274-P274.  |     | 2         |
| 860 | P1-015: PROTEIN KINASE ACTIVITY DECREASES WITH BRAAK STAGE IN HIPPOCAMPAL POSTMORTEM BRAIN TISSUE AS REVEALED BY USING A PEPTIDE-BASED MICROARRAY PLATFORM. , 2014, 10, P309-P309.  |     | 0         |
| 861 | P1-385: RATIONALE AND DESIGN OF THE NL-ENIGMA STUDY, A DUTCH 24-WEEK RANDOMISED CONTROLLED STUDY TO EXPLORE THE EFFECT OF A NUTRITIONAL INTERVENTION ON BRAIN GLUCOSE METABOLISM IN EARLY ALZHEIMER'S DISEASE. , 2014, 10, P455-P456. |     | 0         |
| 862 | O2-07-04: COGNITIVE SUBTYPES IN DEMENTIA DUE TO ALZHEIMER'S DISEASE IDENTIFIED BY LATENT CLASS ANALYSIS. , 2014, 10, P178-P179.   |     | 0         |
| 863 | P1-381: EFFECTS OF THE MEDICAL FOOD SOUVENOID ON PLASMA NUTRIENT LEVELS IN MILD ALZHEIMER'S DISEASE DURING 48 WEEKS. , 2014, 10, P454-P454.   |     | 0         |
| 864 | O5-05-04: MATRIX METALLOPROTEINASES IN RELATION TO ALZHEIMER'S DISEASE AND CAA. , 2014, 10, P300-P300.  |     | 0         |

| #   | ARTICLE   | IF | CITATIONS |
|-----|---|----|-----------|
| 865 | IC-P-057: CLASSIFICATION OF PATHOLOGY USING BRAIN SUBSTRUCTURE VOLUMES IN POST MORTEM CONFIRMED DEMENTIAS. , 2014, 10, P32-P33.   |    | 0         |
| 866 | IC-P-077: LOBAR MICROBLEEDS PREDICT STROKE IN PATIENTS WITH ALZHEIMER'S DISEASE: THE MISTRAL STUDY. , 2014, 10, P43-P44.  |    | 0         |
| 867 | P3-403: CAPTURING CHANGES IN EVERYDAY FUNCTIONING. , 2014, 10, P778-P778.   |    | 0         |
| 868 | O4-01-06: NEURODEGENERATIVE AND COGNITIVE PROFILE OF PATIENTS WITH A TYPICAL PHENOTYPE OF AD BUT WITH A NEGATIVE AMYLOID SCAN. , 2014, 10, P250-P251.   |    | 0         |
| 869 | O4-07-05: ADDED VALUE OF MRI BIOMARKERS TO NEUROPSYCHOLOGICAL TEST PERFORMANCE FOR PREDICTION OF AD IN SUBJECTS WITH MCI. , 2014, 10, P265-P265.  |    | 1         |
| 870 | IC-P-076: WHITE MATTER HYPERINTENSITIES PREDICT MILD COGNITIVE IMPAIRMENT AND DEMENTIA IN PATIENTS WITH SUBJECTIVE COGNITIVE COMPLAINTS. , 2014, 10, P42-P43.   |    | 1         |
| 871 | O1-09-06: A EUROPEAN BIOBANK FOR THE VALIDATION OF NEW MARKERS FOR ALZHEIMER'S AND PARKINSON'S DISEASE: THE BIOMARKAPD PROJECT. , 2014, 10, P148-P148.  |    | 0         |
| 872 | O2-14-03: THE REST-ACTIVITY RHYTHM IS RELATED TO THE LEVEL OF PHYSICAL ACTIVITY IN EARLY-ONSET DEMENTIA. , 2014, 10, P197-P198.   |    | 0         |
| 873 | IC-P-056: MORE ATROPHY OF DEEP GRAY MATTER STRUCTURES IN BEHAVIORAL VARIANT FRONTOTEMPORAL DEMENTIA COMPARED TO ALZHEIMER'S DISEASE. , 2014, 10, P31-P32.   |    | 0         |
| 874 | IC-P-109: RATIONALE AND DESIGN OF THE NL-ENIGMA STUDY: A DUTCH 24-WEEK RANDOMISED CONTROLLED STUDY TO EXPLORE THE EFFECT OF NUTRITIONAL INTERVENTION ON BRAIN GLUCOSE METABOLISM IN EARLY ALZHEIMER DISEASE. , 2014, 10, P61-P61. |    | 1         |
| 875 | P1-134: LOSS OF NETWORK INTEGRATION IS RELATED TO COGNITIVE IMPAIRMENT IN DEMENTIA WITH LEWY BODIES. , 2014, 10, P349-P349.   |    | 0         |
| 876 | P1-149: CSF VILIP-1 AND YKL-40, NOVEL CANDIDATE BIOMARKERS TO DIAGNOSE, PREDICT, AND MONITOR ALZHEIMER'S DISEASE. , 2014, 10, P355-P355.  |    | 0         |
| 877 | P1-233: MULTIMODAL BRAIN NETWORK ALTERATIONS IN ALZHEIMER'S DISEASE AND MILD COGNITIVE IMPAIRMENT PATIENTS. , 2014, 10, P389-P390.  |    | 0         |
| 878 | P2-196: RESTING STATE CEREBRAL PERFUSION AND METABOLISM IN SUBJECTIVE MEMORY COMPLAINTS: ALZHEIMER'S DISEASE AND FRONTOTEMPORAL DEMENTIA-TWO SIDES OF THE SAME COIN?. , 2014, 10, P543-P543.                                      |    | 1         |
| 879 | P4-273: CEREBROSPINAL FLUID NEUROGRANIN AS A PROGNOSTIC MARKER IN MILD COGNITIVE IMPAIRMENT AND ALZHEIMER'S DISEASE. , 2014, 10, P884-P884.   |    | 0         |
| 880 | O1-02-04: 7T T2*-WEIGHTED MRI REVEALS CORTICAL PHASE DIFFERENCES BETWEEN EARLY- AND LATE-ONSET AD. , 2014, 10, P132-P133.   |    | 0         |
| 881 | O2-08-05: THE DIGITAL ALZHEIMER CENTER: A NEXT STEP TOWARD INNOVATIVE DEMENTIA CARE. , 2014, 10, P181-P181.   |    | 0         |
| 882 | O2-13-01: PREVALENCE AND PROGNOSIS OF PRODROMAL ALZHEIMER'S DISEASE: A COMPARISON OF THE INTERNATIONAL WORKING GROUP CRITERIA AND NATIONAL INSTITUTE OF AGING-ALZHEIMER'S ASSOCIATION CRITERIA. , 2014, 10, P193-P193.            |    | 0         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 883 | O4-01-01: DIAGNOSTIC VALUE OF AMYLOID IMAGING IN EARLY ONSET DEMENTIA. , 2014, 10, P248-P248.   |     | 1         |
| 884 | P3-096: MAGNETOENCEPHALOGRAPHY IN DEMENTIA: THE STATE OF THE ART. , 2014, 10, P663-P663.  |     | 1         |
| 885 | P1-174: CEREBROVASCULAR DISEASE IN LATE ONSET FRONTAL LOBE SYNDROME. , 2014, 10, P363-P363.   |     | 0         |
| 886 | P1-415: STUDY PROTOCOL: THE EFFECT OF PHYSICAL EXERCISE ON CEREBRAL BLOOD FLOW AND COGNITION IN PATIENTS WITH MILD VASCULAR COGNITIVE IMPAIRMENT. , 2014, 10, P465-P466.  |     | 0         |
| 887 | P2-190: CLASSIFICATION OF PATHOLOGY USING BRAIN SUBSTRUCTURE VOLUMES IN POSTMORTEM CONFIRMED DEMENTIAS. , 2014, 10, P540-P541.  |     | 0         |
| 888 | P4-351: A PLASMA PHOSPHOLIPID BIOMARKER PROFILE FOR DETECTING PRECLINICAL ALZHEIMER'S DISEASE CAN BE MODIFIED BY ORAL INTAKE OF NUTRIENTS THAT INCREASE PHOSPHOLIPID SYNTHESIS. , 2014, 10, P916-P917.              |     | 0         |
| 889 | The Effect of Souvenaid on Functional Brain Network Organisation in Patients with Mild Alzheimer's Disease: A Randomised Controlled Study. PLoS ONE, 2014, 9, e86558.   | 1.1 | 95        |
| 890 | Dementia Due to Neurodegenerative Disease: Molecular Imaging Findings. , 2014, , 185-211.   |     | 1         |
| 891 | Altered distribution of the EphA4 kinase in hippocampal brain tissue of patients with Alzheimer's disease correlates with pathology. Acta Neuropathologica Communications, 2014, 2, 79.                             | 2.4 | 18        |
| 892 | Deterioration of Gait and Balance over Time: The Effects of Age-Related White Matter Change - The LADIS Study. Cerebrovascular Diseases, 2013, 35, 544-553.   | 0.8 | 65        |
| 893 | Cerebral white matter changes are associated with abnormalities on neurological examination in non-disabled elderly: the LADIS study. Journal of Neurology, 2013, 260, 1014-1021.                                   | 1.8 | 34        |
| 894 | Blood Pressure and Progression of Brain Atrophy. JAMA Neurology, 2013, 70, 1046.  | 4.5 | 42        |
| 895 | Mild cognitive impairment and amyloid and beyond. Nature Reviews Neurology, 2013, 9, 493-495.   | 4.9 | 6         |
| 896 | Pharmacological Treatment of Dementia: A Scoping Review of Systematic Reviews. Dementia and Geriatric Cognitive Disorders, 2013, 36, 211-228.   | 0.7 | 47        |
| 897 | Impact of molecular imaging on the diagnostic process in a memory clinic. Alzheimer's and Dementia, 2013, 9, 414-421.   | 0.4 | 159       |
| 898 | Depressive symptoms predict cognitive decline and dementia in older people independently of cerebral white matter changes: the LADIS study. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 1250-1254. | 0.9 | 68        |
| 899 | Alzheimer's disease patients not carrying the apolipoprotein E ε4 allele show more severe slowing of oscillatory brain activity. Neurobiology of Aging, 2013, 34, 2158-2163.  | 1.5 | 19        |
| 900 | The cost-effectiveness of a family meetings intervention to prevent depression and anxiety in family caregivers of patients with dementia: a randomized trial. Trials, 2013, 14, 305.                               | 0.7 | 26        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 901 | Visual ratings of atrophy in MCI: prediction of conversion and relationship with CSF biomarkers. <i>Neurobiology of Aging</i> , 2013, 34, 73-82.   | 1.5 | 41        |
| 902 | Microglial activation in Alzheimer's disease: an (R)-[11C]PK11195 positron emission tomography study. <i>Neurobiology of Aging</i> , 2013, 34, 128-136.  | 1.5 | 145       |
| 903 | Measurements of medial temporal lobe atrophy for prediction of Alzheimer's disease in subjects with mild cognitive impairment. <i>Neurobiology of Aging</i> , 2013, 34, 2003-2013.                       | 1.5 | 86        |
| 904 | S1-02-02: Clinical and neuropsychological features as predictors from MCI to Alzheimer's-type dementia. , 2013, 9, P122-P122.  |     | 0         |
| 905 | O3-05-01: Physical activity, independent functioning and emotional well-being in early-onset dementia. , 2013, 9, P526-P526.   |     | 0         |
| 906 | Cognitive correlates of cerebrospinal fluid biomarkers in frontotemporal dementia. , 2013, 9, 269-275.   |     | 19        |
| 907 | Different patterns of gray matter atrophy in early- and late-onset Alzheimer's disease. <i>Neurobiology of Aging</i> , 2013, 34, 2014-2022.  | 1.5 | 156       |
| 908 | Imaging markers for Alzheimer disease. <i>Neurology</i> , 2013, 81, 487-500.   | 1.5 | 204       |
| 909 | O1-09-01: Diagnostic impact of CSF biomarkers for Alzheimer's disease in a memory clinic setting. , 2013, 9, P144-P145.  |     | 0         |
| 910 | Specific risk factors for microbleeds and white matter hyperintensities in Alzheimer's disease. <i>Neurobiology of Aging</i> , 2013, 34, 2488-2494.  | 1.5 | 66        |
| 911 | Cerebrospinal fluid A $\beta$ 42 is the best predictor of clinical progression in patients with subjective complaints. <i>Alzheimer's and Dementia</i> , 2013, 9, 481-487.                               | 0.4 | 164       |
| 912 | Preface. <i>Medical Clinics of North America</i> , 2013, 97, xiii-xv.  | 1.1 | 4         |
| 913 | Discriminatory and predictive capabilities of enzyme-linked immunosorbent assay and multiplex platforms in a longitudinal Alzheimer's disease study. <i>Alzheimer's and Dementia</i> , 2013, 9, 276-283. | 0.4 | 25        |
| 914 | Diffusion changes predict cognitive and functional outcome: The LADIS study. <i>Annals of Neurology</i> , 2013, 73, 576-583.   | 2.8 | 66        |
| 915 | An MRI Rating Scale for Amyloid-Related Imaging Abnormalities with Edema or Effusion. <i>American Journal of Neuroradiology</i> , 2013, 34, 1550-1555.   | 1.2 | 40        |
| 916 | Prediction of Alzheimer disease in subjects with amnesic and nonamnesic MCI. <i>Neurology</i> , 2013, 80, 1124-1132.   | 1.5 | 110       |
| 917 | Alzheimer's disease: connecting findings from graph theoretical studies of brain networks. <i>Neurobiology of Aging</i> , 2013, 34, 2023-2036.   | 1.5 | 355       |
| 918 | A prediction model to calculate probability of Alzheimer's disease using cerebrospinal fluid biomarkers. <i>Alzheimer's and Dementia</i> , 2013, 9, 262-268.   | 0.4 | 22        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 919 | Progress in Alzheimer's disease research circa 2013: Is the glass half empty or half full?. Alzheimer's Research and Therapy, 2013, 5, 26.  | 3.0 | 1         |
| 920 | International Work Group Criteria for the Diagnosis of Alzheimer Disease. Medical Clinics of North America, 2013, 97, 363-368.  | 1.1 | 72        |
| 921 | Functional segmentation of the hippocampus in the healthy human brain and in Alzheimer's disease. NeuroImage, 2013, 66, 28-35.  | 2.1 | 85        |
| 922 | Treating Alzheimer's disease with monoclonal antibodies: current status and outlook for the future. Alzheimer's Research and Therapy, 2013, 5, 56.  | 3.0 | 51        |
| 923 | Plasma homocysteine, Alzheimer and cerebrovascular pathology: a population-based autopsy study. Brain, 2013, 136, 2707-2716.  | 3.7 | 111       |
| 924 | Confirmatory factor analysis of the Neuropsychological Assessment Battery of the LADIS study: A longitudinal analysis. Journal of Clinical and Experimental Neuropsychology, 2013, 35, 269-278.   | 0.8 | 8         |
| 925 | The Association Between APOE $\epsilon$ 4 and Alzheimer-type Dementia Among Memory Clinic Patients is Confined to those with a Higher Education. The DESCRIPA Study. Journal of Alzheimer's Disease, 2013, 35, 241-246.   | 1.2 | 7         |
| 926 | Validation of the Amsterdam IADL Questionnaire, a New Tool to Measure Instrumental Activities of Daily Living in Dementia. Neuroepidemiology, 2013, 41, 35-41.  | 1.1 | 65        |
| 927 | Cerebral Blood Flow Measured with 3D Pseudocontinuous Arterial Spin-labeling MR Imaging in Alzheimer Disease and Mild Cognitive Impairment: A Marker for Disease Severity. Radiology, 2013, 267, 221-230.   | 3.6 | 206       |
| 928 | Differential effect of APOE $\epsilon$ genotype on amyloid load and glucose metabolism in AD dementia. Neurology, 2013, 80, 359-365.  | 1.5 | 99        |
| 929 | Prediction of dementia in MCI patients based on core diagnostic markers for Alzheimer disease. Neurology, 2013, 80, 1048-1056.  | 1.5 | 161       |
| 930 | Preclinical AD predicts decline in memory and executive functions in subjective complaints. Neurology, 2013, 81, 1409-1416.   | 1.5 | 122       |
| 931 | Assessment of Instrumental Activities of Daily Living in Dementia. Journal of Geriatric Psychiatry and Neurology, 2013, 26, 244-250.  | 1.2 | 45        |
| 932 | Longitudinal Amyloid Imaging Using $^{11}\text{C}$ -PiB: Methodologic Considerations. Journal of Nuclear Medicine, 2013, 54, 1570-1576.   | 2.8 | 148       |
| 933 | Single-Domain Amnesic Mild Cognitive Impairment Identified by Cluster Analysis Predicts Alzheimer's Disease in the European Prospective DESCRIPA Study. Dementia and Geriatric Cognitive Disorders, 2013, 36, 1-19.   | 0.7 | 41        |
| 934 | Anxiety is related to Alzheimer cerebrospinal fluid markers in subjects with mild cognitive impairment. Psychological Medicine, 2013, 43, 911-920.  | 2.7 | 93        |
| 935 | Immunohistochemical characterization of novel monoclonal antibodies against the N-terminus of amyloid $\beta$ -peptide. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2013, 20, 179-187. | 1.4 | 18        |
| 936 | Associations between Magnetic Resonance Imaging Measures and Neuropsychological Impairment in Early and Late Onset Alzheimer's Disease. Journal of Alzheimer's Disease, 2013, 35, 169-178.  | 1.2 | 21        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 937 | Predictors of Progression from Mild Cognitive Impairment to Dementia in the Placebo-Arm of a Clinical Trial Population. <i>Journal of Alzheimer's Disease</i> , 2013, 36, 79-85.  | 1.2 | 21        |
| 938 | Progression to dementia in memory clinic patients without dementia. <i>Neurology</i> , 2013, 81, 1342-1349.   | 1.5 | 21        |
| 939 | The S-Connect study: results from a randomized, controlled trial of Souvenaid in mild-to-moderate Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2013, 5, 59.   | 3.0 | 80        |
| 940 | Increase in Cerebrospinal Fluid F2-Isoprostanes is Related to Cognitive Decline in APOE $\epsilon$ 4 Carriers. <i>Journal of Alzheimer's Disease</i> , 2013, 36, 563-570.   | 1.2 | 19        |
| 941 | Single-Subject Grey Matter Graphs in Alzheimer's Disease. <i>PLoS ONE</i> , 2013, 8, e58921.  | 1.1 | 107       |
| 942 | Integrative EEG biomarkers predict progression to Alzheimer's disease at the MCI stage. <i>Frontiers in Aging Neuroscience</i> , 2013, 5, 58.   | 1.7 | 143       |
| 943 | Clinical Symptoms and Risk Factors in Cerebral Microangiopathy Patients. <i>PLoS ONE</i> , 2013, 8, e53455.   | 1.1 | 44        |
| 944 | Relationships Between White Matter Hyperintensities, Cerebral Amyloid Angiopathy and Dementia in a Population-based Sample of the Oldest Old. <i>Current Alzheimer Research</i> , 2013, 10, 1090-1097.                                    | 0.7 | 12        |
| 945 | Injury markers predict time to dementia in subjects with MCI and amyloid pathology. <i>Neurology</i> , 2012, 79, 1809-1816.   | 1.5 | 129       |
| 946 | Exercise and Early-Onset Alzheimer's Disease: Theoretical Considerations. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2012, 2, 132-145.   | 0.6 | 18        |
| 947 | Amyloid burden and metabolic function in early-onset Alzheimer's disease: parietal lobe involvement. <i>Brain</i> , 2012, 135, 2115-2125.   | 3.7 | 109       |
| 948 | Lessons Learned in Eastern Europe. , 2012, , 99-103.  |     | 0         |
| 949 | Microbleeds in dementia "singing a different ARIA. <i>Nature Reviews Neurology</i> , 2012, 8, 68-70.  | 4.9 | 10        |
| 950 | Early Onset Alzheimer's Disease is Associated with a Distinct Neuropsychological Profile. <i>Journal of Alzheimer's Disease</i> , 2012, 30, 101-108.  | 1.2 | 156       |
| 951 | Blood "brain barrier P-glycoprotein function in Alzheimer's disease. <i>Brain</i> , 2012, 135, 181-189.   | 3.7 | 252       |
| 952 | Atrophy of medial temporal lobes on MRI in "probable" Alzheimer's disease and normal ageing: diagnostic value and neuropsychological correlates: Table 1. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2012, 83, 1038-1040. | 0.9 | 47        |
| 953 | White Matter Lesion Progression in LADIS. <i>Stroke</i> , 2012, 43, 2643-2647.  | 1.0 | 88        |
| 954 | Progression of Alzheimer Disease in Europe: Data from the European ICTUS Study. <i>Current Alzheimer Research</i> , 2012, 9, 902-912.   | 0.7 | 42        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 955 | MRI-based biomarkers of preclinical AD. <i>Neurology</i> , 2012, 78, 80-81.  | 1.5 | 4         |
| 956 | Injury Markers but not Amyloid Markers are Associated with Rapid Progression from Mild Cognitive Impairment to Dementia in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2012, 29, 319-327. | 1.2 | 73        |
| 957 | Efficacy of Souvenaid in Mild Alzheimer's Disease: Results from a Randomized, Controlled Trial. <i>Journal of Alzheimer's Disease</i> , 2012, 31, 225-236.   | 1.2 | 256       |
| 958 | Memantine and Brain Atrophy in Alzheimer's Disease: A 1-Year Randomized Controlled Trial. <i>Journal of Alzheimer's Disease</i> , 2012, 29, 459-469.   | 1.2 | 35        |
| 959 | Identifying target groups for the prevention of depression among caregivers of dementia patients. <i>International Psychogeriatrics</i> , 2012, 24, 298-306.   | 0.6 | 34        |
| 960 | Improving the Accuracy and Precision of Cognitive Testing in Mild Dementia. <i>Journal of the International Neuropsychological Society</i> , 2012, 18, 314-322.  | 1.2 | 15        |
| 961 | Physical Activity Prevents Progression for Cognitive Impairment and Vascular Dementia. <i>Stroke</i> , 2012, 43, 3331-3335.  | 1.0 | 98        |
| 962 | <sc>EFNS</sc> Guidelines on the diagnosis and management of disorders associated with dementia. <i>European Journal of Neurology</i> , 2012, 19, 1159-1179.  | 1.7 | 239       |
| 963 | Increased skin temperature in Alzheimer's disease is associated with sleepiness. <i>Journal of Neural Transmission</i> , 2012, 119, 1185-1194.   | 1.4 | 14        |
| 964 | No Evidence for Additional Blood-Brain Barrier P-Glycoprotein Dysfunction in Alzheimer's Disease Patients with Microbleeds. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2012, 32, 1468-1471.    | 2.4 | 18        |
| 965 | P-Glycoprotein Function at the Blood-Brain Barrier: Effects of Age and Gender. <i>Molecular Imaging and Biology</i> , 2012, 14, 771-776.   | 1.3 | 127       |
| 966 | A new informant-based questionnaire for instrumental activities of daily living in dementia. <i>Alzheimer's and Dementia</i> , 2012, 8, 536-543.   | 0.4 | 80        |
| 967 | Comparison of International Working Group criteria and National Institute on Aging-Alzheimer's Association criteria for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2012, 8, 560-563.           | 0.4 | 47        |
| 968 | S2: Understanding (endo)phenotypical heterogeneity: The role of age and APOE. <i>Alzheimer's and Dementia</i> , 2012, 8, P228.   | 0.4 | 0         |
| 969 | Discrepancy Between Subjective and Objective Sleep Disturbances in Early- and Moderate-Stage Alzheimer Disease. <i>American Journal of Geriatric Psychiatry</i> , 2012, 20, 460-467.                       | 0.6 | 80        |
| 970 | O4: Differential impact of apolipoprotein E genotype on distributions of amyloid load and glucose metabolism in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2012, 8, P618.                      | 0.4 | 0         |
| 971 | Decreased mRNA expression of CCL5 [RANTES] in Alzheimer's disease blood samples. <i>Clinical Chemistry and Laboratory Medicine</i> , 2012, 50, 61-5.   | 1.4 | 21        |
| 972 | The association between white matter hyperintensities and executive decline in mild cognitive impairment is network dependent. <i>Neurobiology of Aging</i> , 2012, 33, 201.e1-201.e8.                     | 1.5 | 48        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 973 | Microglial activation in healthy aging. <i>Neurobiology of Aging</i> , 2012, 33, 1067-1072.   | 1.5 | 125       |
| 974 | Prediction of conversion from mild cognitive impairment to Alzheimer's disease dementia based upon biomarkers and neuropsychological test performance. <i>Neurobiology of Aging</i> , 2012, 33, 1203-1214.e2.   | 1.5 | 346       |
| 975 | Posterior cerebral atrophy in the absence of medial temporal lobe atrophy in pathologically-confirmed Alzheimer's disease. <i>Neurobiology of Aging</i> , 2012, 33, 627.e1-627.e12.                             | 1.5 | 74        |
| 976 | Serial CSF sampling in Alzheimer's disease: specific versus non-specific markers. <i>Neurobiology of Aging</i> , 2012, 33, 1591-1598.   | 1.5 | 52        |
| 977 | Resting-state fMRI changes in Alzheimer's disease and mild cognitive impairment. <i>Neurobiology of Aging</i> , 2012, 33, 2018-2028.  | 1.5 | 337       |
| 978 | Young Alzheimer patients show distinct regional changes of oscillatory brain dynamics. <i>Neurobiology of Aging</i> , 2012, 33, 1008.e25-1008.e31.  | 1.5 | 34        |
| 979 | Microbleeds relate to altered amyloid-beta metabolism in Alzheimer's disease. <i>Neurobiology of Aging</i> , 2012, 33, 1011.e1-1011.e9.   | 1.5 | 55        |
| 980 | Test sequence of CSF and MRI biomarkers for prediction of AD in subjects with MCI. <i>Neurobiology of Aging</i> , 2012, 33, 2272-2281.  | 1.5 | 75        |
| 981 | 68 Cerebral microbleeds: identification, prevalence and clinical relevance. <i>Neurobiology of Aging</i> , 2012, 33, S30.   | 1.5 | 0         |
| 982 | Microbleeds do not affect rate of cognitive decline in Alzheimer disease. <i>Neurology</i> , 2012, 79, 763-769.   | 1.5 | 72        |
| 983 | Episodic memory and the medial temporal lobe: not all it seems. Evidence from the temporal variants of frontotemporal dementia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2012, 83, 1145-1148. | 0.9 | 24        |
| 984 | Dementia: Alzheimer pathology and vascular factors: From mutually exclusive to interaction. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2012, 1822, 340-349.                            | 1.8 | 61        |
| 985 | Disturbed oscillatory brain dynamics in subcortical ischemic vascular dementia. <i>BMC Neuroscience</i> , 2012, 13, 85.   | 0.8 | 24        |
| 986 | Diagnostic and economic evaluation of new biomarkers for Alzheimer's disease: the research protocol of a prospective cohort study. <i>BMC Neurology</i> , 2012, 12, 72.   | 0.8 | 24        |
| 987 | Study protocol: EXERcise and Cognition In Sedentary adults with Early-ONset dementia (EXERCISE-ON). <i>BMC Neurology</i> , 2012, 12, 75.  | 0.8 | 14        |
| 988 | Disruption of Functional Brain Networks in Alzheimer's Disease: What Can We Learn from Graph Spectral Analysis of Resting-State Magnetoencephalography?. <i>Brain Connectivity</i> , 2012, 2, 45-55.            | 0.8 | 85        |
| 989 | Disrupted modular brain dynamics reflect cognitive dysfunction in Alzheimer's disease. <i>NeuroImage</i> , 2012, 59, 3085-3093.   | 2.1 | 190       |
| 990 | Leeftijd: een belangrijke factor voor cognitieve profielen van de ziekte van Alzheimer. <i>Neuropraxis</i> , 2012, 16, 183-191.   | 0.1 | 0         |



| #    | ARTICLE   | IF  | CITATIONS |
|------|---|-----|-----------|
| 991  | Blood-brain barrier P-glycoprotein function in healthy subjects and Alzheimer's disease patients: effect of polymorphisms in the ABCB1 gene. <i>EJNMMI Research</i> , 2012, 2, 57.  | 1.1 | 53        |
| 992  | Does a Family Meetings Intervention Prevent Depression and Anxiety in Family Caregivers of Dementia Patients? A Randomized Trial. <i>PLoS ONE</i> , 2012, 7, e30936.  | 1.1 | 74        |
| 993  | Longitudinal imaging of Alzheimer pathology using [11C]PIB, [18F]FDDNP and [18F]FDG PET. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 990-1000.  | 3.3 | 145       |
| 994  | Reproducibility of quantitative (R)-[11C]verapamil studies. <i>EJNMMI Research</i> , 2012, 2, 1.  | 1.1 | 45        |
| 995  | Activity Dependent Degeneration Explains Hub Vulnerability in Alzheimer's Disease. <i>PLoS Computational Biology</i> , 2012, 8, e1002582.   | 1.5 | 336       |
| 996  | Effectiveness of Family Meetings for Family Caregivers on Delaying Time to Nursing Home Placement of Dementia Patients: A Randomized Trial. <i>PLoS ONE</i> , 2012, 7, e42145.  | 1.1 | 21        |
| 997  | Heterogeneity of small vessel disease: a systematic review of MRI and histopathology correlations. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2011, 82, 126-135.  | 0.9 | 588       |
| 998  | Normal Ageing. , 2011, , 43-57.   |     | 5         |
| 999  | Corpus callosum atrophy as a predictor of age-related cognitive and motor impairment: A 3-year follow-up of the LADIS study cohort. <i>Journal of the Neurological Sciences</i> , 2011, 307, 100-105.   | 0.3 | 57        |
| 1000 | Biomarkers for Alzheimer's disease therapeutic trials. <i>Progress in Neurobiology</i> , 2011, 95, 579-593.   | 2.8 | 119       |
| 1001 | Prevention trials in Alzheimer's disease: An EU-US task force report. <i>Progress in Neurobiology</i> , 2011, 95, 594-600.  | 2.8 | 62        |
| 1002 | Progression from MCI to AD: Predictive value of CSF A $\beta$ 242 is modified by APOE genotype. <i>Neurobiology of Aging</i> , 2011, 32, 1372-1378.   | 1.5 | 12        |
| 1003 | 2001-2011: A Decade of the LADIS (Leukoaraiosis And DISability) Study: What Have We Learned about White Matter Changes and Small-Vessel Disease?. <i>Cerebrovascular Diseases</i> , 2011, 32, 577-588.  | 0.8 | 258       |
| 1004 | The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2011, 7, 263-269. | 0.4 | 12,681    |
| 1005 | Steps to standardization and validation of hippocampal volumetry as a biomarker in clinical trials and diagnostic criterion for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2011, 7, 474.  | 0.4 | 176       |
| 1006 | How golden is the gold standard of neuropathology in dementia?. <i>Alzheimer's and Dementia</i> , 2011, 7, 486-489.   | 0.4 | 65        |
| 1007 | Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: Recommendations from the Alzheimer's Association Research Roundtable Workgroup. , 2011, 7, 367-385.  |     | 531       |
| 1008 | Complexity of MRI White Matter Hyperintensity Assessments in Relation to Cognition in Aging and Dementia from the Sunnybrook Dementia Study. <i>Journal of Alzheimer's Disease</i> , 2011, 26, 379-388.   | 1.2 | 39        |

| #    | ARTICLE   | IF  | CITATIONS |
|------|---|-----|-----------|
| 1009 | Evaluation of Intrathecal Serum Amyloid P (SAP) and C-Reactive Protein (CRP) Synthesis in Alzheimer's Disease with the Use of Index Values. <i>Journal of Alzheimer's Disease</i> , 2011, 22, 1073-1079.  | 1.2 | 21        |
| 1010 | Self-Perceived Memory Complaints Predict Progression to Alzheimer Disease. The LADIS Study. <i>Journal of Alzheimer's Disease</i> , 2011, 27, 491-498.  | 1.2 | 21        |
| 1011 | The use of neuropsychological tests across Europe: the need for a consensus in the use of assessment tools for dementia. <i>European Journal of Neurology</i> , 2011, 18, 279-285.  | 1.7 | 42        |
| 1012 | The World of Dementia Beyond 2020. <i>Journal of the American Geriatrics Society</i> , 2011, 59, 923-927.   | 1.3 | 73        |
| 1013 | Do Instrumental Activities of Daily Living Predict Dementia at 1 and 2 Year Follow Up? Findings from the Development of Screening Guidelines and Diagnostic Criteria for Predementia <sc>A</sc> Alzheimer's Disease Study. <i>Journal of the American Geriatrics Society</i> , 2011, 59, 2273-2281. | 1.3 | 59        |
| 1014 | Early-onset versus late-onset Alzheimer's disease: the case of the missing APOE $\epsilon$ 4 allele. <i>Lancet Neurology</i> , The, 2011, 10, 280-288.  | 4.9 | 273       |
| 1015 | New lexicon and criteria for the diagnosis of Alzheimer's disease " Authors' reply. <i>Lancet Neurology</i> , The, 2011, 10, 300-301.   | 4.9 | 7         |
| 1016 | Utility of imaging for nutritional intervention studies in Alzheimer's disease. <i>European Journal of Pharmacology</i> , 2011, 668, S59-S69.   | 1.7 | 16        |
| 1017 | Visual assessment of posterior atrophy development of a MRI rating scale. <i>European Radiology</i> , 2011, 21, 2618-2625.  | 2.3 | 299       |
| 1018 | Heterogeneity in age-related white matter changes. <i>Acta Neuropathologica</i> , 2011, 122, 171-185.   | 3.9 | 271       |
| 1019 | Efficacy of a medical food on cognition in Alzheimer's Disease: Results from secondary analyses of a randomized, controlled trial. <i>Journal of Nutrition, Health and Aging</i> , 2011, 15, 720-724.   | 1.5 | 45        |
| 1020 | Effect of a medical food on body mass index and activities of daily living in patients with Alzheimer's disease: Secondary analyses from a randomized, controlled trial. <i>Journal of Nutrition, Health and Aging</i> , 2011, 15, 672-676.   | 1.5 | 30        |
| 1021 | Understanding higher level gait disturbances in mild dementia in order to improve rehabilitation: "Last in" first out". <i>Neuroscience and Biobehavioral Reviews</i> , 2011, 35, 699-714.  | 2.9 | 51        |
| 1022 | Clinical Relevance of Improved Microbleed Detection by Susceptibility-Weighted Magnetic Resonance Imaging. <i>Stroke</i> , 2011, 42, 1894-1900.   | 1.0 | 124       |
| 1023 | Hippocampal morphometry in population-based incident Alzheimer's disease and vascular dementia: the HAAS. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2011, 82, 373-377.   | 0.9 | 32        |
| 1024 | Regional Differences in Effects of $\epsilon$ 4 on Cognitive Impairment in Non-Demented Subjects. <i>Dementia and Geriatric Cognitive Disorders</i> , 2011, 32, 135-142.  | 0.7 | 18        |
| 1025 | EEG Abnormalities Are Associated with Different Cognitive Profiles in Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2011, 31, 1-6.   | 0.7 | 21        |
| 1026 | Corpus Callosum Tissue Loss and Development of Motor and Global Cognitive Impairment: The LADIS Study. <i>Dementia and Geriatric Cognitive Disorders</i> , 2011, 32, 279-286.   | 0.7 | 24        |

| #    | ARTICLE   | IF  | CITATIONS |
|------|---|-----|-----------|
| 1027 | Tau and p-tau as CSF biomarkers in dementia: a meta-analysis. <i>Clinical Chemistry and Laboratory Medicine</i> , 2011, 49, 353-366.  | 1.4 | 140       |
| 1028 | An Informant Questionnaire for Detecting Alzheimer's Disease: Are Some Items Better Than Others?. <i>Journal of the International Neuropsychological Society</i> , 2011, 17, 674-681.                                       | 1.2 | 2         |
| 1029 | Hippocampal Atrophy in Subcortical Vascular Dementia. <i>Neurodegenerative Diseases</i> , 2011, 8, 465-469.   | 0.8 | 51        |
| 1030 | EEG abnormalities in early and late onset Alzheimer's disease: understanding heterogeneity. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2011, 82, 67-71.   | 0.9 | 42        |
| 1031 | Disorders Mainly Affecting White Matter. , 2011, , 177-242.   |     | 1         |
| 1032 | The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. , 2011, 7, 263.             |     | 1         |
| 1033 | White Matter Hyperintensities, Medial Temporal Lobe Atrophy, Cortical Atrophy, and Response to Electroconvulsive Therapy in Severely Depressed Elderly Patients. <i>Journal of Clinical Psychiatry</i> , 2011, 72, 104-112. | 1.1 | 37        |
| 1034 | How to Use This Book?. , 2011, , 1-3.   |     | 0         |
| 1035 | Dementias with Associated "Brain Swelling"™. , 2011, , 243-268.   |     | 0         |
| 1036 | Primary Grey Matter Loss. , 2011, , 59-135.   |     | 0         |
| 1037 | The Toolbox. , 2011, , 13-42.   |     | 0         |
| 1038 | Joint Effect of Hypertension and APOE Genotype on CSF Biomarkers for Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2010, 20, 1083-1090.  | 1.2 | 30        |
| 1039 | Prevention of depression and sleep disturbances in elderly with memory-problems by activation of the biological clock with light - a randomized clinical trial. <i>Trials</i> , 2010, 11, 19.                               | 0.7 | 45        |
| 1040 | Use of cerebrospinal fluid biomarkers in diagnosis of dementia across Europe. <i>European Journal of Neurology</i> , 2010, 17, 90-96.   | 1.7 | 65        |
| 1041 | EFNS guidelines for the diagnosis and management of Alzheimer's™ disease. <i>European Journal of Neurology</i> , 2010, 17, 1236-1248.   | 1.7 | 407       |
| 1042 | Glycemia and Levels of Cerebrospinal Fluid Amyloid and Tau in Patients Attending a Memory Clinic. <i>Journal of the American Geriatrics Society</i> , 2010, 58, 1318-1321.  | 1.3 | 11        |
| 1043 | Diagnostic Impact of CSF Biomarkers in a Local Hospital Memory Clinic. <i>Dementia and Geriatric Cognitive Disorders</i> , 2010, 29, 491-497.   | 0.7 | 38        |
| 1044 | Dementia Mimicking Alzheimer's Disease Owing to a Tau Mutation: CSF and PET Findings. <i>Alzheimer Disease and Associated Disorders</i> , 2010, 24, 303-307.  | 0.6 | 26        |

| #    | ARTICLE   | IF  | CITATIONS |
|------|---|-----|-----------|
| 1045 | Clinical Characteristics of Patients With Frontotemporal Dementia With and Without Lobar Atrophy on MRI. <i>Alzheimer Disease and Associated Disorders</i> , 2010, 24, 242-247.   | 0.6 | 19        |
| 1046 | Neurological Signs in Relation to White Matter Hyperintensity Volumes in Memory Clinic Patients. <i>Dementia and Geriatric Cognitive Disorders</i> , 2010, 29, 301-308.   | 0.7 | 6         |
| 1047 | How Useful Is the IQCODE for Discriminating between Alzheimer's Disease, Mild Cognitive Impairment and Subjective Memory Complaints?. <i>Dementia and Geriatric Cognitive Disorders</i> , 2010, 30, 411-416.                  | 0.7 | 35        |
| 1048 | Amyloid- $\beta$ (1-42), Total Tau, and Phosphorylated Tau as Cerebrospinal Fluid Biomarkers for the Diagnosis of Alzheimer Disease. <i>Clinical Chemistry</i> , 2010, 56, 248-253.   | 1.5 | 301       |
| 1049 | New Research Criteria for the Diagnosis of Alzheimer's Disease Applied in a Memory Clinic Population. <i>Dementia and Geriatric Cognitive Disorders</i> , 2010, 30, 1-7.  | 0.7 | 48        |
| 1050 | Diffusion-Weighted Imaging and Cognition in the Leukoarosis and Disability in the Elderly Study. <i>Stroke</i> , 2010, 41, e402-8.  | 1.0 | 82        |
| 1051 | Can Nutrients Prevent or Delay Onset of Alzheimer's Disease?. <i>Journal of Alzheimer's Disease</i> , 2010, 20, 765-775.  | 1.2 | 90        |
| 1052 | Behavioural and psychological symptoms in vascular dementia; differences between small- and large-vessel disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2010, 81, 547-551.                               | 0.9 | 103       |
| 1053 | Vascular Care in Patients With Alzheimer Disease With Cerebrovascular Lesions Slows Progression of White Matter Lesions on MRI. <i>Stroke</i> , 2010, 41, 554-556.  | 1.0 | 71        |
| 1054 | Assessing mental flexibility: neuroanatomical and neuropsychological correlates of the trail making test in elderly people. <i>Clinical Neuropsychologist</i> , 2010, 24, 203-219.  | 1.5 | 104       |
| 1055 | Incidence of Depression and Anxiety in the Spouses of Patients With Dementia: A Naturalistic Cohort Study of Recorded Morbidity With a 6-Year Follow-Up. <i>American Journal of Geriatric Psychiatry</i> , 2010, 18, 146-153. | 0.6 | 131       |
| 1056 | The clinical use of structural MRI in Alzheimer disease. <i>Nature Reviews Neurology</i> , 2010, 6, 67-77.  | 4.9 | 1,505     |
| 1057 | Neuroanatomical and neuropsychological features of elderly euthymic depressed patients with early- and late-onset. <i>Journal of the Neurological Sciences</i> , 2010, 299, 19-23.  | 0.3 | 49        |
| 1058 | Relationship between baseline white-matter changes and development of late-life depressive symptoms: 3-year results from the LADIS study. <i>Psychological Medicine</i> , 2010, 40, 603-610.                                  | 2.7 | 119       |
| 1059 | Whole-brain atrophy rate and CSF biomarker levels in MCI and AD: A longitudinal study. <i>Neurobiology of Aging</i> , 2010, 31, 758-764.  | 1.5 | 90        |
| 1060 | Evaluation of plasma A $\beta$ <sup>240</sup> and A $\beta$ <sup>242</sup> as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment. <i>Neurobiology of Aging</i> , 2010, 31, 539-540.   | 1.5 | 19        |
| 1061 | Inflammatory markers in AD and MCI patients with different biomarker profiles—interpretation of serum and CSF levels. <i>Neurobiology of Aging</i> , 2010, 31, 1655.  | 1.5 | 0         |
| 1062 | Loss of "Small-World" Networks in Alzheimer's Disease: Graph Analysis of fMRI Resting-State Functional Connectivity. <i>PLoS ONE</i> , 2010, 5, e13788.   | 1.1 | 523       |

| #    | ARTICLE   | IF  | CITATIONS |
|------|---|-----|-----------|
| 1063 | Efficacy of a medical food in mild Alzheimer's disease: A randomized, controlled trial. <i>Alzheimer's and Dementia</i> , 2010, 6, 1.   | 0.4 | 235       |
| 1064 | F3-01-01: The development of a new IADL informant-based questionnaire: The Amsterdam IADL questionnaire. , 2010, 6, S115-S116.  |     | 0         |
| 1065 | Simplified parametric methods for [ <sup>18</sup> F]FDDNP studies. <i>NeuroImage</i> , 2010, 49, 433-441.   | 2.1 | 7         |
| 1066 | Molecular imaging in the diagnosis of Alzheimer's disease: visual assessment of [ <sup>11</sup> C]PIB and [ <sup>18</sup> F]FDDNP PET images. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2010, 81, 882-884. | 0.9 | 56        |
| 1067 | Early-Versus Late-Onset Alzheimer's Disease: More than Age Alone. <i>Journal of Alzheimer's Disease</i> , 2010, 19, 1401-1408.  | 1.2 | 359       |
| 1068 | BACE1 Activity in Cerebrospinal Fluid and Its Relation to Markers of AD Pathology. <i>Journal of Alzheimer's Disease</i> , 2010, 20, 253-260.   | 1.2 | 75        |
| 1069 | CSF $\beta$ -Synuclein Does Not Discriminate Dementia with Lewy Bodies from Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2010, 22, 87-95.   | 1.2 | 87        |
| 1070 | Can novel therapeutics halt the amyloid cascade?. <i>Alzheimer's Research and Therapy</i> , 2010, 2, 5.   | 3.0 | 19        |
| 1071 | Prevalence and Clinical Significance of Epileptiform EEG Discharges in a Large Memory Clinic Cohort. <i>Dementia and Geriatric Cognitive Disorders</i> , 2010, 29, 432-437.   | 0.7 | 60        |
| 1072 | MicroRNA Analysis in the Spinal Fluid of Alzheimer Patients: A Methodological Feasibility Study. , 2010, , 275-282.   |     | 2         |
| 1073 | Structural neuroimaging. , 2009, , 58-69.   |     | 31        |
| 1074 | CSF Biomarkers in Alzheimer's Disease and Controls: Associations with APOE Genotype are Modified by Age. <i>Journal of Alzheimer's Disease</i> , 2009, 16, 601-607.   | 1.2 | 45        |
| 1075 | Most rapid cognitive decline in APOE $\epsilon$ 4 negative Alzheimer's disease with early onset. <i>Psychological Medicine</i> , 2009, 39, 1907-1911.   | 2.7 | 101       |
| 1076 | Relationship of Cerebrospinal Fluid Markers to <sup>11</sup> C-PiB and <sup>18</sup> F-FDDNP Binding. <i>Journal of Nuclear Medicine</i> , 2009, 50, 1464-1470.   | 2.8 | 162       |
| 1077 | Detection of Alzheimer Pathology In Vivo Using Both <sup>11</sup> C-PiB and <sup>18</sup> F-FDDNP PET. <i>Journal of Nuclear Medicine</i> , 2009, 50, 191-197.  | 2.8 | 119       |
| 1078 | Hippocampal volume loss and Alzheimer disease progression. <i>Nature Reviews Neurology</i> , 2009, 5, 361-362.  | 4.9 | 22        |
| 1079 | Associations between Patterns of EEG Abnormalities and Diagnosis in a Large Memory Clinic Cohort. <i>Dementia and Geriatric Cognitive Disorders</i> , 2009, 27, 18-23.  | 0.7 | 56        |
| 1080 | Regional White Matter Integrity Differentiates Between Vascular Dementia and Alzheimer Disease. <i>Stroke</i> , 2009, 40, 773-779.  | 1.0 | 90        |

| #    | ARTICLE  | IF   | CITATIONS |
|------|--|------|-----------|
| 1081 | Changes in white matter as determinant of global functional decline in older independent outpatients: three year follow-up of LADIS (leukoaraiosis and disability) study cohort. <i>BMJ: British Medical Journal</i> , 2009, 339, b2477-b2477. | 2.4  | 348       |
| 1082 | Diagnostic Imaging of Patients in a Memory Clinic: Comparison of MR Imaging and 64â€“Detector Row CT. <i>Radiology</i> , 2009, 253, 174-183.   | 3.6  | 121       |
| 1083 | MRI Biomarkers of Vascular Damage and Atrophy Predicting Mortality in a Memory Clinic Population. <i>Stroke</i> , 2009, 40, 492-498.   | 1.0  | 118       |
| 1084 | The clinical profile of right temporal lobe atrophy. <i>Brain</i> , 2009, 132, 1287-1298.  | 3.7  | 277       |
| 1085 | Vascular Factors and Markers of Inflammation in Offspring With a Parental History of Late-Onset Alzheimer Disease. <i>Archives of General Psychiatry</i> , 2009, 66, 1263.   | 13.8 | 73        |
| 1086 | A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer's disease. <i>Annals of Clinical Biochemistry</i> , 2009, 46, 235-240.  | 0.8  | 157       |
| 1087 | CSF levels of PSA and PSAâ€“ACT complexes in Alzheimer's disease. <i>Annals of Clinical Biochemistry</i> , 2009, 46, 477-483.  | 0.8  | 9         |
| 1088 | Quantification of amyloid-beta 40 in cerebrospinal fluid. <i>Journal of Immunological Methods</i> , 2009, 348, 57-66.  | 0.6  | 21        |
| 1089 | Functional neural network analysis in frontotemporal dementia and Alzheimer's disease using EEG and graph theory. <i>BMC Neuroscience</i> , 2009, 10, 101.   | 0.8  | 317       |
| 1090 | Autosomal recessive paraparesis with amyotrophy of the hands and feet. <i>Acta Neurologica Scandinavica</i> , 2009, 87, 443-445.   | 1.0  | 7         |
| 1091 | Modelâ€“free group analysis shows altered BOLD fMRI networks in dementia. <i>Human Brain Mapping</i> , 2009, 30, 256-266.  | 1.9  | 129       |
| 1092 | White matter tract integrity in aging and Alzheimer's disease. <i>Human Brain Mapping</i> , 2009, 30, 1051-1059.   | 1.9  | 227       |
| 1093 | Quantitation of brain tissue changes associated with white matter hyperintensities by diffusionâ€“weighted and magnetization transfer imaging: The LADIS (leukoaraiosis and disability in the) Tj ETQq1 1107843148gBT /O                       |      |           |
| 1094 | Evaluation of Tracer Kinetic Models for Analysis of [18F]FDDNP Studies. <i>Molecular Imaging and Biology</i> , 2009, 11, 322-333.  | 1.3  | 20        |
| 1095 | Test-retest variability of quantitative [11C]PIB studies in Alzheimerâ€™s disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2009, 36, 1629-1638.  | 3.3  | 62        |
| 1096 | Nutrition and dementia. <i>European Journal of Neurology</i> , 2009, 16, iii-iv.   | 1.7  | 1         |
| 1097 | Moving forward with nutrition in Alzheimerâ€™s disease. <i>European Journal of Neurology</i> , 2009, 16, 19-22.  | 1.7  | 18        |
| 1098 | Accelerating regional atrophy rates in the progression from normal aging to Alzheimerâ€™s disease. <i>European Radiology</i> , 2009, 19, 2826-2833.  | 2.3  | 88        |

| #    | ARTICLE   | IF  | CITATIONS |
|------|---|-----|-----------|
| 1099 | Patients With Alzheimer Disease With Multiple Microbleeds. <i>Stroke</i> , 2009, 40, 3455-3460.   | 1.0 | 202       |
| 1100 | Graph theoretical analysis of magnetoencephalographic functional connectivity in Alzheimer's disease. <i>Brain</i> , 2009, 132, 213-224.  | 3.7 | 895       |
| 1101 | Dementia: THE BARE ESSENTIALS. <i>Practical Neurology</i> , 2009, 9, 241-251.   | 0.5 | 35        |
| 1102 | Progression of Mild Cognitive Impairment to Dementia. <i>Stroke</i> , 2009, 40, 1269-1274.  | 1.0 | 128       |
| 1103 | Inflammatory markers in AD and MCI patients with different biomarker profiles. <i>Neurobiology of Aging</i> , 2009, 30, 1885-1889.  | 1.5 | 135       |
| 1104 | CSF biomarker levels in early and late onset Alzheimer's disease. <i>Neurobiology of Aging</i> , 2009, 30, 1895-1901.   | 1.5 | 121       |
| 1105 | MRI-Defined Subcortical Ischemic Vascular Disease: Baseline Clinical and Neuropsychological Findings. <i>Cerebrovascular Diseases</i> , 2009, 27, 336-344.  | 0.8 | 78        |
| 1106 | Longitudinal Cognitive Decline in Subcortical Ischemic Vascular Disease – The LADIS Study. <i>Cerebrovascular Diseases</i> , 2009, 27, 384-391.   | 0.8 | 167       |
| 1107 | Can we do better in developing new drugs for Alzheimer's disease?. <i>Alzheimer's and Dementia</i> , 2009, 5, 489-491.  | 0.4 | 25        |
| 1108 | Altered temporal correlations in parietal alpha and prefrontal theta oscillations in early-stage Alzheimer disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 1614-1619.                                | 3.3 | 256       |
| 1109 | CSF Biomarkers and Incipient Alzheimer Disease in Patients With Mild Cognitive Impairment. <i>JAMA - Journal of the American Medical Association</i> , 2009, 302, 385.  | 3.8 | 1,009     |
| 1110 | Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. <i>Lancet Neurology</i> , The, 2009, 8, 619-627. | 4.9 | 542       |
| 1111 | Neuroanatomical and Neuropsychological Features of Euthymic Patients with Bipolar Disorder. <i>American Journal of Geriatric Psychiatry</i> , 2009, 17, 1012-1021.  | 0.6 | 37        |
| 1112 | The effect of anxiety and depression on decline of memory function in Alzheimer's disease. <i>International Psychogeriatrics</i> , 2009, 21, 1142-1147.   | 0.6 | 16        |
| 1113 | Imaging in Alzheimer's disease. <i>Dialogues in Clinical Neuroscience</i> , 2009, 11, 191-199.  | 1.8 | 34        |
| 1114 | Clinical Evaluation and Treatment of Cognitive Dysfunction and Dementia. , 2009, , 103-127.   |     | 0         |
| 1115 | Are Biomarkers Valid as Surrogates for Treatment Effects in Alzheimer's Disease?. <i>European Neurological Review</i> , 2009, 4, 13.  | 0.5 | 0         |
| 1116 | Progressive dementia and mesiotemporal atrophy on brain MRI: Neurosyphilis mimicking pre-senile Alzheimer's disease?. <i>European Journal of Neurology</i> , 2008, 15, e14-5.   | 1.7 | 17        |

| #    | ARTICLE   | IF  | CITATIONS |
|------|---|-----|-----------|
| 1117 | The renin-angiotensin-aldosterone system in cerebral small vessel disease. <i>Journal of Neurology</i> , 2008, 255, 993-1000.   | 1.8 | 31        |
| 1118 | Periventricular white matter hyperintensities increase the likelihood of progression from amnesic mild cognitive impairment to dementia. <i>Journal of Neurology</i> , 2008, 255, 1302-8.   | 1.8 | 86        |
| 1119 | Small vessel versus large vessel vascular dementia. <i>Journal of Neurology</i> , 2008, 255, 1644-1651.   | 1.8 | 55        |
| 1120 | (Cost)-effectiveness of family meetings on indicated prevention of anxiety and depressive symptoms and disorders of primary family caregivers of patients with dementia: design of a randomized controlled trial. <i>BMC Geriatrics</i> , 2008, 8, 2. | 1.1 | 29        |
| 1121 | Development of quality indicators for memory clinics. <i>International Journal of Geriatric Psychiatry</i> , 2008, 23, 119-128.   | 1.3 | 37        |
| 1122 | Behavioural and psychological symptoms are not related to white matter hyperintensities and medial temporal lobe atrophy in Alzheimer's disease. <i>International Journal of Geriatric Psychiatry</i> , 2008, 23, 387-392.                            | 1.3 | 34        |
| 1123 | Urinary Complaints in Nondisabled Elderly People with Age-Related White Matter Changes: The Leukoaraiosis And Disability (LADIS) Study. <i>Journal of the American Geriatrics Society</i> , 2008, 56, 1638-1643.                                      | 1.3 | 81        |
| 1124 | Hyperglycaemia as a determinant of cognitive decline in patients with type 1 diabetes. <i>European Journal of Pharmacology</i> , 2008, 585, 88-96.  | 1.7 | 95        |
| 1125 | Alzheimer's disease: a broad overview. <i>Lancet Neurology</i> , The, 2008, 7, 31.  | 4.9 | 0         |
| 1126 | Revised research diagnostic criteria for Alzheimer's disease. <i>Lancet Neurology</i> , The, 2008, 7, 668-670.  | 4.9 | 21        |
| 1127 | Transcranial Doppler Blood Flow Assessment in Patients With Mild Heart Failure: Correlates With Neuroimaging and Cognitive Performance. <i>Congestive Heart Failure</i> , 2008, 14, 61-65.  | 2.0 | 41        |
| 1128 | Global dynamical analysis of the EEG in Alzheimer's disease: Frequency-specific changes of functional interactions. <i>Clinical Neurophysiology</i> , 2008, 119, 837-841.   | 0.7 | 91        |
| 1129 | Investigation of resting-state EEG functional connectivity in frontotemporal lobar degeneration. <i>Clinical Neurophysiology</i> , 2008, 119, 1732-1738.  | 0.7 | 46        |
| 1130 | EEG functional connectivity and ApoE genotype in Alzheimer's disease and controls. <i>Clinical Neurophysiology</i> , 2008, 119, 2727-2732.  | 0.7 | 26        |
| 1131 | Efficacy, safety and tolerability of rivastigmine capsules in patients with probable vascular dementia: the VantagE study. <i>Current Medical Research and Opinion</i> , 2008, 24, 2561-2574.   | 0.9 | 124       |
| 1132 | CSF and MRI markers independently contribute to the diagnosis of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2008, 29, 669-675.   | 1.5 | 103       |
| 1133 | Distortions in resting activity rhythm in aging relate to white matter hyperintensities. <i>Neurobiology of Aging</i> , 2008, 29, 1265-1271.  | 1.5 | 24        |
| 1134 | The role of white matter hyperintensities and medial temporal lobe atrophy in age-related executive dysfunctioning. <i>Brain and Cognition</i> , 2008, 68, 128-133.   | 0.8 | 43        |



| #    | ARTICLE   | IF  | CITATIONS |
|------|---|-----|-----------|
| 1135 | Detecting Alzheimer pathology in vivo: Comparing regional binding of [11C]PIB and [18F]FDDNP. <i>NeuroImage</i> , 2008, 41, T118.   | 2.1 | 0         |
| 1136 | Simplified parametric methods for [11C]PIB studies. <i>NeuroImage</i> , 2008, 42, 76-86.  | 2.1 | 85        |
| 1137 | The pilot European Alzheimer's Disease Neuroimaging Initiative of the European Alzheimer's Disease Consortium. , 2008, 4, 255-264.  |     | 39        |
| 1138 | Feature Extraction and Strategy of Analyzing Structural Neuroimaging in Dementia. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2008, 89, 75-86.                    | 1.0 | 1         |
| 1139 | Heterogeneity of white matter hyperintensities in Alzheimer's disease: post-mortem quantitative MRI and neuropathology. <i>Brain</i> , 2008, 131, 3286-3298.                                      | 3.7 | 246       |
| 1140 | Variability in longitudinal cerebrospinal fluid tau and phosphorylated tau measurements. <i>Clinical Chemistry and Laboratory Medicine</i> , 2008, 46, 1300-4.                                    | 1.4 | 16        |
| 1141 | Reliability and Sensitivity of Visual Scales versus Volumetry for Evaluating White Matter Hyperintensity Progression. <i>Cerebrovascular Diseases</i> , 2008, 25, 247-253.                        | 0.8 | 79        |
| 1142 | Early-Onset Dementia Is Associated with Higher Mortality. <i>Dementia and Geriatric Cognitive Disorders</i> , 2008, 26, 147-152.  | 0.7 | 82        |
| 1143 | Diagnostic Accuracy of Consensus Diagnostic Criteria for Frontotemporal Dementia in a Memory Clinic Population. <i>Dementia and Geriatric Cognitive Disorders</i> , 2008, 25, 157-164.            | 0.7 | 35        |
| 1144 | Distribution of APOE Genotypes in a Memory Clinic Cohort. <i>Dementia and Geriatric Cognitive Disorders</i> , 2008, 25, 433-438.  | 0.7 | 35        |
| 1145 | Multi-Center Comparison of Medial Temporal Atrophy in Patients with Alzheimer's Disease &ndash; Data from the ICTUS Study. <i>Dementia and Geriatric Cognitive Disorders</i> , 2008, 26, 314-322. | 0.7 | 8         |
| 1146 | Neurological Signs in Relation to Type of Cerebrovascular Disease in Vascular Dementia. <i>Stroke</i> , 2008, 39, 317-322.  | 1.0 | 80        |
| 1147 | Progression of White Matter Hyperintensities and Incidence of New Lacunes Over a 3-Year Period. <i>Stroke</i> , 2008, 39, 1414-1420.  | 1.0 | 348       |
| 1148 | Serum Amyloid P Component as a Biomarker in Mild Cognitive Impairment and Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2008, 26, 522-527.                             | 0.7 | 27        |
| 1149 | Cerebral Blood Flow by Using Pulsed Arterial Spin-Labeling in Elderly Subjects with White Matter Hyperintensities. <i>American Journal of Neuroradiology</i> , 2008, 29, 1296-1301.               | 1.2 | 72        |
| 1150 | White Matter Hyperintensities and Working Memory: An Explorative Study. <i>Aging, Neuropsychology, and Cognition</i> , 2008, 15, 384-399.   | 0.7 | 17        |
| 1151 | White Matter Changes Contribute to Corpus Callosum Atrophy in the Elderly: The LADIS Study. <i>American Journal of Neuroradiology</i> , 2008, 29, 1498-1504.                                      | 1.2 | 51        |
| 1152 | Amnesic Mild Cognitive Impairment: Structural MR Imaging Findings Predictive of Conversion to Alzheimer Disease. <i>American Journal of Neuroradiology</i> , 2008, 29, 944-949.                   | 1.2 | 162       |

| #    | ARTICLE  | IF  | CITATIONS |
|------|--|-----|-----------|
| 1153 | Cognitive Impairment No Dementia – Neuropsychological and Neuroimaging Characterization of an Amnesic Subgroup. <i>Dementia and Geriatric Cognitive Disorders</i> , 2008, 25, 238-247.   | 0.7 | 18        |
| 1154 | Simon B. Thompson, <i>Dementia and Memory: A Handbook for Students and Professionals</i> , Ashgate, Aldershot, Hampshire, 2006, 256 pp., hbk £50.00, ISBN 13: 978-0-7546-4633-4. <i>Ageing and Society</i> , 2008, 28, 2137-138.   |     | 1         |
| 1155 | Whole-Brain Atrophy Rate and Cognitive Decline: Longitudinal MR Study of Memory Clinic Patients. <i>Radiology</i> , 2008, 248, 590-598.  | 3.6 | 133       |
| 1156 | Development of Screening Guidelines and Clinical Criteria for Predementia Alzheimer's Disease. <i>Neuroepidemiology</i> , 2008, 30, 254-265.   | 1.1 | 86        |
| 1157 | On the Etiology of Incident Brain Lacunes. <i>Stroke</i> , 2008, 39, 3083-3085.  | 1.0 | 76        |
| 1158 | Resting-State Oscillatory Brain Dynamics in Alzheimer Disease. <i>Journal of Clinical Neurophysiology</i> , 2008, 25, 187-193.   | 0.9 | 75        |
| 1159 | Brain magnetic resonance imaging abnormalities in patients with heart failure. <i>European Journal of Heart Failure</i> , 2007, 9, 1003-1009.  | 2.9 | 130       |
| 1160 | Differential impact of cerebral white matter changes, diabetes, hypertension and stroke on cognitive performance among non-disabled elderly. The LADIS study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2007, 78, 1325-1330.                                    | 0.9 | 136       |
| 1161 | Application of Automated Medial Temporal Lobe Atrophy Scale to Alzheimer Disease. <i>Archives of Neurology</i> , 2007, 64, 849.  | 4.9 | 60        |
| 1162 | The Contribution of Medial Temporal Lobe Atrophy and Vascular Pathology to Cognitive Impairment in Vascular Dementia. <i>Stroke</i> , 2007, 38, 3182-3185.   | 1.0 | 107       |
| 1163 | Qualitative Estimates of Medial Temporal Atrophy as a Predictor of Progression From Mild Cognitive Impairment to Dementia. <i>Archives of Neurology</i> , 2007, 64, 108.   | 4.9 | 178       |
| 1164 | Magnetic Resonance Imaging Predictors of Cognition in Mild Cognitive Impairment. <i>Archives of Neurology</i> , 2007, 64, 1023.  | 4.9 | 67        |
| 1165 | Cognitive impairment and MRI correlates in the elderly patients with type 2 diabetes mellitus. <i>Age and Ageing</i> , 2007, 36, 164-170.  | 0.7 | 135       |
| 1166 | Comparison of the Alzheimer's Disease Assessment Scale Cognitive Subscale and the Vascular Dementia Assessment Scale in Differentiating Elderly Individuals with Different Degrees of White Matter Changes. <i>Dementia and Geriatric Cognitive Disorders</i> , 2007, 24, 73-81. | 0.7 | 45        |
| 1167 | Apolipoprotein E Genotype Influences Presence and Severity of Delusions and Aggressive Behavior in Alzheimer Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2007, 23, 42-46.   | 0.7 | 49        |
| 1168 | Neuroimaging and Correlates of Cognitive Function among Patients with Heart Failure. <i>Dementia and Geriatric Cognitive Disorders</i> , 2007, 24, 418-423.  | 0.7 | 91        |
| 1169 | Clinicopathological concordance and discordance in three monozygotic twin pairs with familial Alzheimer's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2007, 78, 1039-1039.   | 0.9 | 1         |
| 1170 | Brain Lesions on MRI in Elderly Patients with Type 2 Diabetes Mellitus. <i>European Neurology</i> , 2007, 57, 70-74.   | 0.6 | 115       |

| #    | ARTICLE   | IF  | CITATIONS |
|------|---|-----|-----------|
| 1171 | Cognitive Impairment in Alzheimer's Disease Is Modified by APOE Genotype. <i>Dementia and Geriatric Cognitive Disorders</i> , 2007, 24, 98-103.   | 0.7 | 66        |
| 1172 | Nonlinear Changes in Brain Activity During Continuous Word Repetition: An Event-Related Multiparametric Functional MR Imaging Study. <i>American Journal of Neuroradiology</i> , 2007, 28, 1715-1721.                 | 1.2 | 8         |
| 1173 | Chapter 15 Advances in Neuroimaging. <i>Blue Books of Neurology</i> , 2007, 30, 381-410.  | 0.1 | 0         |
| 1174 | All patients with suspected dementia should be scanned at least once with CT or MRI. <i>International Psychogeriatrics</i> , 2007, 19, 533-534.   | 0.6 | 2         |
| 1175 | Clinical significance of corpus callosum atrophy in a mixed elderly population. <i>Neurobiology of Aging</i> , 2007, 28, 955-963.   | 1.5 | 67        |
| 1176 | CSF biomarkers and medial temporal lobe atrophy predict dementia in mild cognitive impairment. <i>Neurobiology of Aging</i> , 2007, 28, 1070-1074.  | 1.5 | 160       |
| 1177 | Endogenous cortisol level interacts with noradrenergic activation in the human amygdala. <i>Neurobiology of Learning and Memory</i> , 2007, 87, 57-66.  | 1.0 | 146       |
| 1178 | Improved reliability of hippocampal atrophy rate measurement in mild cognitive impairment using fluid registration. <i>NeuroImage</i> , 2007, 34, 1036-1041.  | 2.1 | 39        |
| 1179 | Hippocampal shape analysis in Alzheimer's disease: A population-based study. <i>NeuroImage</i> , 2007, 36, 8-18.  | 2.1 | 101       |
| 1180 | SPM analysis of parametric (R)-[11C]PK11195 binding images: Plasma input versus reference tissue parametric methods. <i>NeuroImage</i> , 2007, 35, 1473-1479.   | 2.1 | 26        |
| 1181 | Cognitive impairment in heart failure: A systematic review of the literature. <i>European Journal of Heart Failure</i> , 2007, 9, 440-449.  | 2.9 | 445       |
| 1182 | CSF Neurofilaments in Frontotemporal Dementia Compared with Early Onset Alzheimer's Disease and Controls. <i>Dementia and Geriatric Cognitive Disorders</i> , 2007, 23, 225-230.                                      | 0.7 | 64        |
| 1183 | Whole brain analysis of T2* weighted baseline fMRI signal in dementia. <i>Human Brain Mapping</i> , 2007, 28, 1313-1317.  | 1.9 | 32        |
| 1184 | Evaluation of Methods for Generating Parametric (R)-[11C]PK11195 Binding Images. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2007, 27, 1603-1615.  | 2.4 | 32        |
| 1185 | Evaluation of Reference Regions for (R)-[11C]PK11195 Studies in Alzheimer's Disease and Mild Cognitive Impairment. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2007, 27, 1965-1974.                        | 2.4 | 53        |
| 1186 | Diabetes mellitus, hypertension and medial temporal lobe atrophy: the LADIS study. <i>Diabetic Medicine</i> , 2007, 24, 166-171.  | 1.2 | 88        |
| 1187 | No evidence for increased self-reported cognitive failure in Type 1 and Type 2 diabetes: a cross-sectional study. <i>Diabetic Medicine</i> , 2007, 24, 735-740.   | 1.2 | 12        |
| 1188 | ASSOCIATION BETWEEN VITAMIN B6 AND WHITE MATTER HYPERINTENSITIES IN PATIENTS WITH ALZHEIMER'S DISEASE NOT MEDIATED BY HOMOCYSTEINE METABOLISM. <i>Journal of the American Geriatrics Society</i> , 2007, 55, 956-958. | 1.3 | 10        |

| #    | ARTICLE  | IF  | CITATIONS |
|------|--|-----|-----------|
| 1189 | Profile of Cognitive Impairment in Chronic Heart Failure. <i>Journal of the American Geriatrics Society</i> , 2007, 55, 1764-1770.   | 1.3 | 160       |
| 1190 | Subcortical white matter pathology as a mediating factor for age-related decreased performance in dichotic listening. <i>Neuropsychologia</i> , 2007, 45, 2322-2332.   | 0.7 | 10        |
| 1191 | Getting a grip on Alzheimer's disease: imaging amyloid in the brain. <i>Lancet Neurology</i> , The, 2007, 6, 204-206.  | 4.9 | 2         |
| 1192 | Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEX study. <i>Lancet Neurology</i> , The, 2007, 6, 501-512.   | 4.9 | 314       |
| 1193 | Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. <i>Lancet Neurology</i> , The, 2007, 6, 734-746.   | 4.9 | 3,755     |
| 1194 | Use of proteomic approaches to identify disease biomarkers. <i>Lancet Neurology</i> , The, 2007, 6, 1036-1037.   | 4.9 | 6         |
| 1195 | Shifting Paradigms in Dementia: Toward Stratification of Diagnosis and Treatment Using MRI. <i>Annals of the New York Academy of Sciences</i> , 2007, 1097, 215-224.   | 1.8 | 27        |
| 1196 | Precuneus atrophy in early-onset Alzheimer's disease: a morphometric structural MRI study. <i>Neuroradiology</i> , 2007, 49, 967-976.  | 1.1 | 251       |
| 1197 | Cognitive performance in type 1 diabetes patients is associated with cerebral white matter volume. <i>Diabetologia</i> , 2007, 50, 1763-1769.  | 2.9 | 105       |
| 1198 | Glucocorticoids Decrease Hippocampal and Prefrontal Activation during Declarative Memory Retrieval in Young Men. <i>Brain Imaging and Behavior</i> , 2007, 1, 31-41.   | 1.1 | 119       |
| 1199 | Consistent resting-state networks across healthy subjects. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 13848-13853.  | 3.3 | 3,817     |
| 1200 | Mild cognitive impairment. <i>Lancet</i> , The, 2006, 367, 1262-1270.  | 6.3 | 2,401     |
| 1201 | Attention modulates hemispheric differences in functional connectivity: Evidence from MEG recordings. <i>NeuroImage</i> , 2006, 30, 245-253.   | 2.1 | 33        |
| 1202 | Magnetoencephalographic evaluation of resting-state functional connectivity in Alzheimer's disease. <i>NeuroImage</i> , 2006, 32, 1335-1344.   | 2.1 | 282       |
| 1203 | Mild cognitive impairment (MCI) in medical practice: a critical review of the concept and new diagnostic procedure. Report of the MCI Working Group of the European Consortium on Alzheimer's Disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2006, 77, 714-718. | 0.9 | 539       |
| 1204 | Progressive, isolated language disturbance: Its significance in a 65-year-old-man. A case report with implications for treatment and review of literature. <i>Journal of the Neurological Sciences</i> , 2006, 240, 45-51.   | 0.3 | 14        |
| 1205 | Pain intensity and pain affect in relation to white matter changes. <i>Pain</i> , 2006, 125, 74-81.  | 2.0 | 26        |
| 1206 | Multicenter assessment of reliability of cranial MRI. <i>Neurobiology of Aging</i> , 2006, 27, 1051-1059.  | 1.5 | 96        |

| #    | ARTICLE  | IF  | CITATIONS |
|------|--|-----|-----------|
| 1207 | White Matter Lesions Are Associated With Progression of Medial Temporal Lobe Atrophy in Alzheimer Disease. <i>Stroke</i> , 2006, 37, 2248-2252.  | 1.0 | 50        |
| 1208 | Peripheral electrical nerve stimulation and rest-activity rhythm in Alzheimer's disease. <i>Journal of Sleep Research</i> , 2006, 15, 415-423.   | 1.7 | 14        |
| 1209 | Diabetes and cognitive impairment. <i>Journal of Neurology</i> , 2006, 253, 477-482.   | 1.8 | 72        |
| 1210 | Simple versus complex assessment of white matter hyperintensities in relation to physical performance and cognition: the LADIS study. <i>Journal of Neurology</i> , 2006, 253, 1189-1196.              | 1.8 | 109       |
| 1211 | Diabetic encephalopathy: a concept in need of a definition. <i>Diabetologia</i> , 2006, 49, 1447-1448.   | 2.9 | 176       |
| 1212 | Voxel-based morphometry demonstrates reduced grey matter density on brain MRI in patients with diabetic retinopathy. <i>Diabetologia</i> , 2006, 49, 2474-2480.  | 2.9 | 156       |
| 1213 | Risk of dementia in diabetes mellitus: a systematic review. <i>Lancet Neurology</i> , The, 2006, 5, 64-74.   | 4.9 | 1,791     |
| 1214 | Corpus callosum size correlates with asymmetric performance on a dichotic listening task in healthy aging but not in Alzheimer's disease. <i>Neuropsychologia</i> , 2006, 44, 208-217.                 | 0.7 | 66        |
| 1215 | Diagnostic tools for the study of vascular cognitive dysfunction in hypertension and antihypertensive drug research. , 2006, 109, 274-283.   |     | 16        |
| 1216 | Relationship between periventricular and deep white matter lesions and depressive symptoms in older people. The LADIS Study. <i>International Journal of Geriatric Psychiatry</i> , 2006, 21, 983-989. | 1.3 | 94        |
| 1217 | Development of a Neuropsychological Battery for the Leukoaraiosis and Disability in the Elderly Study (LADIS): Experience and Baseline Data. <i>Neuroepidemiology</i> , 2006, 27, 101-116.             | 1.1 | 67        |
| 1218 | Cholinergic challenge in Alzheimer patients and mild cognitive impairment differentially affects hippocampal activation—a pharmacological fMRI study. <i>Brain</i> , 2006, 129, 141-157.               | 3.7 | 110       |
| 1219 | Infratentorial Abnormalities in Vascular Dementia. <i>Stroke</i> , 2006, 37, 105-110.  | 1.0 | 31        |
| 1220 | Raloxifene Treatment Enhances Brain Activation during Recognition of Familiar Items: a Pharmacological fMRI Study in Healthy Elderly Males. <i>Neuropsychopharmacology</i> , 2006, 31, 1508-1518.      | 2.8 | 38        |
| 1221 | Impact of diagnostic disclosure in dementia on patients and carers: Qualitative case series analysis. <i>Aging and Mental Health</i> , 2006, 10, 525-531.  | 1.5 | 73        |
| 1222 | Impact of White Matter Hyperintensities Scoring Method on Correlations With Clinical Data. <i>Stroke</i> , 2006, 37, 836-840.  | 1.0 | 269       |
| 1223 | Microvascular Disease in Type 1 Diabetes Alters Brain Activation: A Functional Magnetic Resonance Imaging Study. <i>Diabetes</i> , 2006, 55, 334-340.  | 0.3 | 63        |
| 1224 | Cognitive slowing in multiple sclerosis is strongly associated with brain volume reduction. <i>Multiple Sclerosis Journal</i> , 2006, 12, 760-768.   | 1.4 | 53        |

| #    | ARTICLE   | IF  | CITATIONS |
|------|---|-----|-----------|
| 1225 | Corpus callosum atrophy is associated with mental slowing and executive deficits in subjects with age-related white matter hyperintensities: the LADIS Study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2006, 78, 491-496. | 0.9 | 90        |
| 1226 | Intrathecal Chemokine Synthesis in Mild Cognitive Impairment and Alzheimer Disease. <i>Archives of Neurology</i> , 2006, 63, 538.   | 4.9 | 268       |
| 1227 | The Auditory Oddball Paradigm in Patients with Vascular Cognitive Impairment: A Prolonged Latency of the N <sub>2</sub> Complex. <i>Dementia and Geriatric Cognitive Disorders</i> , 2006, 21, 322-327.                                     | 0.7 | 11        |
| 1228 | Receiving a diagnosis of dementia. <i>Dementia</i> , 2006, 5, 397-410.  | 1.0 | 78        |
| 1229 | Age, Hypertension, and Lacunar Stroke Are the Major Determinants of the Severity of Age-Related White Matter Changes. <i>Cerebrovascular Diseases</i> , 2006, 21, 315-322.  | 0.8 | 164       |
| 1230 | Effects of High-Frequency Cranial Electrostimulation on the Rest-Activity Rhythm and Salivary Cortisol in Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2006, 22, 267-272.                                       | 0.7 | 14        |
| 1231 | Brain Imaging in Patients With Diabetes: A systematic review. <i>Diabetes Care</i> , 2006, 29, 2539-2548.   | 4.3 | 317       |
| 1232 | Usefulness of Longitudinal Measurements of $\beta$ -Amyloid $_{1-42}$ in Cerebrospinal Fluid of Patients with Various Cognitive and Neurologic Disorders. <i>Clinical Chemistry</i> , 2006, 52, 1604-1606.                                  | 1.5 | 16        |
| 1233 | Can lumbar puncture help to identify patients with incipient Alzheimer's disease?. <i>Nature Clinical Practice Neurology</i> , 2006, 2, 530-531.  | 2.7 | 3         |
| 1234 | Brain Aging in Very Old Men With Type 2 Diabetes: The Honolulu-Asia Aging Study. <i>Diabetes Care</i> , 2006, 29, 2268-2274.  | 4.3 | 172       |
| 1235 | Multiple Diagnostic Tests Are Needed to Assess Multiple Causes of Dementia. <i>Archives of Neurology</i> , 2006, 63, 144.   | 4.9 | 14        |
| 1236 | Structural neuroimaging outcomes in clinical dementia trials, with special reference to disease modifying designs. <i>Journal of Nutrition, Health and Aging</i> , 2006, 10, 123-8; discussion 129-30.                                      | 1.5 | 8         |
| 1237 | A 24-year follow-up of body mass index and cerebral atrophy. <i>Neurology</i> , 2005, 64, 1990-1991.  | 1.5 | 0         |
| 1238 | Retrograde amnesia for semantic information in Alzheimer's disease. <i>Journal of the International Neuropsychological Society</i> , 2005, 11, 40-48.   | 1.2 | 5         |
| 1239 | The impact of diagnostic disclosure in dementia: a qualitative case analysis. <i>International Psychogeriatrics</i> , 2005, 17, 319-326.  | 0.6 | 21        |
| 1240 | LOW VITAMIN B6 LEVELS ARE ASSOCIATED WITH WHITE MATTER LESIONS IN ALZHEIMER'S DISEASE. <i>Journal of the American Geriatrics Society</i> , 2005, 53, 1073-1074.   | 1.3 | 22        |
| 1241 | Altered resting state networks in mild cognitive impairment and mild Alzheimer's disease: An fMRI study. <i>Human Brain Mapping</i> , 2005, 26, 231-239.  | 1.9 | 675       |
| 1242 | Amyloid $\beta$ 38, 40, and 42 species in cerebrospinal fluid: More of the same?. <i>Annals of Neurology</i> , 2005, 58, 139-142.   | 2.8 | 112       |

| #    | ARTICLE  | IF  | CITATIONS |
|------|--|-----|-----------|
| 1243 | Cerebrospinal fluid tau levels in frontotemporal dementia. <i>Annals of Neurology</i> , 2005, 58, 656-657.   | 2.8 | 9         |
| 1244 | Effects of Processing and Storage Conditions on Amyloid $\beta$ (1-42) and Tau Concentrations in Cerebrospinal Fluid: Implications for Use in Clinical Practice. <i>Clinical Chemistry</i> , 2005, 51, 189-195.                    | 1.5 | 151       |
| 1245 | Functional Connectivity in Elderly Controls and AD Patients Using Resting State fMRI: A Pilot Study. <i>Current Alzheimer Research</i> , 2005, 2, 115-116.   | 0.7 | 38        |
| 1246 | Brain atrophy and lesion load as explaining parameters for cognitive impairment in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2005, 11, 524-531.  | 1.4 | 121       |
| 1247 | Differences and Similarities between Two Frequently Used Assays for Amyloid $\beta$ 42 in Cerebrospinal Fluid. <i>Clinical Chemistry</i> , 2005, 51, 1057-1060.  | 1.5 | 9         |
| 1248 | Medial Temporal Lobe Atrophy and APOE Genotype Do Not Predict Cognitive Improvement upon Treatment with Rivastigmine in Alzheimer's Disease Patients. <i>Dementia and Geriatric Cognitive Disorders</i> , 2005, 19, 126-133.       | 0.7 | 28        |
| 1249 | Peripheral Electrical Stimulation in Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2005, 19, 361-368.   | 0.7 | 6         |
| 1250 | Blood Pressure, White Matter Lesions and Medial Temporal Lobe Atrophy: Closing the Gap between Vascular Pathology and Alzheimer's Disease?. <i>Dementia and Geriatric Cognitive Disorders</i> , 2005, 20, 331-337.                 | 0.7 | 23        |
| 1251 | Differential Regional Atrophy of the Cingulate Gyrus in Alzheimer Disease: A Volumetric MRI Study. <i>Cerebral Cortex</i> , 2005, 16, 1701-1708.   | 1.6 | 131       |
| 1252 | Small Vessel Disease and General Cognitive Function in Nondisabled Elderly. <i>Stroke</i> , 2005, 36, 2116-2120.   | 1.0 | 311       |
| 1253 | Disturbed fluctuations of resting state EEG synchronization in Alzheimer's disease. <i>Clinical Neurophysiology</i> , 2005, 116, 708-715.  | 0.7 | 224       |
| 1254 | Noradrenaline mediates amygdala activation in men and women during encoding of emotional material. <i>NeuroImage</i> , 2005, 24, 898-909.  | 2.1 | 182       |
| 1255 | Raloxifene exposure enhances brain activation during memory performance in healthy elderly males; its possible relevance to behavior. <i>NeuroImage</i> , 2005, 25, 63-75.   | 2.1 | 37        |
| 1256 | Delayed rather than decreased BOLD response as a marker for early Alzheimer's disease. <i>NeuroImage</i> , 2005, 26, 1078-1085.  | 2.1 | 129       |
| 1257 | Consensus Paper of the WFSBP Task Force on Biological Markers of Dementia: The role of CSF and blood analysis in the early and differential diagnosis of dementia. <i>World Journal of Biological Psychiatry</i> , 2005, 6, 69-84. | 1.3 | 105       |
| 1258 | Biomarker profiles and their relation to clinical variables in mild cognitive impairment. <i>Neurocase</i> , 2005, 11, 8-13.   | 0.2 | 47        |
| 1259 | The transmethylation cycle in the brain of Alzheimer patients. <i>Neuroscience Letters</i> , 2005, 386, 69-71.   | 1.0 | 48        |
| 1260 | Impact of Age-Related Cerebral White Matter Changes on the Transition to Disability - The LADIS Study: Rationale, Design and Methodology. <i>Neuroepidemiology</i> , 2005, 24, 51-62.  | 1.1 | 387       |

| #    | ARTICLE   | IF   | CITATIONS |
|------|---|------|-----------|
| 1261 | Effects of reference tissue versus plasma input parametric kinetic modelling on statistical parametric analysis of [11C](R)-PK11195 binding in Alzheimer's disease (AD) and young and old subjects. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2005, 25, S643-S643. | 2.4  | 2         |
| 1262 | Midlife Blood Pressure and the Risk of Hippocampal Atrophy. <i>Hypertension</i> , 2004, 44, 29-34.  | 1.3  | 228       |
| 1263 | Medial temporal lobe atrophy on MRI predicts dementia in patients with mild cognitive impairment. <i>Neurology</i> , 2004, 63, 94-100.  | 1.5  | 307       |
| 1264 | Validation of the HIV Dementia Scale in an Elderly Cohort of Patients with Subcortical Cognitive Impairment Caused by Subcortical Ischaemic Vascular Disease or a Normal Pressure Hydrocephalus. <i>Dementia and Geriatric Cognitive Disorders</i> , 2004, 18, 109-114.         | 0.7  | 16        |
| 1265 | An fMRI study of planning-related brain activity in patients with moderately advanced multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2004, 10, 549-555.  | 1.4  | 65        |
| 1266 | Regional Distribution of White Matter Hyperintensities in Vascular Dementia, Alzheimer's Disease and Healthy Aging. <i>Dementia and Geriatric Cognitive Disorders</i> , 2004, 18, 180-188.  | 0.7  | 144       |
| 1267 | Thalamic Lesions in Vascular Dementia. <i>Stroke</i> , 2004, 35, 415-419.   | 1.0  | 52        |
| 1268 | White matter lesions and hippocampal atrophy in Alzheimer's disease. <i>Neurology</i> , 2004, 62, 310-312.  | 1.5  | 119       |
| 1269 | Advances in the early detection of Alzheimer's disease. <i>Nature Medicine</i> , 2004, 10, S34-S41.   | 15.2 | 401       |
| 1270 | P3-043 Inflammatory markers CRP and IL-6 in cerebrospinal fluid and serum in relation to the IL-6 genotype in patients with Alzheimer's disease. <i>Neurobiology of Aging</i> , 2004, 25, S363-S364.  | 1.5  | 0         |
| 1271 | P4-316 The methionine-homocysteine cycle in the brain of Alzheimer patients. <i>Neurobiology of Aging</i> , 2004, 25, S565.   | 1.5  | 0         |
| 1272 | P3-063 Activation in the working memory network in healthy aging, mild cognitive impairment and Alzheimer's disease. <i>Neurobiology of Aging</i> , 2004, 25, S369-S370.  | 1.5  | 0         |
| 1273 | MRI and CT in the diagnosis of vascular dementia. <i>Journal of the Neurological Sciences</i> , 2004, 226, 9-12.  | 0.3  | 65        |
| 1274 | P3-096 Effects of galantamine challenge on episodic and working memory systems in patients with mild cognitive impairment: an fMRI study. <i>Neurobiology of Aging</i> , 2004, 25, S381-S382.   | 1.5  | 0         |
| 1275 | Initial Complaints in Frontotemporal Lobar Degeneration. <i>Dementia and Geriatric Cognitive Disorders</i> , 2004, 17, 302-306.   | 0.7  | 52        |
| 1276 | Biomarkers for Alzheimer's disease. Which way to go?. <i>Neurobiology of Aging</i> , 2004, 25, 695-696.   | 1.5  | 5         |
| 1277 | EEG synchronization likelihood in mild cognitive impairment and Alzheimer's disease during a working memory task. <i>Clinical Neurophysiology</i> , 2004, 115, 1332-1339.   | 0.7  | 227       |
| 1278 | Interindividual differences of medial temporal lobe activation during encoding in an elderly population studied by fMRI. <i>NeuroImage</i> , 2004, 21, 173-180.   | 2.1  | 32        |



| #    | ARTICLE  | IF  | CITATIONS |
|------|--|-----|-----------|
| 1279 | Global and local gray matter loss in mild cognitive impairment and Alzheimer's disease. <i>NeuroImage</i> , 2004, 23, 708-716.   | 2.1 | 522       |
| 1280 | Challenging the cholinergic system in mild cognitive impairment: a pharmacological fMRI study. <i>NeuroImage</i> , 2004, 23, 1450-1459.  | 2.1 | 104       |
| 1281 | P2-200 Patterns of brain atrophy in early-onset versus late-onset Alzheimer's disease: relevance of posterior cingulate atrophy. <i>Neurobiology of Aging</i> , 2004, 25, S285-S286.     | 1.5 | 0         |
| 1282 | P2-201 Microglia activation in mild cognitive impairment. <i>Neurobiology of Aging</i> , 2004, 25, S286.   | 1.5 | 3         |
| 1283 | P2-227 A comparison of medial temporal lobe atrophy ratings with linear and volumetric measures in aging and dementia. <i>Neurobiology of Aging</i> , 2004, 25, S296.                    | 1.5 | 0         |
| 1284 | Pathological Aging of the Brain. <i>Topics in Magnetic Resonance Imaging</i> , 2004, 15, 369-389.  | 0.7 | 60        |
| 1285 | Neuroimaging in old age psychiatry. <i>Current Opinion in Psychiatry</i> , 2004, 17, 449-452.  | 3.1 | 2         |
| 1286 | Memantine in Moderate-to-Severe Alzheimer Disease Evidence and Ethics Based?. <i>Alzheimer Disease and Associated Disorders</i> , 2004, 18, 47-48.                                       | 0.6 | 6         |
| 1287 | Decreased lysophosphatidylcholine/phosphatidylcholine ratio in cerebrospinal fluid in Alzheimer's disease. <i>Journal of Neural Transmission</i> , 2003, 110, 949-955.                   | 1.4 | 163       |
| 1288 | Treatment of Alzheimer's disease; current status and new perspectives. <i>Lancet Neurology</i> , The, 2003, 2, 539-547.  | 4.9 | 664       |
| 1289 | Deficits of memory, executive functioning and attention following infarction in the thalamus; a study of 22 cases with localised lesions. <i>Neuropsychologia</i> , 2003, 41, 1330-1344. | 0.7 | 363       |
| 1290 | Chemokines in serum and cerebrospinal fluid of Alzheimer's disease patients. <i>Annals of Neurology</i> , 2003, 53, 547-548.   | 2.8 | 115       |
| 1291 | EEG synchronization in mild cognitive impairment and Alzheimer's disease. <i>Acta Neurologica Scandinavica</i> , 2003, 108, 90-96.   | 1.0 | 248       |
| 1292 | A paced visual serial addition test for fMRI. <i>Journal of the Neurological Sciences</i> , 2003, 213, 29-34.  | 0.3 | 82        |
| 1293 | A neural complexity measure applied to MEG data in Alzheimer's disease. <i>Clinical Neurophysiology</i> , 2003, 114, 1034-1040.  | 0.7 | 59        |
| 1294 | A comprehensive study of gray matter loss in patients with Alzheimer's disease using optimized voxel-based morphometry. <i>NeuroImage</i> , 2003, 18, 895-907.                           | 2.1 | 388       |
| 1295 | Visual Rating of Age-Related White Matter Changes on Magnetic Resonance Imaging. <i>Stroke</i> , 2003, 34, 441-445.  | 1.0 | 271       |
| 1296 | Identifying confounds to increase specificity during a scene task condition. <i>NeuroImage</i> , 2003, 20, 1236-1245.  | 2.1 | 81        |

| #    | ARTICLE  | IF  | CITATIONS |
|------|--|-----|-----------|
| 1297 | Tau and A $\beta$ 42 protein in CSF of patients with frontotemporal degeneration. <i>Neurology</i> , 2003, 60, 353-354.  | 1.5 | 4         |
| 1298 | Frontotemporal dementia in The Netherlands: patient characteristics and prevalence estimates from a population-based study. <i>Brain</i> , 2003, 126, 2016-2022.   | 3.7 | 423       |
| 1299 | Operational Definitions for the NINDS-AIREN Criteria for Vascular Dementia. <i>Stroke</i> , 2003, 34, 1907-1912.   | 1.0 | 158       |
| 1300 | White-Matter Changes on MRI as Surrogate Marker. <i>International Psychogeriatrics</i> , 2003, 15, 261-265.  | 0.6 | 10        |
| 1301 | Total tau and Phosphorylated tau 181 Levels in the Cerebrospinal Fluid of Patients With Frontotemporal Dementia Due to P301L and G272V tau Mutations. <i>Archives of Neurology</i> , 2003, 60, 1209-13.                    | 4.9 | 69        |
| 1302 | Effects of Transcutaneous Electrical Nerve Stimulation (TENS) on Non-Pain Related Cognitive and Behavioural Functioning. <i>Reviews in the Neurosciences</i> , 2002, 13, 257-70.   | 1.4 | 17        |
| 1303 | Imaging of White Matter Lesions. <i>Cerebrovascular Diseases</i> , 2002, 13, 21-30.  | 0.8 | 128       |
| 1304 | Generalized Synchronization of MEG Recordings in Alzheimer's Disease: Evidence for Involvement of the Gamma Band. <i>Journal of Clinical Neurophysiology</i> , 2002, 19, 562-574.  | 0.9 | 242       |
| 1305 | A new rapid landmark-based regional MRI segmentation method of the brain. <i>Journal of the Neurological Sciences</i> , 2002, 194, 35-40.  | 0.3 | 36        |
| 1306 | Structural magnetic resonance imaging in the practical assessment of dementia: beyond exclusion. <i>Lancet Neurology</i> , The, 2002, 1, 13-21.  | 4.9 | 337       |
| 1307 | Alzheimer's disease is not associated with altered concentrations of the nitric oxide synthase inhibitor asymmetric dimethylarginine in cerebrospinal fluid. <i>Journal of Neural Transmission</i> , 2002, 109, 1203-1208. | 1.4 | 30        |
| 1308 | CSF markers related to pathogenetic mechanisms in Alzheimer's disease. <i>Journal of Neural Transmission</i> , 2002, 109, 1491-1498.   | 1.4 | 32        |
| 1309 | Diagnostic accuracy of the Preclinical AD Scale (PAS) in cognitively mildly impaired subjects. <i>Journal of Neurology</i> , 2002, 249, 312-319.   | 1.8 | 51        |
| 1310 | Magnetic Resonance and Dementia. , 2002, , 1-4.  |     | 1         |
| 1311 | Head trauma and Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> , 2002, 4, 303-308.   | 1.2 | 36        |
| 1312 | Magnetic Resonance: Applications in Dementia. , 2002, , 5-25.  |     | 0         |
| 1313 | Neurodegenerative Disorders. , 2002, , 31-138.   |     | 0         |
| 1314 | The role of the parahippocampal cortex in spatial memory: an fMRI Study. <i>NeuroImage</i> , 2001, 13, 703.  | 2.1 | 0         |

| #    | ARTICLE  | IF  | CITATIONS |
|------|--|-----|-----------|
| 1315 | Anterior Medial Temporal Lobe Activation during Attempted Retrieval of Encoded Visuospatial Scenes: An Event-Related fMRI Study. <i>NeuroImage</i> , 2001, 14, 67-76.  | 2.1 | 63        |
| 1316 | Effect of hydroxychloroquine on progression of dementia in early Alzheimer's disease: an 18-month randomised, double-blind, placebo-controlled study. <i>Lancet</i> , The, 2001, 358, 455-460.                               | 6.3 | 212       |
| 1317 | Structural neuroimaging of Alzheimer's disease and other dementias. <i>Aging Clinical and Experimental Research</i> , 2001, 13, 203-209.   | 1.4 | 15        |
| 1318 | Sporadic Creutzfeldt-Jakob disease in a young Dutch valine homozygote: Atypical molecular phenotype. <i>Annals of Neurology</i> , 2001, 50, 258-261.   | 2.8 | 27        |
| 1319 | A New Rating Scale for Age-Related White Matter Changes Applicable to MRI and CT. <i>Stroke</i> , 2001, 32, 1318-1322.   | 1.0 | 1,506     |
| 1320 | Functional MRI of cortex in sedated 18 month-old infants with or without periventricular leukomalacia. <i>Developmental Medicine and Child Neurology</i> , 2001, 43, 486.  | 1.1 | 33        |
| 1321 | Genetic and biochemical markers for Alzheimer's disease: recent developments. <i>Annals of Clinical Biochemistry</i> , 2000, 37, 593-607.  | 0.8 | 32        |
| 1322 | Contribution of neuroimaging in the diagnosis of Alzheimer's disease and other dementias. <i>Current Opinion in Neurology</i> , 2000, 13, 391-396.   | 1.8 | 61        |
| 1323 | fMRI of visual encoding: Reproducibility of activation. , 2000, 9, 156-164.  |     | 201       |
| 1324 | Cortico-hippocampal communication by way of parallel parahippocampal-subicular pathways. <i>Hippocampus</i> , 2000, 10, 398-410.   | 0.9 | 323       |
| 1325 | MRI volumetric correlates of white matter lesions in dementia with lewy bodies and Alzheimer's disease. <i>International Journal of Geriatric Psychiatry</i> , 2000, 15, 911-916.  | 1.3 | 80        |
| 1326 | Limitations of Clinical Criteria for the Diagnosis of Vascular Dementia in Clinical Trials: Is a Focus on Subcortical Vascular Dementia a Solution?. <i>Annals of the New York Academy of Sciences</i> , 2000, 903, 262-272. | 1.8 | 100       |
| 1327 | Neurocardiovascular Instability, Hypotensive Episodes, and MRI Lesions in Neurodegenerative Dementia. <i>Annals of the New York Academy of Sciences</i> , 2000, 903, 442-445.  | 1.8 | 69        |
| 1328 | Preliminary Results from an MRI/CT-Based Database for Vascular Dementia and Alzheimer's Disease. <i>Annals of the New York Academy of Sciences</i> , 2000, 903, 542-546.   | 1.8 | 30        |
| 1329 | L-Glutamate, L-arginine and L-citrulline levels in cerebrospinal fluid of Parkinson's disease, multiple system atrophy, and Alzheimer's disease patients. <i>Journal of Neural Transmission</i> , 2000, 107, 183-189.        | 1.4 | 51        |
| 1330 | Aspects of Alzheimer's disease. <i>Lancet</i> , The, 2000, 355, 1920.  | 6.3 | 2         |
| 1331 | Unbiased whole-brain analysis of gray matter loss in Alzheimer's disease. <i>Neuroscience Letters</i> , 2000, 285, 231-233.  | 1.0 | 145       |
| 1332 | Magnetoencephalographic analysis of cortical activity in Alzheimer's disease: a pilot study. <i>Clinical Neurophysiology</i> , 2000, 111, 604-612.   | 0.7 | 145       |

| #    | ARTICLE  | IF  | CITATIONS |
|------|--|-----|-----------|
| 1333 | Corticoâ€hippocampal communication by way of parallel parahippocampalâ€subicular pathways. Hippocampus, 2000, 10, 398-410.   | 0.9 | 11        |
| 1334 | Diagnosis and management of Alzheimerâ€™s disease and other disorders associated with dementia. The role of neurologists in Europe. European Journal of Neurology, 2000, 7, 133.   | 1.7 | 63        |
| 1335 | Early diagnosis of dementia: neuroimaging. Journal of Neurology, 1999, 246, 16-20.   | 1.8 | 100       |
| 1336 | Medial temporal lobe atrophy and memory dysfunction as predictors for dementia in subjects with mild cognitive impairment. Journal of Neurology, 1999, 246, 477-485.   | 1.8 | 298       |
| 1337 | Parametric fMRI analysis of visual encoding in the human medial temporal lobe. , 1999, 9, 637-643.   |     | 41        |
| 1338 | Visual assessment of medial temporal lobe atrophy in demented and healthy control subjects: correlation with volumetry. Psychiatry Research - Neuroimaging, 1999, 90, 193-199.   | 0.9 | 58        |
| 1339 | The diagnostic value of electroencephalography in mild senile Alzheimer's disease. Clinical Neurophysiology, 1999, 110, 825-832.   | 0.7 | 97        |
| 1340 | Apolipoprotein E $\epsilon$ 4 Allele, Temporal Lobe Atrophy, and White Matter Lesions in Late-Life Dementias. Archives of Neurology, 1999, 56, 961.  | 4.9 | 82        |
| 1341 | Vascular Dementia: The Role of Cerebral Infarcts. Alzheimer Disease and Associated Disorders, 1999, 13, S38-S48.   | 0.6 | 30        |
| 1342 | Magnetic resonance imaging differences between dementia with Lewy bodies and Alzheimer's disease: a pilot study. Psychological Medicine, 1999, 29, 181-187.  | 2.7 | 51        |
| 1343 | Role of White Matter Lesions in Cognitive Impairment of Vascular Origin. Alzheimer Disease and Associated Disorders, 1999, 13, S49-54.   | 0.6 | 47        |
| 1344 | Imaging of Static Brain Lesions in Vascular Dementia. Alzheimer Disease and Associated Disorders, 1999, 13, S81-90.  | 0.6 | 29        |
| 1345 | Within-Subject Reproducibility of Visual Activation Patterns With Functional Magnetic Resonance Imaging Using Multislice Echo Planar Imaging. Magnetic Resonance Imaging, 1998, 16, 105-113.   | 1.0 | 163       |
| 1346 | White Matter Changes on CT and MRI: An Overview of Visual Rating Scales. European Neurology, 1998, 39, 80-89.  | 0.6 | 244       |
| 1347 | Pathophysiologic Mechanisms in the Development of Age-Related White Matter Changes of the Brain. Dementia and Geriatric Cognitive Disorders, 1998, 9, 2-5.   | 0.7 | 156       |
| 1348 | Cooperation and Networking on White Matter Disorders: The European Task Force on Age-Related White Matter Changes. Dementia and Geriatric Cognitive Disorders, 1998, 9, 44-45.   | 0.7 | 10        |
| 1349 | Emerging Treatments in Dementia. European Neurology, 1997, 38, 184-189.  | 0.6 | 3         |
| 1350 | The Diagnostic Value of Magnetic Resonance Imaging and Technetium 99m-HMPAO Single-Photon-Emission Computed Tomography for the Diagnosis of Alzheimer Disease in a Community-Dwelling Elderly Population. Alzheimer Disease and Associated Disorders, 1997, 11, 63-70. | 0.6 | 55        |

| #    | ARTICLE   | IF  | CITATIONS |
|------|---|-----|-----------|
| 1351 | Qualitative Assessment of Cerebral Atrophy on MRI: Inter- and Intra-Observer Reproducibility in Dementia and Normal Aging. <i>European Neurology</i> , 1997, 37, 95-99.   | 0.6 | 166       |
| 1352 | Comparison of four potential MR parameters for severe tissue destruction in multiple sclerosis lesions. <i>Magnetic Resonance Imaging</i> , 1997, 15, 155-162.  | 1.0 | 43        |
| 1353 | Visual association encoding activates the medial temporal lobe: A functional magnetic resonance imaging study. <i>Hippocampus</i> , 1997, 7, 594-601.   | 0.9 | 134       |
| 1354 | Visual association encoding activates the medial temporal lobe: A functional magnetic resonance imaging study. , 1997, 7, 594.  |     | 2         |
| 1355 | Familial spastic paraplegia: evidence for a fourth locus. <i>Clinical Neurology and Neurosurgery</i> , 1997, 99, 87-90.   | 0.6 | 3         |
| 1356 | Diagnosing Alzheimer's Disease in Community-Dwelling Elderly: A Comparison of EEG and MRI. <i>Dementia and Geriatric Cognitive Disorders</i> , 1997, 8, 198-202.  | 0.7 | 20        |
| 1357 | Circadian restâ€”activity rhythm disturbances in alzheimer's disease. <i>Biological Psychiatry</i> , 1996, 40, 259-270.   | 0.7 | 393       |
| 1358 | The functional basis of ocular dominance: functional MRI (fMRI) findings. <i>Neuroscience Letters</i> , 1996, 221, 1-4.   | 1.0 | 105       |
| 1359 | Inter-and Intraobserver Reproducibility of Cerebral Atrophy Assessment on MRI Scans with Hemispheric Infarcts. <i>European Neurology</i> , 1996, 36, 268-272.   | 0.6 | 383       |
| 1360 | Visual assessment of medial temporal lobe atrophy on magnetic resonance imaging: Interobserver reliability. <i>Journal of Neurology</i> , 1995, 242, 557-560.   | 1.8 | 352       |
| 1361 | No evidence for abnormalities in kinetics of platelet monoamine oxidase in Alzheimer's disease. <i>Clinica Chimica Acta</i> , 1995, 240, 99-102.  | 0.5 | 4         |
| 1362 | A four-generation Dutch family with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), linked to chromosome 19p13. <i>Clinical Neurology and Neurosurgery</i> , 1995, 97, 307-313. | 0.6 | 33        |
| 1363 | Limited duration of the effect of methylprednisolone on changes on MRI in multiple sclerosis. <i>Neuroradiology</i> , 1994, 36, 382-387.  | 1.1 | 53        |
| 1364 | Cerebrospinal fluid acetylcholinesterase homospecific activity in patients with â€œprobable Alzheimer's diseaseâ€•. <i>Biological Psychiatry</i> , 1994, 36, 708-709.   | 0.7 | 4         |
| 1365 | Clinically silent dysfunction of dorsal columns and dorsal spinocerebellar tracts in hereditary spastic paraparesis. <i>Journal of the Neurological Sciences</i> , 1994, 125, 206-211.  | 0.3 | 30        |
| 1366 | Decreased cerebrospinal fluid nitrate levels in Parkinson's disease, Alzheimer's disease and multiple system atrophy patients. <i>Journal of the Neurological Sciences</i> , 1994, 121, 46-49.  | 0.3 | 113       |
| 1367 | Clinical neurophysiology in the diagnosis of Alzheimer's disease. <i>Clinical Neurology and Neurosurgery</i> , 1994, 96, 111-118.   | 0.6 | 11        |
| 1368 | Evidence for Atrophy of the Corpus callosum in Alzheimerâ€™s Disease. <i>European Neurology</i> , 1994, 34, 83-86.  | 0.6 | 30        |

| #    | ARTICLE  | IF  | CITATIONS |
|------|--|-----|-----------|
| 1369 | Small Infarcts in the Centrum ovale: Study of Predisposing Factors. <i>Cerebrovascular Diseases</i> , 1994, 4, 83-87.  | 0.8 | 23        |
| 1370 | Methotrexate induced brain necrosis and severe leukoencephalopathy due to disconnection of an Ommaya device. <i>Journal of Neuro-Oncology</i> , 1993, 15, 269-273.           | 1.4 | 18        |
| 1371 | SPECT, CT and MRI in a Turkish family with huntington's disease. <i>Neuroradiology</i> , 1993, 35, 525-528.  | 1.1 | 5         |
| 1372 | A semiquantative rating scale for the assessment of signal hyperintensities on magnetic resonance imaging. <i>Journal of the Neurological Sciences</i> , 1993, 114, 7-12.    | 0.3 | 870       |
| 1373 | Neuro-imaging in the diagnosis of Alzheimer's disease. <i>Clinical Neurology and Neurosurgery</i> , 1993, 95, 81-91.   | 0.6 | 20        |
| 1374 | Pre- and post-mortem MR imaging of unsuspected multiple sclerosis in a patient with Alzheimer's disease. <i>Journal of the Neurological Sciences</i> , 1993, 117, 175-178.   | 0.3 | 15        |
| 1375 | (99mTc)-HM-PAO SPECT and dementia in Parkinson's disease.. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1992, 55, 981-981.                                     | 0.9 | 4         |
| 1376 | Frontal Lobe Dysfunction in Unilateral Lenticulostriate Infarcts. <i>Archives of Neurology</i> , 1992, 49, 1285.   | 4.9 | 63        |
| 1377 | Leuko-Araiosis: Relationship with the Types of Focal Lesions Occurring in Acute Cerebrovascular Disorders. <i>Cerebrovascular Diseases</i> , 1992, 2, 169-176.               | 0.8 | 49        |
| 1378 | Neuro-imaging in the diagnosis of Alzheimer's disease I. Computer tomography and magnetic resonance imaging. <i>Clinical Neurology and Neurosurgery</i> , 1992, 94, 277-289. | 0.6 | 29        |
| 1379 | Intracerebral haemorrhage in Sneddon's syndrome. <i>Journal of the Neurological Sciences</i> , 1992, 111, 227-228.   | 0.3 | 15        |
| 1380 | White-matter lesions on CT in Alzheimer patients. <i>Acta Neurologica Scandinavica</i> , 1991, 84, 264-264.  | 1.0 | 5         |
| 1381 | Serial quantitative MR assessment of optic neuritis in a case of neuromyelitis optica, using Gadolinium-enhanced STIR imaging. <i>Neuroradiology</i> , 1991, 33, 70-71.      | 1.1 | 19        |
| 1382 | A Dutch family with autosomal dominant pure spastic paraparesis (Strömpell's disease). <i>Acta Neurologica Scandinavica</i> , 1990, 82, 169-173.                             | 1.0 | 25        |
| 1383 | Intracranial ganglioglioma: MR imaging.. <i>American Journal of Roentgenology</i> , 1990, 155, 899-900.  | 1.0 | 1         |
| 1384 | Anterolateral lumbar meningocele presenting as an ovarian cyst, in a patient with neurofibromatosis. <i>Clinical Neurology and Neurosurgery</i> , 1989, 91, 351-354.         | 0.6 | 5         |
| 1385 | Man with subjective complaints but abnormal CSF. , 0, , 13-17.   |     | 0         |
| 1386 | Cerebrospinal fluid biomarkers of frontotemporal lobar degeneration. , 0, , 143-152.   |     | 0         |